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Abstract 
Amniotic fluid-derived stem cells (AFSCs) are a unique stem cell source that 
demonstrate great potential for use in bone and cartilage tissue engineering (TE) 
due to their pluripotentiality. One of the major problems in TE is graft failure in 
vivo due to core degradation and avascular necrosis in constructs designed to 
regenerate thick tissues such as bone. The engraftment of these constructs post-
implantation relies on the rapid formation of stable and functional vasculature, as 
cell-seeded constructs lack an inherent vascular network. One approach to 
overcoming this vascularisation problem involves engineering a nascent 
vasculature in vitro prior to implantation in vivo. This pre-vascularisation approach 
reduces reliance on vessel invasion from the host, improving the possibility of 
successful implant engraftment. AFSCs have also previously demonstrated 
angiogenic potential and as a result, may offer a potential cell source for use in 
pre-vascularisation. 
The primary aim of the research presented in this thesis was to investigate the 
angiogenic potential of AFSCs in order to develop a novel co-culture system to 
engineer, in vitro, an inherent network of vessel-like structures within highly 
porous collagen-composite scaffolds. The application of this co-culture to 
different scaffolds could allow for the creation of a host of vascularised TE 
constructs with potential for use in a variety of clinical applications. Hypoxia is a 
well-known physiological stimulus of angiogenesis so, in order to potentially 
enhance the formation of vessel-like structures, the effect of hypoxic culture on 
this co-culture system was also investigated. The final part of the research 
presented in this thesis aimed to investigate the chondrogenic potential of AFSCs 
with the aim of creating a novel construct for use in cartilage repair, another major 
area of orthopaedic TE. 
Firstly, Chapter 2 of this thesis investigated the ability of AFSCs to differentiate 
down an endothelial lineage in order to create an endothelial-like cell for use in 
pre-vascularisation. This study demonstrated that AFSCs subjected to 
endothelial stimuli display an endothelial gene expression profile and functional 
endothelial cell characteristics indicative of early endothelial differentiation. 
Culture in continuous hypoxia enhanced endothelial gene expression but did not 
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enhance functional endothelial cell characteristics. However, AFSCs were 
ultimately unable to adopt the mature endothelial cell phenotype necessary for 
the formation of vessel-like structures required for pre-vascularisation. In Chapter 
3, the suitability of AFSCs for use in the role of pericyte in a co-culture with human 
umbilical vein endothelial cells (HUVECs) was investigated. It was demonstrated 
that AFSCs were capable of functioning as pericytes and that an AFSC-HUVEC 
co-culture was capable of successfully pre-vascularising a collagen-chondroitin 
sulphate (CCS) scaffold via the formation of a robust network of vessel-like 
structures. In addition, it was found that intermittent and continuous hypoxia 
reduced vessel-like structure formation and that of the three O2 conditions 
studied, normoxia promoted the highest level of vessel-like structure formation 
within CCS scaffolds. 
In Chapter 4, this AFSC-HUVEC co-culture was demonstrated to be capable of 
pre-vascularising two other collagen-based scaffolds from our lab that are the 
closest to clinical translation: a collagen-hydroxyapatite (CHA) and a collagen-
hyaluronic (CHyA) scaffold, indicating the adaptability of this co-culture for use in 
pre-vascularisation. It was demonstrated that both scaffold types were capable 
of facilitating similar levels of cell density and vessel-like structure formation, 
making this approach suitable for use in a variety of TE applications.  
In Chapter 5, by utilising the knowledge gained in the earlier studies, the focus 
switched to cartilage repair in order to develop a novel construct which combined 
AFSCs, the CHyA scaffold and hypoxic culture. It was demonstrated that AFSCs 
were capable of undergoing chondrogenic differentiation as evidenced by 
production of cartilage-like matrix. Hypoxic pre-culture accelerated early stage 
chondrogenic differentiation and inhibited late stage differentiation towards 
hypertrophy, indicating that hypoxia may enhance the chondrogenic potential of 
AFSCs. Collectively, this thesis has demonstrated the potential and adaptability 
of AFSCs for use in both bone and cartilage TE.  The research presented in this 
thesis has led to the development of three pre-vascularised collagen-based 
scaffolds that have potential for use in a wide range of TE applications. 
Furthermore, a novel construct composed of AFSCs seeded on a CHyA scaffold 
has been developed that may have significant implications in the development of 
advanced TE strategies for cartilage defect repair. 
5 
 
Table of contents 
Acknowledgements .................................................................................................. 11 
Publications, Prizes and Presentations .................................................................. 13 
List of Figures ........................................................................................................... 17 
List of Tables ............................................................................................................ 21 
Nomenclature ............................................................................................................ 21 
 
1. Introduction and literature review        
1.1 Tissue engineering overview ............................................................................. 27 
1.2 Bone .................................................................................................................... 30 
1.3 Vasculogenesis and angiogenesis .................................................................... 33 
1.4 Scaffolds for tissue engineering and vascularisation challenges .................. 35 
1.4.1 The inherent difficulties of vascularising thick TE biomaterials ........................... 35 
1.4.2 Scaffold properties for successful vascularisation and tissue engineering ....... 37 
1.4.3 Scaffold biomaterials ................................................................................................. 39 
1.4.4 Collagen-based composite scaffolds ...................................................................... 42 
1.5 Cell sources to promote vascularisation .......................................................... 45 
1.5.1 Endothelial cells .......................................................................................................... 45 
1.5.2 Multipotent stem cells ................................................................................................ 46 
1.5.3 Endothelial progenitor cells ....................................................................................... 48 
1.5.4 Co-culture systems .................................................................................................... 49 
1.6 Human amniotic fluid-derived stem cells .......................................................... 52 
1.7 Strategies to enhance cell-based approaches to vascularisation ................... 55 
1.8 Hypoxia and the HIF-1 pathway ......................................................................... 59 
1.8.1 Overview ...................................................................................................................... 59 
1.8.2 The HIF-1 pathway ..................................................................................................... 60 
1.8.3 Methods of HIF-1 pathway activation ...................................................................... 61 
1.9 The role of tissue engineering in cartilage repair ............................................. 63 
1.10 Thesis objectives .............................................................................................. 67 
6 
 
Chapter 2: The effect of hypoxic culture on the 
endothelial differentiation of human amniotic 
fluid-derived stem cells 
 
2.1 Introduction ......................................................................................................... 70 
2.2 Methods ............................................................................................................... 72 
2.2.1 Cell culture................................................................................................................... 72 
Culture of AFSCs ............................................................................................................. 72 
Induction of endothelial differentiation of AFSCs ........................................................ 73 
AFSC hypoxic culture regime ......................................................................................... 73 
Culture of human umbilical vein endothelial cells (HUVECs) .................................... 74 
2.2.2 Assessing the effect of hypoxic culture on endothelial differentiation ................ 75 
The effect of hypoxic culture on HIF-1α protein expression ...................................... 75 
The effect of hypoxic culture on gene expression ....................................................... 76 
The effect of hypoxic culture on VEGF secretion ........................................................ 77 
The effect of hypoxic culture on CD31 cell-surface expression ................................ 77 
2.2.3 Assessing the effect of hypoxic culture on endothelial-like functionality ........... 78 
The effect of hypoxic culture on ac-LDL uptake .......................................................... 78 
The effect of hypoxic culture on tubule formation on Matrigel™ ............................... 79 
2.2.4 Statistical analysis ...................................................................................................... 79 
2.3 Results ................................................................................................................. 80 
2.3.1 Hypoxic culture enhances endothelial differentiation ........................................... 80 
Hypoxic culture upregulates HIF-1α protein expression in AFSCs .......................... 80 
Hypoxic culture enhances the endothelial gene expression profile of AFSCs ....... 80 
Hypoxic culture enhances VEGF secretion by AFSCs ............................................... 87 
Hypoxic culture does not affect CD31 cell-surface expression in AFSCs ............... 88 
2.3.2 Hypoxic culture does not enhance functional endothelial characteristics 
adopted by AFSCs ............................................................................................................... 90 
Hypoxic culture does not affect the uptake of ac-LDL by AFSCs ............................. 90 
Hypoxic culture does not affect the ability of AFSCs to form tubules on Matrigel™
 ............................................................................................................................................ 92 
2.4 Discussion .......................................................................................................... 95 
2.5 Conclusion ........................................................................................................ 100 
7 
 
Chapter 3: The pre-vascularisation of a collagen-
chondroitin sulphate scaffold using human 
amniotic fluid-derived stem cells to enhance and 
stabilise endothelial cell-mediated vessel 
formation  
 
3.1 Introduction ....................................................................................................... 102 
3.2 Methods ............................................................................................................. 104 
3.2.1 Cell culture................................................................................................................. 104 
AFSC-HUVEC co-culture seeding techniques........................................................... 106 
3.2.2 Assessing the optimal AFSC-HUVEC co-culture seeding technique for vessel-
like structure formation on a 2D monolayer ................................................................... 107 
3.2.3 Assessing the optimal AFSC-HUVEC co-culture seeding technique for vessel-
like structure formation on CCS scaffolds ...................................................................... 108 
3.2.4 Assessing the effect of hypoxic culture on the formation of vessel-like 
structures by an AFSC-HUVEC co-culture .................................................................... 111 
Hypoxic culture regime .................................................................................................. 111 
The effect of hypoxic culture on the formation of vessel-like lumina in a CCS 
scaffold ............................................................................................................................. 111 
The effect of hypoxic culture on cell density .............................................................. 112 
The effect of hypoxic culture on VEGF and PDGF-BB secretion ........................... 113 
The effect of hypoxic culture on gene expression of VEGF, VEGFR1 and VEGFR2
 .......................................................................................................................................... 113 
3.2.5 Statistical analysis .................................................................................................... 114 
3.3 Results ............................................................................................................... 114 
3.3.1 Addition of AFSCs prior to HUVECs results in enhanced formation of vessel-
like structures on both a 2D monolayer and on CCS scaffolds................................... 114 
3.3.2 Hypoxic culture exerts no beneficial effects on vessel-like structures formed by 
an AFSC-HUVEC co-culture ............................................................................................ 117 
Hypoxic culture reduces formation of vessel-like lumina by an AFSC-HUVEC co-
culture in CCS scaffolds ................................................................................................ 125 
Hypoxic culture negatively affects the cell density of the AFSC-HUVEC co-culture
 .......................................................................................................................................... 128 
Hypoxic culture enhances VEGF and PDGF-BB protein secretion ........................ 129 
Hypoxic culture upregulates gene expression of VEGF and VEGFR1 but 
downregulates VEGFR2 ............................................................................................... 132 
8 
 
3.4 Discussion ........................................................................................................ 135 
3.5 Conclusion ........................................................................................................ 141 
Chapter 4: Investigation of the ability of an AFSC-
HUVEC co-culture to pre-vascularise collagen-
hydroxyapatite and collagen-hyaluronic acid 
scaffolds 
 
4.1 Introduction ....................................................................................................... 143 
4.2 Methods ............................................................................................................. 145 
4.2.1 Scaffold fabrication ................................................................................................... 145 
4.2.2 Cell culture................................................................................................................. 147 
4.2.3 Assessing the ability of CHA and CHyA scaffolds to support vessel-like 
structure formation ............................................................................................................. 148 
CD31 staining for vessel–like structure formation in cell-seeded scaffolds .......... 148 
Confocal imaging of CD31 stained cell-seeded scaffolds ........................................ 148 
VEGF and PDGF-BB protein secretion by AFSC-HUVEC co-cultures and HUVEC 
monocultures seeded on CHA and CHyA scaffolds ................................................. 149 
Cell density of AFSC-HUVEC co-cultures and HUVEC monocultures seeded on 
CHA and CHyA scaffolds .............................................................................................. 149 
Quantifying vessel-like structure formation in CHA and CHyA scaffolds .............. 149 
4.2.4 Statistical analysis .................................................................................................... 150 
4.3 Results ............................................................................................................... 151 
4.3.1 The AFSC-HUVEC co-culture forms vessel-like structures within CHA scaffolds
 .............................................................................................................................................. 151 
AFSC-HUVEC co-cultures seeded on CHA scaffolds display VEGF and PDGF-BB 
secretion patterns indicative of vessel-like structure formation ............................... 152 
4.3.2 The AFSC-HUVEC co-culture forms vessel-like structures within CHyA 
scaffolds ............................................................................................................................... 154 
AFSC-HUVEC co-cultures seeded on CHyA scaffolds display VEGF and PDGF-
BB secretion patterns indicative of vessel-like structure formation ........................ 155 
4.3.3 CHA and CHyA scaffolds maintain consistent cell density over a 14 day culture 
period ................................................................................................................................... 157 
4.3.4 CHA and CHyA scaffolds support similar levels of vessel-like structure 
formation .............................................................................................................................. 158 
4.4 Discussion ........................................................................................................ 160 
4.5 Conclusion ........................................................................................................ 164 
9 
 
Chapter 5: Investigation of the ability of human 
amniotic fluid-derived stem cells to undergo 
chondrogenic differentiation within a collagen-
hyaluronic acid scaffold 
 
5.1 Introduction ....................................................................................................... 167 
5.2 Materials and methods ..................................................................................... 170 
5.2.1 Scaffold fabrication ................................................................................................... 170 
5.2.2 Cell culture................................................................................................................. 170 
Culture of AFSCs ........................................................................................................... 170 
Scaffold seeding ............................................................................................................. 170 
Hypoxic pre-culture regime ........................................................................................... 171 
5.2.3 Analysis of cell density ............................................................................................ 172 
5.2.4 Analysis of gene expression ................................................................................... 172 
5.2.5 Analysis of cartilage-like matrix production .......................................................... 173 
Analysis of sulphated GAG production ....................................................................... 173 
Analysis of collagen type 2 and aggrecan deposition............................................... 174 
5.2.6 Statistical analysis .................................................................................................... 175 
5.3 Results ............................................................................................................... 175 
5.3.1 AFSCs adopt a chondrogenic gene expression pattern that is accelerated by 
hypoxic pre-culture ............................................................................................................. 175 
5.3.2 AFSCs produce cartilage-like matrix in both normoxic and hypoxic pre-culture 
groups .................................................................................................................................. 179 
AFSCs deposit sulphated GAG in both normoxic and hypoxic pre-culture groups
 .......................................................................................................................................... 179 
AFSCs deposit collagen type 2 and aggrecan in both normoxic and hypoxic pre-
culture groups ................................................................................................................. 181 
5.4 Discussion ........................................................................................................ 185 
5.5 Conclusion ........................................................................................................ 189 
 
 
10 
 
Chapter 6: Discussion, future work and 
conclusions 
 
6.1 Discussion ........................................................................................................ 192 
6.1.1 Overview .................................................................................................................... 192 
6.1.2 The effect of hypoxic culture on the endothelial differentiation of human 
amniotic fluid-derived stem cells (Chapter 2) ................................................................. 195 
6.1.3 Pre-vascularisation of a collagen-chondroitin sulphate scaffold using human 
amniotic fluid-derived stem cells to enhance and stabilise endothelial cell-mediated 
vessel formation (Chapter 3) ............................................................................................ 197 
6.1.4 Investigation of the ability of an AFSC-HUVEC co-culture to pre-vascularise 
collagen-hydroxyapatite and collagen-hyaluronic acid scaffolds (Chapter 4) ........... 200 
6.1.5 Investigation of the ability of human amniotic fluid-derived stem cells to 
undergo chondrogenic differentiation within a collagen-hyaluronic acid scaffold 
(Chapter 5) .......................................................................................................................... 201 
6.2 Future work ....................................................................................................... 203 
6.3 Thesis conclusions ........................................................................................... 206 
6.4 References ........................................................................................................ 208 
 
 
  
11 
 
Acknowledgements 
There was no way I could have ever made it through this PhD by myself and as 
a result there is a danger of this being the longest section in the thesis. Apologies 
in advance. 
First of all, I would like to thank my two supervisors, Dr. Garry Duffy and Prof. 
Fergal O’Brien for their continued support over the last three years. Your 
guidance has been inspiring and has helped shape my scientific career thus far. 
I am sure it will continue to do so for many years. It has been a privilege to be a 
part of your group. 
Thank you to everyone in the REPAIR lab in Mainz, Germany, especially to 
Roman, Laura, Tijna and Thomas for making me feel at home. I cannot 
adequately express how grateful I am to Dr. Ron Unger and Prof. James 
Kirkpatrick for allowing me to join their lab and to enable me to learn so much in 
such a short time. To Anne, thank you for putting up with all of my questions and 
for being such a gracious and patient teacher, vielen Dank!  
It has been a pleasure to work all of the folks in TERG over the years. I can 
honestly say that I have never met a more talented, smart and resourceful group 
in my life. So thank you (in no particular order) Sarah-Louise, Lauren, Orlaith, 
Ciara, Caroline, Ryan, Tanya, Andrew, John Gleeson, Alan R., Alan H., Cian, 
Hugo, Stephen, Nick, Rob, Emmet, Claire B, Amro, Greg, Sara, Nicola, Ash, 
Rukmani, Caroline H and everyone else (there are now far too many to list!). 
Thanks to Johnny for technical support. 
Thank you to all of the guys in the office (Irene, Erica, Conn, Elaine and Rosie) 
for all the laughs (and Gin Clubs) over the years and apologies for never wearing 
shoes. 
Thank you to Brenton for all of your imaging help and know-how. 
Sincere thanks to Tara for her continued guidance and for giving me the idea to 
start co-culturing in first place! My sincerest gratitude to Amos for all of his sage 
advice, the help with all of my projects over the years and for proof-reading (I am 
sure it has taken a couple years off his life at least!).  
12 
 
Thank you to my family (Mam, Cal and Hannah) who were always supportive of 
me no matter what. You were always there to remind me that there is more to life 
than work. Also, thank you to Mary Martin for the vast amount of advice and the 
many free lunches over the years! 
Thank you to all of my friends, new and old, who have always had the time to go 
for a drink or to just chat. Thanks all my fellow RCSI-ers over the years; 
Guillaume, Megan, Jimmer, Naadiya, Lorna, Katie, Gary, Mollie, Colm, Chris, 
Linda, Paul and Anna-Chiara (and everyone else!).  
To Casey, Jonjo, Brian Byrne, Egg, Silvi, Bennett, Jenny, Dr. Marc Fernandez, 
Ali, Kev, Ross, Katie, Ivan, Jonesy, Aideen, Laura, Tara, Sara, Bairdy, Arnold, 
Nic and the countless others for years of comradery and good (and often blurry) 
times. You’ll be seeing a lot more of me now. 
To Ash, Rica and Hector, thank you for giving me a home away from home. 
To Triona, I do not know where to even begin. Your support and love over the 
past four years has often been the single factor that has kept me going. I look 
forward to all the holidays and general nonsense we’ll be getting up to soon 
enough! 
I gratefully acknowledge grant support from the Health Research Board in Ireland 
(PhD/2007/11), the European Research Council and the EMBO Short Term 
Travel Fellowship. 
  
13 
 
Publications, Prizes and Presentations  
Journal publications: 
Cai Lloyd-Griffith, Tara M. McFadden, Garry P. Duffy, Fergal J. O’Brien. Tissue 
Engineering Constructs: In Vitro Vascularization. Encyclopaedia of Biomedical 
Polymers and Polymeric Biomaterials. In press (December 2014). 
Cai Lloyd-Griffith, Garry P. Duffy, Fergal J. O’Brien. The effect of hypoxic culture 
on the endothelial differentiation of human amniotic fluid-derived stem cells. In 
preparation. 
Cai Lloyd-Griffith, Tara M. McFadden, Ronald E. Unger, Charles J. Kirkpatrick, 
Garry P. Duffy, Fergal J. O’Brien. The pre-vascularisation of a collagen-
chondroitin sulphate scaffold using human amniotic fluid-derived stem cells to 
enhance and stabilise endothelial cell-mediated vessel formation. In preparation. 
Cai Lloyd-Griffith, Amos Matsiko, Garry P. Duffy, Fergal J. O’Brien. Investigation 
of the ability of human amniotic fluid-derived stem cells to undergo chondrogenic 
differentiation within a collagen-hyaluronic acid scaffold. In preparation. 
Prizes: 
Travel fellowship for the 19th Annual Conference of the Section of 
Bioengineering of the Royal Academy of Medicine in Ireland (BinI) (Meath, 
Ireland) (2013): Awarded funding to the value of the price of accommodation and 
conference registration. 
EMBO Short Term Travel Fellowship (2014): Awarded funding to the value of 
approximately €8000 to travel to the Laboratory for Regenerative Pathology & 
Interface Research (REPAIR LAB) in Johannes Gutenberg University, Mainz, 
Germany in order to complete work as part of Chapter 3 of this thesis, entitled 
“The pre-vascularisation of a collagen-chondroitin sulphate scaffold using human 
amniotic fluid-derived stem cells to enhance endothelial cell-mediated vessel 
formation”.  
 
14 
 
Other: 
An image entitled “Formation of blood vessel-like structures on a collagen-
glycosaminoglycan scaffold” was selected as a finalist in the “ARTERMIS” image 
competition as part of TERMIS 2014 in Genoa, Italy. 
The work contained in this thesis has been presented at the following 
international and national conferences: 
International Conferences: 
Cai Lloyd-Griffith, Garry P. Duffy and Fergal J. O’Brien (2012) 
Effect of Hypoxia on the Induction of Angiogenic Differentiation in Human 
Amniotic Fluid Derived Stem Cells (hAFSCs).  
Tissue Engineering and Regenerative Medicine International Society, 3rd World 
Congress, Vienna, Austria. 
 
Cai Lloyd-Griffith, Amos Matsiko, Garry P. Duffy and Fergal J. O’Brien (2013) 
The Effect of Hypoxia on Endothelial and Chondrogenic Differentiation of Human 
Amniotic Fluid-Derived Stem Cells (hAFSCs) for Use in Orthopaedic Tissue 
Engineering.  
Anatomical Society Summer Meeting, Royal College of Surgeons in Ireland, 
Dublin, Ireland. 
 
Cai Lloyd-Griffith, Garry P. Duffy and Fergal J. O’Brien (2013)  
The Effect of Hypoxia on the Chondrogenic Differentiation of Human Amniotic 
Fluid-Derived Stem Cells (hAFSCs) for Use in Orthopaedic Tissue Engineering.  
Tissue Engineering and Regenerative Medicine International Society, European 
conference, Istanbul, Turkey. 
 
15 
 
 
 
Cai Lloyd-Griffith, Garry P. Duffy and Fergal J. O’Brien (2014)  
The Effect of Hypoxic Pre-Culture on Chondrogenic Differentiation of Human 
Amniotic Fluid-Derived Stem Cells in a Collagen-Hyaluronic Acid Scaffold. 
60th Annual Meeting of the Orthopaedic Research Society, New Orleans, USA. 
 
Cai Lloyd-Griffith, Tara M. McFadden, Paula Murphy, Ronald E. Unger, 
Charles J. Kirkpatrick, Garry P. Duffy and Fergal J. O’Brien (2014)  
The effect of hypoxia on the vascularisation of Collagen-GAG scaffolds using a 
HUVEC-AFSC coculture.  
Tissue Engineering and Regenerative Medicine International Society, European 
conference, Genoa, Italy 
 
National Conferences: 
Cai Lloyd-Griffith, Garry P. Duffy and Fergal J. O’Brien (2012) 
 Investigation into the effect of external stimuli on the induction of osteogenic and 
angiogenic differentiation in Human Amniotic Fluid Derived Stem Cells (hAFSCs). 
The 18th Annual Conference of the Section of Bioengineering of the Royal 
Academy of Medicine in Ireland, Belfast, Ireland. 
 
Cai Lloyd-Griffith, Garry P. Duffy and Fergal J. O’Brien (2012) 
 Investigating the effect of hypoxia on inducing angiogenic differentiation of 
Human Amniotic Fluid-Derived Stem Cells (hAFSCs).  
Royal College of Surgeons in Ireland, Research Day. 
16 
 
Cai Lloyd-Griffith, Garry P. Duffy and Fergal J. O’Brien (2012) 
Investigating the effect of hypoxia on inducing angiogenic differentiation of 
Human Amniotic Fluid-Derived Stem Cells (hAFSCs).  
International Mesenchymal Stem Cell Conference, Galway, Ireland 
 
Cai Lloyd-Griffith, Garry P. Duffy and Fergal J. O’Brien (2013) 
The Effect of Hypoxia on Endothelial Differentiation of Human Amniotic Fluid-
Derived Stem Cells (hAFSCs). 
The 19th Annual Conference of the Section of Bioengineering of the Royal 
Academy of Medicine in Ireland, Meath, Ireland. 
 
Cai Lloyd-Griffith, Garry P. Duffy and Fergal J. O’Brien (2013)  
The Effect of Hypoxia on Endothelial Differentiation in Human Amniotic Fluid-
Derived Stem Cells. 
Royal College of Surgeons in Ireland, Research Day. 
 
Cai Lloyd-Griffith, Tara M. McFadden, Paula Murphy, Ronald E. Unger, 
Charles J. Kirkpatrick, Garry P. Duffy and Fergal J. O’Brien (2014)  
Using Hypoxia in Combination with HUVEC/AFSC Co-Cultures to Engineer 
Vessel Formation in Collagen-GAG Scaffolds.  
Young Life Scientists Ireland 2014 symposium, Dublin, Ireland. 
  
17 
 
List of Figures  
Figure 1.1: The Tissue Engineering triad………………………………………….28 
Figure 1.2: Annual spending and sales in billions ($) for the tissue engineering 
industry for the years 2007 and 2011.……………………………….……………...30 
Figure 1.3: Scanning Electron Micrograph (1000x) of a collagen nano-
hydroxyapatite scaffold (Cunniffe et al., 2010) depicting the typical porous nature 
of TE scaffolds.…………………………………………………………………….….33 
Figure 1.4: Bone formation by (A) endochondral ossification and (B) 
intramembraneous ossification (Wojcicka et al., 2013)……..……………………35 
Figure 1.5: The process of blood vessel formation.………………….……………39 
Figure 1.6: Diagrammatic representation of structure of both collagen fibrils and 
a proteoglycan complex………………………………….…………………………..43 
Figure 1.7: Photon micrograph demonstrating vessel formation by a delayed 
addition co-culture model consisting co-culture of human MSCs and HUVECs 
seeded in a CCS scaffold in vitro. …………………………………………………..51 
Figure 1.8: The isolation and expansion of AFSCs…………………………..…..53 
Figure 1.9: HIF-1α regulation by proline hydroxylation…………………………...61 
Figure 2.1: A 856-HYPO/EXP model hypoxia chamber in use. ………………..74 
Figure 2.2: The effect of hypoxia on HIF-1α protein expression in AFSCs after 3 
days of culture as visualised using western blotting……………………………….80 
Figure 2.3: qRT-PCR analysis investigating the expression of the endothelial 
markers (A) Angiopoietin 1, (B) TIE-2, (C) VEGFR2, (D) CD31 and (E) vWF by 
AFSCs at day 7 of culture………………………….………………………………..82 
Figure 2.4: qRT-PCR analysis investigating the expression of the endothelial 
markers (A) Angiopoietin 1, (B) TIE-2, (C) VEGFR2, (D) CD31 and (E) vWF by 
AFSCs at day 14 of culture………………………………………………………….84 
18 
 
Figure 2.5: VEGF secretion by AFSCs over the course of 14 days in response to 
endothelial stimuli in various O2 conditions………………………………………...88 
Figure 2.6: Fluorescent staining indicating CD31 expression by AFSCs in the 
presence of endothelial stimuli at day 7 and 14 of culture………………………...89 
Figure 2.7: Florescent imaging demonstrating ac-LDL uptake by AFSCs over the 
course of 14 days in response to endothelial stimuli in all three O2 conditions….91 
Figure 2.8: Quantification of tubule formation by AFSCs on Matrigel™ after 7 
days of culture in normoxia, intermittent hypoxia or continuous hypoxia………..93 
Figure 2.9: Quantification of tubule formation by AFSCs on Matrigel™ after 14 
days of culture in normoxia, intermittent hypoxia or continuous hypoxia………..94 
Figure 3.1: A human umbilical cord clamped and filled with collagenase during 
the process of HUVEC isolation……………………………………………………105 
Figure 3.2: Representative images of fluorescent CD31 staining indicating 
vessel-like structure formation by the AFSC>HUVEC co-culture on a 2D 
monolayer at day 14………………………………………………………………...115 
Figure 3.3: Representative images of fluorescent CD31 staining indicating 
vessel-like structure formation by the AFSC>HUVEC co-culture on a CCS 
scaffold at day 14 of culture………………………………………………………...116 
Figure 3.4: Representative images of fluorescent CD31 staining demonstrating 
the formation of vessel-like structures by the AFSC-HUVEC co-culture on a 2D 
monolayer after 7 days in (A) normoxia, (C) intermittent hypoxia and (E) 
continuous hypoxia…………………………………………………………………118 
Figure 3.5: Representative images of fluorescent CD31 staining indicating the 
formation of vessel-like structures by the AFSC-HUVEC co-culture on a 2D 
monolayer after 14 days in (A) normoxia, (C) intermittent hypoxia and (E) 
continuous hypoxia…………………………………………………………………120 
Figure 3.6: Confocal microscopy demonstrating the ability of the AFSC-HUVEC 
co-culture to form networks of vessel-like structures within a CCS scaffold after 7 
days of culture……………………………………………………………………….122 
19 
 
Figure 3.7: Confocal microscopy demonstrating the ability of the AFSC-HUVEC 
co-culture to form networks of vessel-like structures within a CCS scaffold after 
14 days of culture……………………………………………………………………124 
Figure 3.8: Representative images of CD31 immunostaining for lumina within 
CCS scaffolds……………………………………………………………………….126 
Figure 3.9: Quantification of lumina formed within CCS scaffolds using CD31 
immunostaining……………………………………………………………………..127 
Figure 3.10: The effect of hypoxic culture on the dsDNA concentration of a (A) 
AFSC-HUVEC co-culture, (B) HUVEC monoculture and (C) AFSC monoculture 
seeded on CCS scaffolds…………………………………………………………..129 
Figure 3.11: The effect of hypoxic culture on VEGF protein secretion by a (A) 
AFSC-HUVEC co-culture, (B) HUVEC monoculture and (C) AFSC monoculture 
seeded on a CCS scaffold………………………………………………………….130 
Figure 3.12: The effect of hypoxic culture on the PDGF-BB protein secretion by 
the (A) AFSC-HUVEC co-culture, (B) HUVEC monoculture and (C) AFSC 
monoculture seeded on a CCS scaffold…………………………………………..132 
Figure 3.13: qRT-PCR analysis investigating the expression of the angiogenic 
growth factor VEGF and its receptors VEGFR1 and VEGFR2…………………134 
Figure 4.1: Vessel-like structure formation by the AFSC-HUVEC co-culture 
within a CHA scaffold at day 7 and 14 of culture as demonstrated by confocal 
microscopy…………………………………………………………………………..151 
Figure 4.2: VEGF protein secretion by an (A) AFSC-HUVEC co-culture and (B) 
HUVEC monoculture seeded on a CHA scaffold at day 4, 7, 10 and 14 of 
culture………………………………………………………………………………..153 
Figure 4.3: PDGF-BB protein secretion by an (A) AFSC-HUVEC co-culture and 
(B) HUVEC monoculture seeded on a CHA scaffold at day 7 and 14 of 
culture………………………………………………………………………………..154 
20 
 
Figure 4.4: Vessel-like structure formation by the AFSC-HUVEC co-culture 
within a CHyA scaffold at 7 and 14 days of culture as demonstrated by confocal 
microscopy. …………………………………………………………………………155 
Figure 4.5: VEGF protein secretion by an (A) AFSC-HUVEC co-culture and (B) 
HUVEC monoculture seeded on a CHyA scaffold at day 4, 7, 10 and 14 of culture. 
……………………………………………………………………………..…………156 
Figure 4.6: PDGF-BB protein secretion by an (A) HUVEC-AFSC co-culture and 
a (B) HUVEC monoculture seeded on CHyA scaffolds at day 7 and 14 of 
culture…………………………………………………………………………….….157 
Figure 4.7: dsDNA concentration of an A) AFSC-HUVEC co-culture and (B) 
HUVEC monoculture seeded on CHA and CHyA scaffolds at day 4, 7, 10 and 14 
of culture.……………………………………………………………………….……158 
Figure 4.8: Representative 3D renderings of vessel-like structure networks in 
CHA (A-B) and CHyA (C-D) scaffolds at day 7 and 14 and the quantification of 
total surface area of these renderings (E).……………………………………… 159 
Figure 5.1: qRT-PCR analysis investigating the expression of the early-stage 
chondrogenic marker SOX9 by AFSCs pre-cultured in either normoxia or hypoxia 
at day 0 (A) and 7 (B) of culture. …………………………..………………………176 
Figure 5.2: qRT-PCR analysis investigating the expression of intermediate-stage 
chondrogenic markers COL2 (A, C) and ACAN (B, D) by AFSCs pre-cultured in 
either normoxia or hypoxia at day 14 and 21 of 
culture………………………………………………………………….…………….177 
Figure 5.3: qRT-PCR analysis investigating the expression of the late-stage 
chondrogenic marker COLX (A, C) and the endothelial growth factor VEGF (B, 
D) by AFSCs pre-cultured in either normoxia or hypoxia at day 14 and 21 of 
culture. ………………………………………………………..……..………………178 
Figure 5.4: The effect of hypoxic pre-culture on sulphated GAG production...180 
21 
 
Figure 5.5: Safranin-O staining of histological sections of AFSC-seeded CHyA 
scaffolds for the detection of sulphated GAG deposition by AFSCs in normoxia 
and hypoxia groups. ……………………………………..…………………………181 
Figure 5.6: Immunohistochemical staining of CHyA scaffolds for collagen type 2 
indicating deposition by AFSCs over the course of 21 days in normoxia and 
hypoxia groups. ………………………………………………………..……………182 
Figure 5.7: Immunohistochemical staining of CHyA scaffolds for aggrecan 
indicating the level of matrix deposition by AFSCs over the course over 21 days 
in normoxia and hypoxia groups. …………………………………….……………184 
List of Tables  
Table 2.1: Summary of culture conditions………………………………………….74 
Table 2.2: Comparison of expression levels of endothelial markers in continuous 
hypoxia at day 7 and 14 compared to HUVECs at day 14………………………..86 
Table 3.1: Summary of culture conditions………………………………………..111 
Table 5.1: Summary of culture conditions………………………………………..172 
Nomenclature 
%- Percentage 
°C- Degrees Celsius 
μm- Micrometre 
™- Trade Mark 
2D- Two Dimensional 
3D- Three Dimensional 
αSMA- Alpha Smooth Muscle Actin 
ac-LDL- acetyl Low Density Lipoprotein 
ACI- Autologous Chondrocyte Implantation 
AFSCs- Amniotic Fluid-Derived Stem Cells 
ANOVA- Analysis of Variance 
22 
 
ARNT- Aryl Hydrocarbon Receptor Nuclear Translocator 
ASCs- Adipose Stem Cells 
BAFC- Basic Amniotic Fluid Cell 
bFGF- basic Fibroblast Growth Factor 
BMP-2- Bone Morphogenetic Protein-2 
BSA- Bovine Serum Albumin 
CCS- Collagen-Chondroitin Sulphate 
CHA-Collagen- Hydroxyapatite 
CHyA- Collagen- Hyaluronic Acid 
CP- Calcium Phosphate 
CO2- Carbon Dioxide 
CoCl2- Cobalt Chloride 
COL2- Collagen Type 2 
COLX- Collagen Type 10 
CS- Chondroitin Sulphate 
∆∆Ct- delta-delta Ct  
DAB- 3,3-Diaminobenzidine 
DAPI- 4',6-Diamidino-2-Phenylindole 
DFO- Desferrioxamine 
dH2O- Distilled Water 
DHT- Dehydrothermal 
DMEM- Dulbecco’s Modified Eagle’s Medium 
DMOG- Dimethyloxaloylglycine 
DNA- Deoxyribonucleic Acid 
DPX- Di-N-Butyl Phthalate in Xylene 
dsDNA- Double Stranded Deoxyribonucleic Acid 
ECs- Endothelial Cells 
ECM- Extracellular Matrix 
EDAC- 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide  
23 
 
EDTA- Ethylenediaminetetraacetic Acid 
EGF- Epidermal Growth Factor 
ELISA- Enzyme Linked Immunosorbent Assay 
EPCs- Endothelial Progenitor Cells 
ESCs- Embryonic Stem Cells 
ES-FBS- Embryonic Stem Cell Qualified- Fetal Bovine Serum  
FBS- Foetal Bovine Serum 
FDA- Food and Drug Administration 
FITC- Fluorescein-Isothiocyanate 
GAG- Glycosaminoglycan 
GFP- Green Fluorescent Protein 
GPR- Gesundheits- und Pflegezentrum Rüsselsheim clinic 
h- Hour(s) 
H&E- Haematoxylin and Eosin 
HA- Hydroxyapatite 
HCAECs- Human Coronary Artery Endothelial Cells 
HCL- Hydrochloric Acid 
HDMECs- Human Dermal Microvascular Endothelial Cells 
HGF- Hepatocyte Growth Factor 
HIF- Hypoxia Inducible Factor 
HOS- Human Osteoblasts 
HRE- Hypoxia Response Element 
HRP- Horseradish Peroxidase 
HUVECs- Human Umbilical Vein Endothelial Cells 
HyA- Hyaluronic Acid 
IGF-1- Insulin-like Growth Factor 1 
M- Molar 
min- minutes 
mL- Millilitre 
24 
 
mm- Millimetre 
mM- Milimolar 
mRNA- messenger Ribonucleic Acid 
MAPCs- Multipotent Adult Progenitor Cells  
MSCs- Mesenchymal Stem Cells 
mTorr- Millitorr  
NHS- N-Hydroxysuccinimide 
ng- Nanogram  
nm- Nanometre 
O2- Oxygen 
ODDD- Oxygen Dependent Degradation Domain 
OECs- Outgrowth Endothelial Cells 
PBS- Phosphate buffered saline 
PCL- Poly (ε-caprolactone) 
PDGF-BB- Platelet Derived Growth Factor-BB 
PDGFR-β- Platelet Derived Growth Factor Receptor beta 
PECAM- Platelet Endothelial Cell Adhesion Molecule 
PenStrep- Penicillin/Streptomycin 
PFA- Paraformaldehyde 
PGF- Placental Growth Factor 
pH- Potential for Hydrogen Ion Concentration 
PHDs- Prolyl Hydroxylase  
PHI- Prolyl Hydroxylase Inhibitor 
PLG- Poly(lactide-co-glycolide)  
PLGA- poly(lactic-co-glycolic acid) 
PLA- Polylactic Acid 
qPCR- Quantitative Real-Time Polymerase Chain Reaction 
RCSI- Royal College of Surgeons in Ireland 
R&D- Research and Development 
25 
 
RNA- Ribonucleic Acid 
Rh- Recombinant Human 
RUNX- Runt-related transcriptional factor 
rpm- Revolutions per Minute 
SD- Standard Deviation 
SEM- Standard Error of the Mean 
Shh- Sonic Hedgehog 
SMCs- Smooth Muscle Cells 
SOX - SRY-type HMG box Tissue 
SPCL- Starch Polycaprolactone 
TE- Tissue Engineering 
Tf- Freezing Temperature 
TGF-β- Transforming Growth Factor Beta 
TIE-2- Endothelium-Specific Receptor Tyrosine Kinase 
VE-Cadherin- Vascular Endothelial-Cadherin 
VEGF- Vascular Endothelial Growth Factor 
VEGFR1- Vascular Endothelial Growth Factor Receptor 1 
VEGFR2- Vascular Endothelial Growth Factor Receptor 2 
VHL- Von Hippel-Lindau Factor 
VOI- Volume of Interest 
vWF- Von Willebrand Factor 
WST- Water Soluble Tetrazolium 
wt%- Weight Percent 
w/v- Weight/Volume 
X- Magnification 
  
26 
 
1. Introduction and literature review        
Contents 
1.1 Tissue engineering overview ............................................................................. 27 
1.2 Bone .................................................................................................................... 30 
1.3 Vasculogenesis and angiogenesis .................................................................... 33 
1.4 Scaffolds for tissue engineering and vascularisation challenges .................. 35 
1.4.1 The inherent difficulties of vascularising thick TE biomaterials ........................ 35 
1.4.2 Scaffold properties for successful vascularisation and tissue engineering ...... 37 
1.4.3 Scaffold biomaterials ...................................................................................... 39 
1.4.4 Collagen-based composite scaffolds .............................................................. 42 
1.5 Cell sources to promote vascularisation .......................................................... 45 
1.5.1 Endothelial cells ............................................................................................. 45 
1.5.2 Multipotent stem cells ..................................................................................... 46 
1.5.3 Endothelial progenitor cells ............................................................................ 48 
1.5.4 Co-culture systems ......................................................................................... 49 
1.6 Human amniotic fluid-derived stem cells .......................................................... 52 
1.7 Strategies to enhance cell-based approaches to vascularisation ................... 55 
1.8 Hypoxia and the HIF-1 pathway ......................................................................... 59 
1.8.1 Overview ........................................................................................................ 59 
1.8.2 The HIF-1 pathway ......................................................................................... 60 
1.8.3 Methods of HIF-1 pathway activation .............................................................. 61 
1.9 The role of tissue engineering in cartilage repair ............................................. 63 
1.10 Thesis objectives .............................................................................................. 67 
 
 
  
27 
 
1.1 Tissue engineering overview   
The body naturally responds to injury by attempting to repair itself; however, the 
ability of most tissues in the body to undergo self-repair is limited, so depending 
on the severity of the injury, surgical intervention may be required (Yannas, 
2001). Conventional therapeutic approaches to the replacement and repair of 
tissue include autografting, allografting and xenografting. Autografting is 
commonly considered the current gold standard for many tissues and is often 
associated with the best clinical outcome (Janicki and Schmidmaier, 2011). This 
procedure involves the transplantation of healthy tissue from a donor site on the 
patient to the injured area. Allografting is similar procedure which involves 
sourcing donor tissue from a member of same species, which is commonly stored 
in a tissue bank until needed. Xenografting involves the use of donor tissue from 
another species, for example, porcine tissue has previously been used as a graft 
treatment for skin loss (Davis and Arpey, 2000). 
Despite the effectiveness of these techniques, there are a number of 
disadvantages associated with their use. For example, autografts are constrained 
by obtainable tissue quantity and the requirement for additional surgical 
procedures, which is associated with increased donor-site morbidity (Betz, 2002, 
Baumhauer et al., 2014). Allografts (and to some extent xenografts) are limited 
by the possibility of donor pain, donor site morbidity, graft rejection, infection and 
fracture in the transplanted material (Berrey et al., 1990, Giannoudis et al., 2005, 
Campana et al., 2014). In the United States alone, an estimated one in five people 
who reach the age of 65 will receive temporary or permanent organ-replacement 
therapy during their remaining life span (Lysaght and Reyes, 2001). Therefore, 
there is a dire need for an alternative approach to tissue regeneration. The field 
of tissue engineering (TE) has emerged as an alternative approach to the 
regeneration of both individual tissues and whole organs. 
TE can be defined as a highly interdisciplinary field that aims to regenerate 
damaged tissues by combining cells from the body with biomaterials that act as 
templates for tissue regeneration, with the aim to restore, maintain or improve 
tissue function. The typical TE approach is based on the concept that primary 
cells can be isolated from a patient, expanded in vitro and seeded onto a 
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substrate that can be then grafted back into the patient to restore the function of 
damaged or degenerated tissue in vivo or to culture tissue in vitro which can be 
used for subsequent implantation. This TE approach relies on three fundamental 
components for the development of a successful TE construct: 1) A scaffold that 
provides structure and substrate for tissue growth and development. 2) A source 
of cells to facilitate required tissue formation. 3) Growth factors or biophysical 
stimuli to direct the growth and differentiation of cells within the scaffold (Yang et 
al., 2001). Each element is integral and directly influences the other two. All three 
elements are necessary to complete the “Tissue Engineering triad” (Fig. 1.1). 
 
Figure 1.1: The Tissue Engineering triad. The scaffold provides the substrate and support 
necessary to facilitate cell growth. The cells provide the materials necessary for tissue 
formation and the growth factors provide the signals required to direct the growth and 
differentiation of the cells in an appropriate manner.  
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The TE and stem cell therapeutics industry continues to expand year after year. 
By mid-2007, there were approximately 50 companies offering commercial 
tissue-regenerative products and services with annual sales in excess of $1.3 
billion. At the time these companies employed approximately 3000 employees 
(Lysaght et al., 2008). By 2011, the number of companies offering these products 
and services had increased over two-fold to 106, while annual sales had almost 
tripled to $3.5 billion. The number of people employed in the industry also 
expanded to almost 14,000 (Jaklenec et al., 2012).  
Figure 1.2 (Jaklenec et al., 2012) summarises collected spending data for the 
industry and compares it to commercial sales figures for 2007 and 2011. From 
this figure it can be seen that total annual spending for the industry has increased 
from $2.4 billion to $3.6 billion, including an approximate two-fold increase in 
commercial stage spending from $1.6 billion from $2.8 billion over four years. 
Total spending has increased one and a half-fold in the last 4 years, however, 
sales have increased almost three-fold, indicating that sales have increased at 
almost twice the rate of spending. Overall, it is clear that total spending per year 
was twice the amount generated by sales for the industry in 2007. However, by 
2011 total annual sales has doubled, nearly equalling spending. 
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Figure 1.2: Annual spending and sales in billions ($) for the tissue engineering industry for the 
years 2007 and 2011. Spending on preclinical and clinical trials is shown in dark grey while 
spending on the commercial stage is coloured light grey (Jaklenec et al., 2012). Total sales 
increased almost three-fold between 2007 and 2011 spending increased one and a half-fold, 
indicating that sales increased at almost twice the rate of spending. 
The growth of both spending and sales demonstrates the overall expansion of 
the industry (and the field of TE as whole) and indicates promise for the future, 
especially for the millions of patients worldwide whose needs are currently unmet 
by current therapeutic approaches. 
1.2 Bone 
Bone is a dynamic, highly vascularised tissue with a unique capacity to 
regenerate and remodel without scarring. However, a requirement for bone 
grafting still arises from critical sized defects resulting from disease or trauma. 
Bone is the second most transplanted tissue after blood with a reported 600,000 
bone graft procedures carried out in the United States each year and up to 2.2 
million procedures carried out worldwide. The market for bone grafting is valued 
at approximately $2.5 billion each year (Marino and Ziran, 2010). Bone is a 
nanocomposite material that consists of both organic and inorganic components. 
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The organic phase of bone consists of the various cells of bone tissue and 
osteoid, which constitutes one-third of the bone-matrix. Osteoid is composed 
mostly of collagen fibres. The organic phase of bone adds to both the structure 
of bone and its tensile strength, allowing the tissue a remarkable resistance to 
stretch and twisting. The inorganic phase accounts for almost two- thirds of the 
total weight of bone, and comprises of hydroxyapatite (HA) nanocrystals and 
small amounts calcium carbonate, sodium, magnesium and fluoride salts. This 
phase accounts for the characteristic hardness of bone and is responsible for its 
high resistance to compression, which enables it to endure large shear loads. 
The proper combination of these phases is what allows bone to be exceedingly 
durable and somewhat flexible without becoming brittle, therefore providing the 
necessary strength and structural support to the body (Salgado et al., 2004, 
Marieb, 2010, Martini, 2012). 
The cellular component of bone is critical to the formation, structure and function 
of the tissue. There are four main cell types found in bone: osteoprogenitor cells, 
osteocytes, osteoblasts and osteoclasts. Osteoprogenitor cells are derived from 
mesenchymal stem cells (MSCs) and are found in small numbers in bone. These 
cells differentiate into osteoblasts and are responsible for the maintenance of 
osteoblast number in the body. Osteoblasts are fully differentiated cells that are 
involved in converting osteoid to bone via increasing calcium and phosphate 
levels and inducing salt deposition within the new matrix. Osteocytes develop 
from osteoblasts surrounded completely by bone matrix and reside in a space in 
this matrix known as a lacuna. Osteocytes maintain the protein and mineral 
content of the surrounding bone matrix and also participate in bone repair as they 
are capable of converting into osteoblasts or osteoprogenitor cells once released 
from the lacuna. (Cohen, 2006, Marieb, 2010, Martini, 2012). Osteoclasts are 
large multinucleated cells derived from the haematopoietic stem cell niche. Their 
main function is the reabsorption of bone via a process known as osteolysis 
(Owen et al., 1990, Marieb, 2010). 
The process of osteoblast differentiation and subsequent bone formation is 
known as osteogenesis. Bone development can occur via two distinct processes: 
intramembranous ossification and endochondral ossification (Fig. 1.3). Both of 
32 
 
these processes rely on the formation of an inherent vasculature in order to 
facilitate growth, homeostasis and regeneration. 
The majority of all bone formation below the base of the skull occurs through a 
process known as endochondral ossification (Fig. 1.3 A). During foetal 
development, a hyaline cartilage model is deposited by chondrocytes, which lays 
out the pattern for bone formation. The chondrocytes proliferate, undergo 
hypertrophy and then apoptose. This is followed by an invasion of osteoclasts, 
bone marrow cells, osteoblasts and blood vessels that is mediated by the release 
of a number of systemic and locally secreted factors, such as vascular endothelial 
growth factor (VEGF). The cartilage model is invaded by blood vessels first at its 
centre and later at each end, which establishes the primary and secondary 
centres of ossification. These centres of ossification gradually encroach on the 
remaining cartilage, ultimately leading to its removal and replacement with 
trabecular bone and bone marrow (except at the articular surfaces) (Gerber et 
al., 1999, White and Wallis, 2001, Mackie et al., 2008, Marieb, 2010). 
Intramembranous ossification also occurs during embryonic development and is 
mainly associated with flat bones e.g. the cranial bone of the skull. This process 
occurs when MSCs cluster together and deposit osteoid matrix which 
subsequently becomes mineralised (Fig. 1.3 B). The MSCs then differentiate into 
osteoblasts and begin to deposit new bone matrix which eventually fuses to form 
trabeculae. The trabeculae increase in size and number to become 
interconnected woven bone which is ultimately replaced by highly organised and 
structurally strong lamellar bone. Ossification spreads out through the matrix from 
the primary site, which is known as the ossification centre. During this process, 
the invasion of capillaries into the mesenchymal space occurs as the newly 
forming bone (and all bone) is reliant on blood vessel invasion for the supply of 
oxygen (O2) and nutrients (Martini, 2012, Percival and Richtsmeier, 2013). 
From the developmental processes by which bone is formed, it is clear that an 
extensive vascular supply is critical to normal bone formation, development and 
homeostasis. Therefore, it is also clear that in order for any TE construct 
developed for use in bone regeneration must be properly vascularised in order to 
be effective. 
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Figure 1.3: Bone formation by (A) endochondral ossification and (B) intramembraneous 
ossification (Wojcicka et al., 2013) 
1.3 Vasculogenesis and angiogenesis 
The formation of a functional vascular system is vital for the proper development 
of most tissues in the human body. There are two processes by which new blood 
vessels are formed: angiogenesis and vasculogenesis. Angiogenesis is the 
creation of blood vessels from pre-existing vasculature and vasculogenesis is the 
creation of an entirely new vascular system via the production of de novo 
endothelial cells (ECs) from endothelial progenitor cells. 
Angiogenesis is the fundamental process by which new blood vessels are 
formed. It is essential in reproduction, development, and wound repair (Folkman, 
1992). Sprouting angiogenesis is a tightly regulated multi-step process, which 
involves the release of pro-angiogenic growth factors, matrix degradation by 
34 
 
proteases, EC migration and proliferation, sprout and network formation as well 
as vessel maturation (Fig. 1.4 B) (Laschke et al., 2011). There are six basic steps 
associated with angiogenic vessel growth (Nomi et al., 2002): 1) The parent 
vessel vasodilates in order to separate adjacent ECs. 2) The basement 
membrane of the parent vessel is degraded by proteolytic enzymes. 3) ECs 
migrate to the edge of the site of degradation and begin to proliferate. 4) A tube-
like structure begins to form (complete with lumen). 5) A basement membrane is 
synthesised for the new tubule structure. 6) Pericytes and smooth muscle cells 
are then recruited in order to stabilise the nascent vessel. 
Until recently, it was believed that vasculogenesis was restricted to the prenatal 
period. However, it has  been implicated in a number of adult stage processes 
such as wound healing (Kassmeyer et al., 2009) and bone fracture repair (Lee et 
al., 2008). Vasculogenesis is integral to the process of endochondral ossification 
as previous described in Section 1.2. Vasculogenesis consists of five steps (Fig. 
1.4 A) (Drake et al., 1998): 1) ECs are generated from embryonic mesenchymal 
cells known as angioblasts. 2) ECs form the vessel primordia and cell-cell 
arrangements but no lumen is present. 3) An immature tube-like structure is 
formed containing polarised ECs. 4) A vascular network is established from 
several EC tubules. 5) This vascular network is stabilised through the recruitment 
of perivascular cells.  
Another process known as arteriogenesis is responsible for the provision of a 
blood to tissues that have suffered from a reduced supply. Arteriogenesis 
involves an increase in diameter of existing arterial blood vessels. The trigger for 
arteriogenesis is primarily fluid shear stress and results in the remodelling of 
arterioles into developed and highly functional arteries (Carmeliet, 2000, Heil et 
al., 2006, Cai and Schaper, 2008). 
In the context of creating a functional vasculature for a therapeutic construct, both 
vasculogenesis and angiogenesis can be the relevant process, depending on the 
cell type used (endothelial progenitor cells for vasculogenesis and ECs for 
angiogenesis). 
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Figure 1.4: The process of blood vessel formation. This occurs via several processes: 
vasculogenesis; where the primary networks are formed, followed by angiogenic remodelling that 
involves the modification of pre-existing vasculature. Other stages involved are: stabilisation and 
maturation, destabilisation, regression and the sprouting of capillaries from pre-existing vessels 
(Rouwkema et al., 2008). 
1.4 Scaffolds for tissue engineering and vascularisation challenges 
1.4.1 The inherent difficulties of vascularising thick TE biomaterials 
The successful engraftment of TE constructs designed to regenerate thick tissues 
(such as bone) relies on the rapid formation of stable and functional vasculature 
post-implantation (Laschke et al., 2006, Unger et al., 2010). Forming this 
vasculature is a major challenge and as such, success has been primarily limited 
to the replacement of thin, avascular tissues such as skin. In most tissues, cells 
are capable of surviving only within the range of O2 and nutrient diffusion 
(approximately 150-200µm) of the nearest network of blood vessels (Folkman 
and Hochberg, 1973). This is especially true in thicker tissues, where proximity 
to a vascular network is essential for cell survival and homeostasis. This is due 
to delayed nature of O2 diffusion, which occurs more slowly than its consumption. 
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As a result, the absence of a sufficient vascular supply has been established as 
a major limiting factor in cell survival and implant success in TE (Ishaug-Riley et 
al., 1998, Cheema et al., 2012). Core degradation and avascular necrosis are 
major concerns for non-vascularised thick constructs implanted in vivo. Core 
degradation can be caused by the encapsulation of the implanted construct due 
to matrix deposition by seeded cells, which prevents in-growth of vessels and 
consequently, vascularisation of the construct by the host (Lyons et al., 2010). 
A recent approach involving the engineering of a nascent vasculature within a 
construct in vitro prior to implantation has emerged as a potential solution to 
overcome the issue of implant failure as a result of core degradation.  
Consequently, this approach has become the focus of an increasing number of 
studies (Montano et al., 2010, Unger et al., 2010, Duffy et al., 2011). This method 
of pre-vascularisation provides functional vasculature within the construct prior to 
implantation, therefore reducing the reliance on vessel invasion from the host, 
which often occurs too slowly to permit construct viability. Host vessel invasion is 
thought to occur at a rate of approximately 5 μm/h and vessel infiltration into TE 
constructs is often limited to a depth of several hundred micrometres from the 
implant surface (Jabbarzadeh et al., 2008, Wang et al., 2010). Although this 
system does not provide an instantaneous blood supply, it does allow for quick 
anastomosis with the host vessels through a process known as “wrapping and 
tapping”, in which the nascent vessels surround nearby host vessels and disrupt 
underlying host endothelium, leading to the formation of connected, functional 
vasculature that links the two networks (Cheng et al., 2011). This connection of 
vasculature between construct and host significantly enhances the effectiveness 
of the implanted construct by facilitating the perfusion of O2 and nutrients 
throughout (Chen et al., 2009b). In this thesis, this pre-vascularisation approach 
was utilised in order to generate an inherent network of vessel-like structures in 
a number of collagen-composite scaffolds. The next section of this chapter 
concerns the various characteristics of these TE constructs and how these 
characteristics affect their ability to facilitate vascularisation and tissue repair. 
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1.4.2 Scaffold properties for successful vascularisation and tissue 
engineering 
When creating TE scaffolds for defect or damage repair, a number of factors must 
be considered. This ensures the manufacture of the necessary structural 
framework to restore functionality to damaged tissues, as well as the provision of 
a suitable environment to support and promote cellular attachment, proliferation 
and differentiation (O'Brien, 2011, Lee et al., 2013a). Implanted scaffolds must 
replace the extracellular matrix (ECM), closely mimic the host environment and 
be able to function from the time of implantation to the completion of the 
remodelling process (Hutmacher, 2000, O'Brien, 2011). For successful 
implantation, scaffolds require certain characteristics which include (but are not 
limited to): biocompatibility, biodegradability, mechanical properties and scaffold 
architecture (including porosity, pore size, pore interconnectivity and structure) 
(Hutmacher, 2000, Kim et al., 2000, O'Brien, 2011).  
Biocompatibility and biodegradability 
The most important consideration when choosing a suitable biomaterial for tissue 
repair is biocompatibility. Biocompatibility is the ability of a scaffold to support cell 
adherence, growth and proliferation without eliciting a severe or chronic immune 
reaction which could lead to the rejection of the scaffold. Localised inflammation 
is required to an extent in order to induce healing and tissue repair (Arroyo and 
Iruela-Arispe, 2010) and promote the vascularisation of an avascular construct. 
However, it is essential that this localised inflammation does not become chronic, 
as this may result in an immune response which could be detrimental to the 
healing process (Mikos et al., 1998, Hutmacher, 2000). Biodegradability is also a 
major consideration in the design of biomaterials. An implanted biomaterial 
should not be permanent, as it must degrade in order to allow the body to produce 
its own matrix to replace the damaged tissue, allowing for natural healing to take 
place (Mikos et al., 1998). This natural degradation bypasses the need for later 
removal of the construct via surgery (Temenoff and Mikos, 2000), which could 
lead to further damage, thus preventing the injured tissue from fully healing. Any 
by-products from the process of degradation should not have a toxic effect on the 
surrounding cells and it is also vital that these products be easily removed via 
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standard metabolic pathways to minimise disturbance to the host (Kim et al., 
2000). 
Substrate stiffness 
A scaffold should have mechanical properties consistent with the anatomical site 
into which it is to be implanted. From a practical perspective, it must also be 
robust enough to be handled without the risk of it becoming damaged, for 
example, the scaffold should still be compliant enough to fill and contour to the 
defect while still somewhat retaining its shape. The mechanical properties of a 
scaffold also have a major effect on its ability to support vascularisation. The 
stiffness of a scaffold has been shown to affect the type of vasculature formed, 
for example, Yamamura et al. showed that the stiffness of a collagen gel directly 
influenced the nature of the 3D vessel-like tubule network formed by bovine 
pulmonary microvascular endothelial cells. The less-rigid gels facilitated greater 
cell migration but the vascular branches formed were thin with small lumens, 
whereas the rigid gels restricted migration but promoted the growth of a thick and 
continuous network that penetrated deeper into the gel (Yamamura et al., 2007). 
Despite this thicker network formation, it is commonly believed that stiffer 
substrates negatively affect the quality of vessels formed (Saunders and 
Hammer, 2010). This may be due to the fact that ECs are unable to form stable 
vascular structures on more rigid substrates as the cells are unable to generate 
the necessary contractile forces to remodel the substrate and manipulate their 
environment (Yamamura et al., 2007, Califano and Reinhart-King, 2009, 
Kniazeva and Putnam, 2009). Substrate stiffness has also been implicated in cell 
infiltration into a scaffold as it is believed that stiffer materials may lead to pore 
architecture being better maintained, thereby allowing for improved diffusion of 
cells and nutrients throughout (Keogh et al., 2010). 
Scaffold architecture  
Architecture is an important consideration in the development of scaffold 
geometry designed for the promotion of vascularisation. Scaffold architecture, in 
particular pore size (Fig. 1.5), has been shown to have a profound effect on a 
number of important stem cell characteristics, for example, our lab has shown 
that the mean pore size of collagen-chondroitin sulphate (CCS) scaffolds can 
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effect cell migration, infiltration and adhesion of the stem cells seeded within it 
(Murphy et al., 2010a). There is no consensus on the optimal architecture for 
vascularisation but Bai et al., using a β-tricalcium phosphate scaffold with pores 
that could be accurately adjusted using slip casting, demonstrated that an 
increase in pore size to an upper limit of 400 μm led to an increase in both the 
size and number of blood vessels distributed throughout the scaffold (Bai et al., 
2010a). Along with pore size, interconnectivity between pores is necessary for 
the undisturbed continuation of the developing vascular network through the 
scaffold (Lu et al., 1999, Kuboki et al., 2002, Mastrogiacomo et al., 2006, Kolk et 
al., 2012). These interconnections can also dictate the physical characteristics of 
the vessels formed. It was also found that interconnections between pores less 
than 150 μm produced a “bottleneck” effect which inhibited vessel growth 
whereas larger interconnections facilitated larger vessel growth (Lu et al., 1999, 
Mastrogiacomo et al., 2006, Bai et al., 2010a). These architectural considerations 
greatly affect the development of scaffolds for vascularisation.  
 
Figure 1.5: Scanning Electron Micrograph (300x) of a collagen nano-hydroxyapatite scaffold 
(Cunniffe et al., 2010) depicting the typical porous nature of collagen-based scaffolds. 
1.4.3 Scaffold biomaterials 
The biomaterials used to produce scaffolds used for regenerative purposes 
broadly fall into three categories; i) ceramics, ii) synthetic polymers and iii) natural 
polymers, each group having its own benefits and limitations.  
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Ceramic scaffolds such as calcium phosphate (CP) and HA are characterised by 
their high mechanical stiffness and low elasticity. Despite being composed of 
synthetic material, ceramics have both been shown to be biocompatible and 
capable of supporting both bone and vascular network formation (Mastrogiacomo 
et al., 2006, Bai et al., 2010a, Mirabella et al., 2013). For example, Choong et al. 
demonstrated that HA-coated polycaprolactone (PCL) substrates were superior 
for the attachment and proliferation of a co-culture of bone marrow–derived 
fibroblasts and ECs created for the purpose of vascularisation, in comparison to 
untreated PCL substrates (Choong et al., 2006). The inherent biocompatibility of 
ceramics is possibly due to their chemical and structural similarity to the mineral 
phase of bone. However, the use of ceramic scaffolds has a number of 
drawbacks e.g. they are brittle, hard to manipulate and display a slow rate of 
biodegradation, thus limiting their suitability for vascularisation and soft tissue 
repair.  
Synthetic polymers such as poly(lactic-co-glycolic acid) (PLGA) (Geuze et al., 
2012) polylactide acid (PLA), polyglycolic acid (PGA) and PCL (Singh et al., 2011, 
Navarro, 2011) have shown promise for use in regenerative medicine. More 
importantly, synthetic polymer scaffolds have previously been shown to be 
capable of supporting vascular network formation (Druecke et al., 2004, Santos 
et al., 2009, Ghanaati et al., 2011a). For example, Fuchs et al. successfully 
induced the formation of vessel-like structures on starch PCL fibre meshes using 
a co-culture of outgrowth endothelial cells (OECs) and human primary 
osteoblasts (Fuchs et al., 2009a). One of the major advantages of synthetic 
polymer scaffolds is that they can be specifically tailored (via their polymer 
composition) to meet the requirements for the repair of specific tissues (for 
example, degradation rate and physical properties). However, a major 
disadvantage of synthetic scaffolds is that they have been known to release acidic 
degradation products which lower the pH at the implantation site, which could 
lead to tissue necrosis or adversely affect biocompatibility leading to a foreign-
body response by the immune system (Yang et al., 2001, Liu et al., 2006).  
It is common practice to use natural polymers such as collagen, 
glycosaminoglycans (GAGs), elastin, silk and fibrin for the creation of scaffolds 
for tissue repair (O'Brien et al., 2004, Unger et al., 2004a, Unger et al., 2004b, 
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Yamamura et al., 2007, Duffy et al., 2011, Matsiko et al., 2012). These polymers 
are isolated from the native ECM and as such, naturally contain ligands 
associated with cell adhesion and proliferation. The advantage of using natural 
scaffolds over other available materials is that they act as bio-mimetic constructs 
providing cells with an environment similar to that of native ECM in which they 
can attach to, proliferate and differentiate within. These scaffolds are also highly 
biocompatible, have a high porosity and produce non-toxic degradation products 
(Lyons et al., 2008a). A large body of the work regarding natural biomaterials has 
been carried out using hydrogels rather than porous scaffolds (Graupe et al., 
2008, Chen et al., 2009b, Laschke et al., 2009, Lee and Niklason, 2010a, Allen 
et al., 2010, Melero-Martin et al., 2010). Vascularising a hydrogel is a less 
complex process than vascularising 3D porous scaffolds as the complex scaffold 
architecture can restrict movement of vessel-forming cells that attach to the 
scaffold struts and are less free to move and form networks than within the fine 
protein mesh of a hydrogel. This is due to the fact that hydrogels provide an 
environment that is easily manipulated. Much progress has been made 
vascularising natural hydrogels such as Matrigel (Usami et al., 2009, Melero-
Martin et al., 2010, Lee and Niklason, 2010a). Matrigel is a hydrogel-based 
biomaterial consisting of an assortment of ECM proteins that have been extracted 
from Englebreth-Holm-Swarm tumours in mice (Hughes et al., 2010). However, 
due to its origins, Matrigel could be potentially tumorigenic, rendering it unsuitable 
for clinical application despite its pro-angiogenic properties (Fridman et al., 1990, 
Bonfil et al., 1994). A major disadvantage of natural-polymer based biomaterials 
in general is that they do not provide high mechanical strength which, while 
possibly not affecting their vascularisation capability, may limit their use in load-
bearing applications such as bone repair.  
In order to overcome to the disadvantages of available biomaterials, a 
considerable amount of research has focused on the development of scaffolds 
which consist of a combination of natural, synthetic or ceramic materials. These 
combination scaffolds are referred to as “composites”. Composite scaffolds are 
typically designed in order to utilise the key properties of each biomaterial while 
minimising (or possibly eliminating) the negative attributes of the other. 
Combinations of all three groups have arisen, with a number of groups utilising 
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synthetic/natural polymer composites (Califano and Reinhart-King, 2009, Nelson, 
2010b, Nelson, 2010a), while others have focused on incorporating ceramic 
material in natural polymer-based scaffolds (Lucitti et al., 2007, Gleeson et al., 
2010, Brodney et al., 2011, Tierney et al., 2012) and creating synthetic/ceramic 
composites (Choong et al., 2006, Liu et al., 2006, Saunders and Hammer, 2010). 
The creation of composite material using components from the same category 
(e.g. a natural/natural polymer composite) in order to enhance their capacity for 
tissue repair is also common practice (O'Connor et al., 2010, Yan et al., 2011, 
Matsiko et al., 2012). 
1.4.4 Collagen-based composite scaffolds  
Our lab specialises in the development of collagen-composite scaffolds for use in 
a range of TE applications. These collagen composite scaffolds are typically 
made from collagen type 1, a fibrillar forming collagen that comprises 
approximately 95% of the entire collagen content of bone (Niyibizi and Eyre, 
1994) and is one of the most abundant proteins in the body. Collagen has a triple-
helix structure that is constituted by three polypeptide chains (α-chains) and 
functions to resist tensile, shear, or compression forces, including tendon, bone, 
cartilage, and skin (Viguet-Carrin et al., 2006).  
These collagen-composite scaffolds are fabricated using a freeze-
drying/lyophilisation technique. This method is based on the formation of ice 
crystals within the scaffold during the freezing process and subsequent 
sublimation of this ice through drying, which leads to the production of a highly 
porous material with uniform pore size. The freezing temperature used during this 
process is directly responsible for the pore size of the scaffold. The mean pore 
sizes that can be achieved this process range from approximately 85-325 µm 
(O'Brien et al., 2004, Murphy et al., 2010a, Haugh et al., 2010). As previously 
outlined in Section 1.4.2, pore size can have a major effect on the ability of a 
scaffold to support the development or in growth of vasculature. 
In our lab, these collagen scaffolds are combined with different materials in order 
to allow them to acquire different mechanical and biological properties. Our group 
specialises in the use of collagen-GAG composite scaffolds in particular. GAGs 
are linear polysaccharides containing repeating disaccharide units of an amino 
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sugar. There are four structurally distinct families of GAGs: heparin sulphate, 
keratin sulphate (found in the form of proteoglycans on the cell surface and ECM), 
hyaluronic acid (HyA) (a nonsulfated GAG found in the ECM, particularly in 
connective tissue) and chondroitin sulphate (CS). Three specific collagen-based 
composite scaffolds will be utilised in this thesis.  
 
Figure 1.6: Diagrammatic representation of structure of both collagen fibrils and a proteoglycan 
complex. The collagen fibres have a triple-helical structure composed of three α-chains. The 
proteoglycan complex is composed of sulphated-GAG-rich regions attached to a protein core, 
with link proteins facilitating binding of proteoglycans to hyaluronic acid. These complexes are, in 
turn, intertwined around collagen fibrils (Hardin, 2012). 
 
Collagen-chondroitin sulphate scaffold 
The CCS scaffold is a natural polymer composite composed of collagen type 1 
and chondroitin-6-sulphate (O'Brien et al., 2004, O'Brien et al., 2005). This 
scaffold was originally developed by Ioannis Yannas in the Massachusetts 
Institute of Technology with an application for skin regeneration and received 
Food and Drug Administration (FDA) approval to regenerate skin in burn patients 
(Yannas and Burke, 1980, Dagalakis et al., 1980, Burke et al., 1981, Yannas et 
al., 1989). These scaffolds offer a number of advantages over other available 
biomaterials, as they act as bio-mimetic constructs that can provide cells with an 
environment similar to that of native ECM, in which they can attach, proliferate 
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and differentiate (O'Brien et al., 2005, Murphy et al., 2010a). These scaffolds 
have been optimised with the ideal pore size, architecture and stiffness to 
promote bone regeneration (Tierney et al., 2009a, Murphy et al., 2010a, Haugh 
et al., 2011). The CCS scaffold has been also used for a number of TE 
applications including skin, lung, nerve, conjunctiva and brain repair (Butler et al., 
1999, Hsu et al., 2000, Chen et al., 2005, Yannas et al., 2011, Huang et al., 2012). 
The CCS scaffold is a highly porous and tailored for cell proliferation and 
ultimately, vascularisation. It has a mean pore size of approximately 325 μm, 
which has been shown to positively affect the cell migration, infiltration and 
adhesion of the stem cells seeded within it (Murphy et al., 2010a). These 
scaffolds are also highly biocompatible, have a high porosity, produce non-toxic 
degradation products (Lyons et al., 2010) and have previously been shown to 
support vascular network formation in vitro (Duffy et al., 2011) and in vivo 
(McFadden, 2013).  
Collagen-hyaluronic acid scaffold 
The collagen-hyaluronic acid (CHyA) scaffold is composed of collagen type 1 and 
HyA sodium salt derived from the bacterium Streptococcus equi. It was recently 
developed by our group specifically for use in cartilage repair (Matsiko et al., 
2012). Hyaluronic acid is a non-sulphated GAG that functions as a ‘backbone’ 
component in the binding and retention of other GAGs to form aggregating 
proteoglycans. These aggregating proteoglycans bind to collagen fibrils, 
enhancing the structural stability of cartilage. Hyaluronic acid is also found in the 
synovial fluid, providing it with the viscoelastic properties that allow for lubrication 
within the joints (Gloria et al., 2012). CHyA scaffolds have been previously 
demonstrated to enhance both the chondrogenic gene expression and 
cartilaginous matrix deposition by MSCs in comparison to standard CCS 
scaffolds (Matsiko et al., 2012).  
Collagen-hydroxyapatite scaffold 
Collagen-composite scaffolds that incorporate ceramic material have also been 
developed by our lab. Ceramic-based scaffolds are a natural choice for bone 
defect repair due to the natural presence of ceramic material such as HA in bone 
tissue. However, these ceramics are considered too stiff and brittle to be used 
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alone (Wang, 2003). The addition of a ceramic to a collagen scaffold has a 
number of advantages as they combine the osteoinductive potential of ceramic 
material with the porous and interconnected structure of the collagen scaffold. 
The collagen also improves the tensile strength of the scaffold while the HA 
increases its stiffness, creating a scaffold with balanced properties for use in bone 
defect repair. With this in mind, the collagen-hydroxyapatite (CHA) scaffold was 
developed by Gleeson et al. by incorporating HA particles into a porous collagen-
based scaffold with the aim of creating a construct with enhanced osteogenic 
potential for use in bone repair. This scaffold has been shown to exhibit 
significantly improved bioactivity and mineralisation potential of MSCs in vitro and 
was capable of healing of a critical-sized bone defect in vivo (Gleeson et al., 
2010) and have also been shown to improve bone healing in a rabbit radius 
osteotomy defect model compared to a CCS scaffold (Lyons et al., 2014). This 
scaffold type has also been incorporated into a multi-layered scaffold with CHyA 
for use in full osteochondral repair with the CHyA layer functioning to regenerate 
the articular cartilage and the CHA regenerating the underlying osteochondral 
bone (Levingstone et al., 2014).  
1.5 Cell sources to promote vascularisation  
1.5.1 Endothelial cells 
In order to evaluate cell-based model systems for vasculogenesis and 
angiogenesis, it is crucial to select the appropriate cell-type. ECs are commonly 
selected for investigation and have proved highly valuable for cellular therapy, 
disease models, drug delivery studies and especially for TE applications such as 
the generation of pre-vascularised constructs (Kim and von Recum, 2008). ECs 
can differ in structure and phenotype depending on the vessel type from which 
they are extracted (Ghitescu and Robert, 2002) and there are an number of EC 
sources available for TE, for example, microvascular (human dermal 
microvascular endothelial cells (HDMECs) (Unger et al., 2010)) and 
macrovascular sources (human coronary artery endothelial cells (He et al., 
2005)). Therefore, selection of an EC source is highly dependent on the specific 
purpose of investigation and there are associated advantages and disadvantages 
with every choice. For in vitro vascularisation of TE constructs, macrovascular 
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human umbilical vein endothelial cells (HUVECs) are a commonly utilised EC 
type due to the fact that they have been shown to spontaneously self-organise to 
produce functional vessel-like structures in vitro and in vivo (Melero-Martin et al., 
2007, Briganti et al., 2009, Chen et al., 2009b, Verseijden et al., 2010, Correia et 
al., 2011). HUVECs are mature, committed ECs and are often used to study EC 
function, morphology and responses to stimuli such as flow and shear stresses 
for vascular development (Park et al., 2006). Compared to other sources of ECs, 
HUVECs are easily extracted from an available supply of discarded umbilical 
cords and can be expanded to large numbers. These cells are an appealing 
source of ECs due to their abundance and availability from a tissue which would 
otherwise be discarded. The suitability of HUVECs for use in the pre-
vascularisation of collagen-composite scaffolds as part of a co-culture will be 
investigated in this thesis. 
In order to produce larger and more complex TE constructs, a readily available 
source of ECs are required and isolation of ECs from sources such as the aorta 
is not feasible for clinical translation. Furthermore, fully mature ECs have been 
shown to have a slow expansion rate and limited proliferation capabilities, 
requiring that a large number of ECs be harvested for therapeutic use (Chen et 
al., 2009b). Therefore, there is an increased need to obtain an alternative EC 
source for vascularisation. Recent research has established that multipotent stem 
cells types may have potential for this purpose (Chen et al., 2009b). 
1.5.2 Multipotent stem cells  
Multipotent stem cells are a cell type frequently used in TE due to their ability to 
differentiate down a number of different cell lineages. Of particular interest to the 
area of pre-vascularisation, mesenchymal stem cells (MSCs) have been shown 
to differentiate into EC-like cells both in vitro and in vivo (Oswald et al., 2004, 
Silva et al., 2005b). Initial studies carried out by Oswald et al. demonstrated that 
MSCs cultured in VEGF-supplemented media for 7 days acquired major 
characteristics of mature ECs; expressing von Willebrand Factor (vWF), VEGF 
receptor 1 (VEGFR1) and VEGF receptor 2 (VEGFR2), VE-cadherin and VCAM-
1. CD31 and CD34 were not shown to be expressed although they are known to 
occur later in EC differentiation (Oswald et al., 2004). In some cases, 
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supplementation with VEGF alone has been sufficient to induce expression of 
CD31 after 10 days in culture whereas other groups have shown that a 
combination of supplements lead to more advanced differentiation e.g. VEGF and 
Insulin-like Growth Factor (IGF-1) (Jazayeri et al., 2008) or VEGF and basic 
fibroblast growth factor (bFGF) (Liu et al., 2008). MSCs isolated from other 
tissues such as Wharton’s Jelly have demonstrated an increased capacity to 
differentiate down an EC lineage with increased expression of VEGFR2, vWF 
and VE-cadherin compared to bone marrow-derived MSCs (Chen et al., 2009a).  
Adipose tissue is another readily available source of multipotent adult stem cells 
for use in TE. Adipose-derived stem cells (ASCs) derived from an aged 
population revealed that neither advanced age or co-morbidity negatively impacts 
stem cell harvest or differentiation capacity (Zhang et al., 2011b), which is often 
an issue with other sources of stem cells (Caplan, 2007, Caplan, 2009). There 
has been evidence to suggest that ASCs are also capable of differentiating down 
an EC lineage (Cao et al., 2005, Fischer et al., 2009, Zhang et al., 2011b, Zonari 
et al., 2012). It has been shown that ASCs cultured in EC media and exposed to 
shear stress were capable of forming vessel-like structures, uptake of acetylated 
low density lipoprotein (ac-LDL) and expression of CD31. However, expression 
of eNOS and vWF was not achieved (Fischer et al., 2009). More recently, ASCs 
cultured on an electrospun fibre mesh in endothelial growth media (containing 
VEGF and bFGF) expressed mature EC markers such as VE-cadherin and vWF 
after 21 days, thus indicating their potential as an accessible source of ECs for 
the purposes of pre-vascularisation (Zonari et al., 2012). 
There is still a question over whether ECs derived from stem cells are ideal for in 
vitro and in vivo vascularisation as there is doubt over their functionality with this 
acquired phenotype (Au et al., 2008). These cells require a great amount of 
manipulation and long culture times to achieve EC differentiation and often do 
not differentiate fully down this lineage, with the lack of mature marker expression 
often evident (Au et al., 2008, Fischer et al., 2009). More recent evidence 
suggests that MSCs, which are found in perivascular locations, are in fact 
pericytes (Caplan, 2008, Crisan et al., 2008) and have been shown to support in 
vitro vessel formation in co-culture with ECs. Our group has specifically shown 
that delayed addition of MSCs to pre-formed nascent EC-generated vascular 
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networks in a collagen chondroitin sulphate (CCS) scaffold results in vessel-like 
structure in vitro which can then successfully anastomose with host vessels in 
vivo (McFadden, 2013). Other cell types such as endothelial progenitor cells 
(EPCs) are already positive for CD34, CD133, VEGFR1 and VEGFR2 or 
multipotent adult progenitor cells (MAPCs), positive for VEGFR1 and VEGFR2 
(Oswald et al., 2004) may also have potential for endothelial cell differentiation.  
1.5.3 Endothelial progenitor cells  
In recent years, EPCs have come to the forefront as an alternative source of 
vessel forming cells (Ingram et al., 2004, Fuchs et al., 2006). EPCs offer an 
accessible, autologous source of ECs. They can be easily isolated from 
peripheral and umbilical cord blood (Ingram et al., 2004) and demonstrate robust 
proliferation, self-renewal, and superior vessel-forming ability compared with 
mature ECs (Ingram et al., 2004). EPCs are also clinically safer to use than, for 
example, embryonic stem cells (ESCs), as they differentiate exclusively down an 
endothelial lineage. Several studies have demonstrated the vasculogenic ability 
of EPCs to form functional blood vessels in vivo, similar to those formed by 
HUVECs (Mukai et al., 2008) and have been frequently used in the 
vascularisation of TE constructs (Melero-Martin et al., 2007, Graupe et al., 2008, 
Geuze et al., 2009, Seebach et al., 2009, Allen et al., 2010, Ghanaati et al., 
2011a, Singh et al., 2011). EPCs consist of two different subpopulations, termed 
early and late EPCs. Although both EPCs are derived from mononuclear cells 
and express EC markers, they have different morphologies and growth patterns. 
Early EPCs exhibit a spindle-like morphology and the majority are derived from 
CD14-positive subpopulations (CD14-positive subpopulations are monocytes 
capable of differentiating into different cells types). Late EPCs, named because 
of their late outgrowth potential, exhibit a cobblestone-like morphology and are 
derived from CD14-negative fractions. In particular, late EPCs are better suited 
for in vitro vascularisation as they have been characterised for production of 
VEGF, the expression of numerous vascular cell surface markers such as CD31, 
vWF and VEGFR2 and they also lack expression of hematopoietic specific CD45 
and CD14 markers (Lin et al., 2000, Hur et al., 2004, Yoon et al., 2005, Mukai et 
al., 2008, Singh et al., 2011).  
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1.5.4 Co-culture systems 
Even if the ideal EC source for vascularisation is determined, it would still be 
necessary to simulate the relevant cellular and molecular microenvironment in 
order to replicate the vasculature in a physiologically accurate fashion (Kirkpatrick 
et al., 2007). This is due to the fact that nascent vessels formed by endothelial 
progenitors (or from other vessels during angiogenesis) are immature, unstable 
structures that are susceptible to regression and require stabilisation from 
support cells commonly referred to as pericytes (Darland and D'Amore, 1999, 
Gerhardt and Betsholtz, 2003, von Tell et al., 2006). Larger, more developed 
blood vessels (veins and arteries) also require support, but from vascular smooth 
muscle cells (SMCs). A major distinction between SMCs and pericytes is that 
pericytes cover smaller vessels, like capillaries, one cell at a time, while SMCs 
cover vessels in either mono or multi-layers (Gerhardt and Betsholtz, 2003). 
Pericyte-mediated stabilisation of the vessel is achieved through two basic 
mechanisms: the assembly of the vascular basement membrane and the 
recruitment and integration of perivascular cells into the vessel wall (von Tell et 
al., 2006). Stabilisation not only relies on physical and mechanical stimulation but 
on the release of signals that promote EC quiescence and differentiation (Armulik 
et al., 2005a). Angiogenic cytokines secreted by pericytes also play a large role 
in the support of vessel formation, enhancing the migration, proliferation and 
vessel-forming abilities of ECs (Kitahara et al., 2005, Levenberg et al., 2005, 
Pedroso et al., 2011, Roubelakis et al., 2013). The mechanism by which pericytes 
function is not understood in great detail, possibly due their heterogeneous nature 
and the inherent difficulty in outlining their development. It is suggested that both 
SMCs and pericytes represent phenotypic variants of a continuous population of 
mural cells, sharing the same lineage (Gerhardt and Betsholtz, 2003) indicating 
that despite their physical variation, this heterogeneous group of cells can still 
carry out a similar function.  
The creation of a successful co-culture is a complex process. Early attempts at 
using co-cultures consisting of calf pulmonary artery endothelial veins, retinal 
fibroblasts and SMCs in fibrin gel to generate nascent vessels in vitro were 
unsuccessful (Nehls et al., 1994). Numerous groups have since used various co-
culture systems for vascularisation (Rouwkema et al., 2009, Unger et al., 2010, 
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Roubelakis et al., 2013). Similar to the debate over EC sources, there is still no 
consensus on the ideal cell source for pericytes. Multipotent stem cells are a 
common choice for use as pericytes due to both their physical and molecular 
properties. Both ASCs and MSCs have been shown to be capable of enhancing 
and stabilising vessel formation by ECs on a number of different substrates both 
in vitro and in vivo (Melero-Martin et al., 2008, Traktuev et al., 2008, Verseijden 
et al., 2010, Merfeld-Clauss et al., 2010, Saleh et al., 2011, Allen et al., 2011, 
Butler and Sefton, 2012, McFadden, 2013). Lin et al. demonstrated that murine 
MSCs derived from bone marrow, adipose, myocardial and skeletal muscle 
sources all behaved in a similar perivascular manner when co-implanted with 
endothelial colony forming cells in Matrigel (Lin et al., 2012).  
Although stem cells clearly have potential for use as pericytes, non-stem cell 
types such as human fibroblasts also offer a promising source (Saito et al., 2003, 
Choong et al., 2006, Chen et al., 2009b). Human fibroblasts have been shown to 
be as effective as bone marrow-derived MSCs at supporting vessel formation by 
endothelial colony-forming cells in a collagen scaffold for use as an engineered 
skin substitute (Athanassopoulos et al., 2012). In our laboratory, rat aortic SMCs 
have also been proven, both in 2D and in 3D, to be capable of stabilising an EC-
generated microcapillary network in a scaffold, in this case a CCS scaffold (Duffy 
et al., 2011). Cell sources for co-culture generated vasculature are also not 
limited to cells directly associated with the vascular system, for example, a co-
culture consisting of human osteoblasts and HDMECs have previously been 
shown to be capable of vascularising a number of scaffolds both in vitro (Unger 
et al., 2007) and in vivo (Unger et al., 2010). The method of action by which HOS 
successfully promote vessel formation by their EC counterpart is poorly 
understood. However, it is theorised that the HOS lay down a bone specific matrix 
that both supports the nascent vessels formed by the HDMECs and stimulates 
host inflammatory cells to promote invasion of the construct by host vessels 
(Ghanaati et al., 2011b). This invasion of host vessels would be induced partly 
by the release of pro-angiogenic cytokines such as platelet-derived growth factor 
(PDGF-BB) and transforming growth factor beta (TGF-β) by platelets from the 
blood which come into contact with the implanted construct and later by 
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macrophages recruited to the site of inflammation (Diegelmann and Evans, 
2004).  
 
Figure 1.7: 2-Photon micrograph demonstrating vessel formation by a delayed addition co-culture 
model consisting co-culture of human MSCs and HUVECs seeded in a CCS scaffold in vitro. 
Nuclei are stained using 4',6-diamidino-2-phenylindole (DAPI). 
Recently, a more complex approach to co-culture-mediated vascularisation has 
emerged that involves a tri-culture of cell types (Levenberg et al., 2005, Caspi et 
al., 2007, Lesman et al., 2011). For example, keratinocytes, fibroblasts and ECs 
were cultured together to generate a functional vasculature network in a collagen 
sponge in vitro, which was then shown to be capable of anastomosis with murine 
host vasculature as indicated by the presence of erythrocytes in the nascent 
vessel network (Tremblay et al., 2005). Levenberg et al. engineered vascularised 
muscle tissue constructs using a tri-culture system composed of myoblasts, 
embryonic fibroblasts and ECs. It was found that constructs pre-vascularised 
using the tri-culture system displayed both increased VEGF protein expression 
and increased vascular density in vitro compared to constructs pre-vascularised 
using only ECs and myoblasts (Levenberg et al., 2005). These studies indicate a 
future role for more complex pre-vascularised constructs in TE. 
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Generating long-lasting vasculature via co-culture/tri-culture may be the most 
viable approach for in vitro vascularisation, as it is not only more physiologically 
accurate, but it has already produced vasculature that has demonstrated stability 
for up to one year post implantation (Koike et al., 2004). However, the complexity 
of these systems may make them difficult to implement. 
Human amniotic fluid-derived stem cells (AFSCs) are a another cell source that 
display great potential for filling an angiogenic niche in TE, whether that is in the 
role of endothelial-like cell or pericyte. As a result, these cells are a major focus 
of this thesis. These cells are covered in detail in the next section. 
1.6 Human amniotic fluid-derived stem cells  
The use of pluripotent stem cell types (cells that possess the ability to form all the 
cells of the body) for tissue repair is an area of TE that shows great potential. 
However, the widespread use of pluripotent stem cells has been somewhat 
impeded due to the controversy surrounding the use of embryonic stem cells 
(ESCs). As ESCs require the destruction of an embryo in order to be harvested, 
research into this area has been hampered greatly due to the ethical problems 
posed by this process. The discovery of the pluripotentiality of AFSCs has 
presented a way for this ethical dilemma to be bypassed.   
AFSCs make up around 1% of the cells found in amniotic fluid and are isolated 
from back-up amniotic fluid samples that are retrieved during routine 
amniocentesis (Fig. 1.7) (De Coppi et al., 2007a). AFSC extractions can be 
performed relatively safely and painlessly using a minimally invasive ultrasound-
guided procedure (Shaw et al., 2011). This retrieved amniotic fluid is used for the 
prenatal genetic diagnosis of disease and chromosomal abnormalities 
(Trounson, 2007, Shaw et al., 2011). These back-up samples would otherwise 
be discarded. Although AFSCs can be isolated using a number of different 
techniques and have no defining marker of their own (Phermthai et al., 2010, 
Klemmt et al., 2011), they are most effectively isolated using immunoselection for 
the multipotent, haemopoietic stem cell surface marker C-kit (CD117) (De Coppi 
et al., 2007a). They are also easier to obtain than ESCs as they pose no obvious 
moral or ethical problems in their extraction and are not subject to the same legal 
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restrictions. AFSCs express OCT3/4 (Prusa et al., 2003) and SSEA-4, common 
markers of the undifferentiated state of ESCs (Carraro et al., 2008). AFSCs have 
been found to be capable of differentiating down lineages from all three germ 
layers, theoretically allowing them to form any tissue type in the body (De Coppi 
et al., 2007a). They have so far been shown to be capable of differentiating down 
the adipogenic, osteogenic, myogenic, chondrogenic, endothelial, neurogenic, 
and hepatic pathways among others (Perin et al., 2007, De Coppi et al., 2007a, 
Carraro et al., 2008, Peister et al., 2008, Zhang et al., 2009, Ghinassi et al., 2014). 
Unlike ESCs, AFSCs do not have the potential to form teratocarcinomas (germ 
cell tumours) when implanted in vivo. This greatly improves their feasibility for 
use in a clinical setting. They also do not display any telomere shortening within 
the first 250 passages, allowing them to be maintained in culture for long periods 
of time (Miranda-Sayago et al., 2011). This is a stark contrast to human MSCs (a 
primary adult stem cell type commonly used for this kind of research) which 
display reduced differentiation potential, attenuated expression of specific 
surface markers and reduction in proliferation after 7 passages (Wagner et al., 
2008).  
 
 
Figure 1.8: The isolation and expansion of AFSCs. Amniotic cells are retrieved from back up 
amniotic fluid samples retrieved during routine amniocentesis. AFSCs are then isolated via 
immunoselection for the hematopoietic stem cell marker C-kit. AFSCs have been shown to be 
capable of differentiating into a number of different lineages from all three germ layers (Trounson, 
2007). 
Similar to MSCs, AFSCs have been shown to have immunomodulatory 
properties. Furthermore, according to Moorefield et al., activated AFSCs released 
significantly higher levels of several cytokines than MSCs and may  possess 
some alternative molecular mechanisms to modulate the immune response 
54 
 
(Moorefield et al., 2011). This ability to modulate the immune system makes 
AFSCs appropriate for use in animal models that are not immunocompromised, 
making them more appropriate for orthopaedic therapeutic implant studies in 
general. The ability to modulate immune response may be due to their 
intermediate stage of development, which lies between that of embryonic and 
adult stem cells (Cananzi et al., 2009). They have also previously been used to 
successfully treat a variety of injuries in a number of animal models, for example, 
in the repair of cryo-injures in a rat bladder (De Coppi et al., 2007b), hyperoxic 
injury in mouse lung epithelial tissue (Carraro et al., 2008) and the transplantation 
of AFSCs significantly decreased the fibrosis formation and progression of 
induced cirrhosis in a mouse model (Zhang et al., 2011a). The versatility and 
regenerative capabilities of these cells has identified them as an ideal stem cell 
source for use in a number of areas of TE. 
The focus for the use of these cells in this thesis is scaffold vascularisation. 
AFSCs have previously been successfully differentiated into functional 
endothelial-like cells using standard endothelial cell growth media supplemented 
with varying concentrations of VEGF. These differentiated endothelial-like cells 
displayed up-regulated expression of endothelial markers such as vWF, eNOS, 
VE-cadherin and VEGFR2 and were capable of displaying EC-like functional 
characteristics such as tubule formation on Matrigel and uptake of ac-LDL (Zhang 
et al., 2009, Benavides et al., 2012). This is an area in which little to no research 
has been carried out and an investigation of the use of endothelial-like cells 
derived from AFSCs to vascularise a scaffold has yet to take place. AFSCs have 
also emerged as a stem cell source suitable for the support and enhancement of 
vascularisation due to their innate similarity to MSCs in terms of protein and gene 
expression patterns despite their primitive origin in amniotic fluid (Roubelakis et 
al., 2007). It has recently been shown that these cells can act as a pericyte and 
can significantly improve vessel formation by endothelial colony forming cells in 
Matrigel plugs implanted in a murine model in comparison to both MSCs and 
human dermal fibroblasts (HDFs). This is thought to be due, in part, to the distinct 
angiogenic growth factor profile produced by AFSCs (Teodelinda et al., 2011, 
Roubelakis et al., 2013). They have been shown to act a reservoir of angiogenic 
factors that could be beneficial to the angiogenic potential of cell-seeded 
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construct implanted in vivo as they could potentially act to recruit host cells to the 
scaffold in order to aid in both vascularisation and stabilisation of the nascent 
vasculature formed. The secretome of AFSCs seeded in Matrigel and implanted 
in the ischemic hind-limb murine model has been shown to be capable of inducing 
neo-arteriogenesis, minimising capillary loss and tissue necrosis in the affected 
limb (Teodelinda et al., 2011), demonstrating the importance of these secreted 
factors to development of nascent vascular networks. In this thesis, the 
angiogenic potential of AFSCs as both an endothelial-like cell and a pericyte will 
be investigated. 
1.7 Strategies to enhance cell-based approaches to vascularisation  
The process of vessel formation and maturation occurs in a spatial and temporal 
manner that involves a number of pathways that control the proliferation, 
migration and morphogenesis of ECs (Jain, 2003, Holderfield and Hughes, 2008). 
As previously stated, EC-pericyte interactions are of critical importance to the 
growth and maturation of the nascent microcapillaries that sprout from these ECs. 
There are a range of bioactive factors associated with these EC-pericyte 
interactions that are frequently utilised to enhance the in vitro vascularisation of 
TE constructs. Two critical factors associated with vascular development are 
VEGF and PDGF-BB, (Evensen et al., 2009, Caplan and Correa, 2011).  
VEGF is a highly potent pro-angiogenic growth factor that is critical to the 
formation of vasculature. VEGF has been shown to affect EC behaviour, 
morphology and survival (Holderfield and Hughes, 2008, Evensen et al., 2009, 
Lee and Niklason, 2010a). Evensen et al. has previously demonstrated that 
knockdown of VEGF expression in smooth muscle cells via RNA interference 
prevented vessel formation by ECs. The effect of this knockdown unaffected by 
the supplementation of recombinant VEGF, thus highlighting the importance for 
pericyte-derived VEGF in driving blood vessel maturation (Evensen et al., 2009). 
Stem cells have been shown to generate large quantities of VEGF to modulate 
EC behaviour and influence vascular assembly (Kaigler et al., 2003, Kasper et 
al., 2007). As a result of its potency, VEGF is an often targeted factor for delivery 
for the enhancement of vessel formation both in vitro and in vivo. Analysis of 
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VEGF concentrations during pre-vascularisation is an important focus of this 
thesis. 
PDGF-BB is also of critical importance to vessel formation, and is capable of 
binding to all PDGF receptor isotypes (Caplan and Correa, 2011). PDGF-BB is a 
potent chemoattractant and mitogen that is secreted by ECs to influence the 
migration of pericytes to the site of vessel assembly (Lee and Niklason, 2010a). 
The PDGF-BB/PDGFR-β pathway is the primary pathway involved in the 
recruitment of pericytes, the movement of these cells around nascent vessels 
and the resulting stabilisation and maturation of this vasculature (Armulik et al., 
2005b, Gaengel et al., 2009). The mitogenic effect of PDGF-BB has previously 
been demonstrated, for example, Au et al. found that the presence of HUVECs 
increased MSC migration in a transwell migration assay. PDGF-BB involvement 
was confirmed by the drug-induced inhibition of its release, which blocked MSC 
migration (Au et al., 2008). The controlled delivery of VEGF, followed by PDGF-
BB delivery, has been previously implemented in the production of large,  mature 
vessels in a poly(lactide-co-glycolide) (PLG) scaffold in an ischemic hindlimb 
mouse model in vivo (Chen et al., 2007). Analysis of PDGF-BB concentration in 
the process of pre-vascularisation is also an important focus of this thesis. 
 
A target protein which has recently been found to demonstrate potential in the 
promotion vessel formation in vitro is sonic hedgehog (Shh). Shh is a morphogen 
that is known to be a  critical regulator of early skeletal and vascular development 
in the embryo and has also been found to be reactivated during adult repair 
processes (Fuchs et al., 2012). In co-cultures of OECs and primary human 
osteoblasts, Shh has been shown to increase expression of pro-angiogenic 
genes at an earlier stage of culture than VEGF. It was also shown to induce the 
p-regulation of a number of factors associates with the stabilisation of vessels 
e.g. αSMA, PDGF-BB and TGF-β (Dohle et al., 2010, Dohle et al., 2011). The 
role of Shh in vessel stabilisation has been further suggested by its implication in 
the PDGF-BB mediated recruitment of smooth muscle cells (Yao et al., 2014). 
A common method of manipulating growth factor secretion in order to enhance 
vascularisation is the use of a cell co-culture system (Section 1.5.4). This system 
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exploits the naturally occurring in vivo cross-talk between ECs and their pericytes 
that is required for functional vessel formation (Villars et al., 2000, Wakui et al., 
2006, von Tell et al., 2006, Gaengel et al., 2009, Correia et al., 2011, Kirkpatrick 
et al., 2011b). Another commonly used method involves the controlled release of 
bioactive factors to enhance vascularisation. In many cases it has been shown 
that delivery of single growth factors is not sufficient and that delivery of multiple 
growth factors produces a faster and longer-lasting repair response (Chen et al., 
2007, Kempen et al., 2009, Saif et al., 2010, Geuze et al., 2011, Xiao et al., 2011, 
Lee et al., 2011). Such methods include growth factor delivery via nano or 
microparticles (Chung et al., 2010, Lim et al., 2011, des Rieux et al., 2011), 
covalent immobilisation of bioactive factors onto scaffolds (Phelps et al., 2010, 
Singh et al., 2011), direct incorporation of bioactive factors into scaffolds (Chen 
et al., 2007) or over-expression of key pro-angiogenic growth factors via gene 
therapy (Duffy et al., 2010).  
The mechanism and timing of growth factor delivery to cells is also important for 
the enhancement of vascularisation. Controlled delivery systems aim to sustain 
the bioactivity of therapeutic molecules in a steady and long-term fashion in order 
to sufficiently induce and accelerate tissue repair (Briganti et al., 2009, Chen et 
al., 2009b, Phelps et al., 2010, Karal-Yilmaz et al., 2011). Hydrogels are 
commonly used for the co-delivery of cells and bioactive factors in order to 
promote vascularisation. Hydrogels produced from natural biomaterials such as 
such as alginate (Kolambkar et al., 2010, Kolambkar et al., 2011), HyA and 
chitosan (Hastings et al., 2012, Raftery et al., 2013) have all proven highly 
successful in the delivery of both genes and growth factors for tissue repair. The 
use of nanoparticles and microparticles for growth factors delivery is also an area 
of growing interest due to the fact that it allows for controllable release patterns. 
The advantages of these materials are that they can easily diffuse into tissues 
and can be taken up by cells to exert the desired effects (Karal-Yilmaz et al., 
2011). In recent years, TE strategies have attempted to incorporate these 
particles into biomaterials in order to influence cell behaviour both in vitro and in 
vivo (Jin et al., 2008). Direct covalent immobilisation of growth factors onto 
scaffolds has also proved successful both in vitro and in vivo (Steffens et al., 
2004, Shen et al., 2008, Chiu and Radisic, 2010). For example, Chiu and Radisic 
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demonstrated that ECs seeded onto collagen scaffolds with covalently 
immobilised VEGF and Angiopoietin-1 displayed increased proliferation and 
improved tubule formation in vitro compared to scaffolds without these 
incorporated growth factors (Chiu and Radisic, 2010).  
Gene therapy is another promising approach to enhance vascularisation. An ideal 
gene delivery system requires a sustained but transient expression of a 
transferred piece of genetic material (or transgene) to exert the desired effect and 
induce rapid tissue repair (Melly et al., 2012). Such approaches may also be 
utilised to enhance vessel formation by cells in vitro and as such, cell-based gene 
therapy can be easily applied for the purposes of vascularisation. This involves 
the transfection of cells to over-express angiogenic factors in order to target host 
cells and enhance vascularisation (Peterson et al., 2005, Jabbarzadeh et al., 
2008, Duffy et al., 2010). Duffy et al. demonstrated that the over-expression of 
Ephrin B2 in MSCs enhanced their pro-angiogenic capacity as they were shown 
to adopt an early EC phenotype under EC culture conditions with increasing 
expression of vWF and VEGFR2. These EC-like cells developed an increased 
ability to form vessel-like structures, produce VEGF and incorporate into newly 
formed EC structures (Duffy et al., 2010). This technique may hold potential for 
use in vivo as transfected cells could target the surrounding host cells to promote 
the invasion of host vessel in the implanted construct, thus enhancing 
vascularisation. Despite the promise presented by gene therapy approaches, 
issues remain with gene transfer efficacy, safety and long-term pro-angiogenic 
expression in vivo. Therefore, more research is required in this area. 
Another approach to enhance vascularisation in vitro involves replicating a more 
physiologically accurate microenvironment in order to enhance the formation of 
nascent vasculature in a TE construct. Bioreactor systems provide 
haemodynamic forces that mimic the shear stress that vessels are likely to 
encounter in vivo and have previously been implemented for the purpose of 
enhancing vascularisation. Fluid flow has been shown to have beneficial effects 
on the endothelial differentiation of stem cells (Yamamoto et al., 2005, Wu et al., 
2008), for example, shear stress significantly induced gene and protein 
expression of CD31, vWF, and VE-cadherin in embryonic stems cells relative to 
static controls (Wang et al., 2005b). Exposing TE constructs to shear stress also 
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been shown to positively promote vessel formation in vitro (Ng et al., 2004, Helm 
et al., 2007, Chang et al., 2010), for example Lee et al. used a low flow rate to 
enhance vascular network formation by a co-culture of rat aortic ECs and MSCs 
in a collagen gel. Specifically, shear stress resulted in increased cell proliferation 
and the formation of denser, wider and more prominent vascular networks in the 
gel when compared to a static control (Lee and Niklason, 2010b).  
Another common method of replicating the natural environment in vivo is the use 
of hypoxia and the manipulation of the Hypoxia Inducible Factor (HIF-1) pathway, 
which is also a major focus of this thesis.  
1.8 Hypoxia and the HIF-1 pathway 
1.8.1 Overview 
Hypoxia represents a potentially beneficial stimulus for the enhancement of both 
angiogenesis and vascularisation. Hypoxia is characterised as a state of low O2 
that leads to inadequate supply to the cells and tissues of the body. Hypoxia and 
the HIF-1 pathway have previously been associated with improved stem cell 
survival and metabolic enhancement (Grayson et al., 2006). It has been found to 
be vital in neovascularisation of ischemic tissues and the induction of 
angiogenesis in the healing of hypoxic wounds (Shweiki et al., 1992). The 
transcription of a number of angiogenic genes can be initiated and up-regulated 
using the HIF-1 pathway, for example, angiopoietin 2, its receptor TIE-2 and most 
commonly, VEGF (Namiki et al., 1995, Forsythe et al., 1996, Willam et al., 2000). 
As discussed in Section 1.7, up-regulated angiogenic growth factors are known 
to have an extremely beneficial effect on vascularisation. Hypoxia also represents 
a more physiologically accurate microenvironment for the stem cells of the body 
(Ivanovic, 2009), for example, both haemopoietic cells of the bone marrow and 
fetal membrane cells (both commonly used stem cell sources for vascularisation) 
experience O2 conditions in vivo that are much lower than what is typically 
encountered in standard cell culture conditions (Chow et al., 2001, Al-Asmakh et 
al., 2007).  
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1.8.2 The HIF-1 pathway 
The heterodimeric transcription factor known as HIF-1 acts as the central 
regulator of hypoxia-mediated gene expression (Fig. 1. 8) (Wang et al., 1995). 
HIF-1 is composed of a constitutively expressed β-subunit (aryl hydrocarbon 
receptor nuclear translocator or ARNT) and an O2-regulated α-subunit. As a result 
of this O2-mediated regulation, HIF-1α acts as the key to the O2 dependant nature 
of the pathway. This reliance on O2 is due to the fact that HIF-1α contains an 
oxygen-dependent degradation domain (ODDD). The ODDD is hydroxylated at 
conserved proline residues 402 and 564 by prolyl-hydroxylase enzymes (PHDs) 
under normal O2 (normoxic) conditions. PHDs are iron (Fe(II))/2-oxoglutarate-
dependent dioxygenases. This means that they require both O2 and iron in order 
to successfully hydroxylate HIF-1α and as such, remain inactive in hypoxic 
conditions (Schofield and Zhang, 1999, Berra et al., 2003). Fe(II) is necessary for 
PHD-mediated hydroxylation as it acts as catalytic cofactor (Ganz and Nemeth, 
2012). Hydroxylation by PHDs facilitates the ubiquitination of HIF-1α by the Von-
Hippel-Landau (VHL) ligase complex, which marks it for rapid proteasomal 
degradation (Huang et al., 1998, Liu and Semenza, 2007). In the case of PHD 
deactivation, HIF-1α will accumulate in the cytoplasm and translocate to the 
nucleus, where it dimerises with HIF-1β to form an active HIF-1 transcription 
complex. This complex then binds to the hypoxia response elements (HREs) 
within the promoter regions of target genes with the aid of the p300/CREB-binding 
protein family of coactivators (Ebert and Bunn, 1998). This leads to the up-
regulation of proteins associated with the HIF-1 pathway.  
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Figure 1.9: HIF-1α regulation by proline hydroxylation. In normoxia, HIF-1α is hydroxylated by 
proline hydroxylases and undergoes degradation. Under hypoxic conditions, proline hydroxylation 
is inhibited. This causes an increase in HIF-1α, which then translocates to the nucleus. There, 
HIF-1α dimerises with HIF-1β and binds to the HRE causing the up-regulation of various 
metabolic and angiogenic genes.  
1.8.3 Methods of HIF-1 pathway activation 
A number of different methods can be used to activate the HIF-1 pathway in a 
target cell for the purpose of enhancing angiogenesis and vascularisation, each 
one with its own specific set of advantages and disadvantages. The most 
commonly used approach is one that most closely mimics physiological hypoxia: 
the manipulation of environmental O2 levels using a specialised hypoxia 
chamber. A number of research groups have used varying hypoxic levels of 
environmental O2 from 5% to as low as 1% to enhance angiogenesis (Annabi et 
al., 2003, Grayson et al., 2006, Al-Najar et al., 2012). Hypoxic culture has been 
shown to significantly improve the plasticity/potency of human MSCs (Grayson et 
al., 2006) and has also been associated with an increase in the angiogenic 
properties of both aged adipose derived stem cells (Efimenko et al., 2011) and 
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murine bone-marrow-derived stromal cells (Annabi et al., 2003), showing the 
potential of using hypoxia to prime stem cells for use in vascularisation. 
Another method has focused on the exploitation of cell-induced physiological 
hypoxia to generate angiogenic growth factors within a construct (Hadjipanayi et 
al., 2010). One such method involved the use of a rolled-collagen gel that induces 
hypoxia via high density cell seeding which is used to create a depot for the 
release of the angiogenic growth factors that the cells subsequently produce. This 
hypoxic depot was capable of successfully enhancing the vascularisation of 3D 
spiral acellular collagen construct within 7 days of implantation in New Zealand 
rabbit model (Hadjipanayi et al., 2011). 
Pharmacological induction of HIF-1α is also a common method of activating the 
HIF-1 pathway. PHD inhibitors such as desferrioxamine (DFO) and cobalt 
chloride (CoCl2) are commonly used to over-express HIF-1α, leading to HIF-1 
pathway activation and angiogenic factor secretion (Potier et al., 2008, Shen et 
al., 2009, Fan et al., 2010). These “hypoxia-mimics” sequester FE(II) (a 
necessary co-factor for the HIF-1 pathway (Schofield and Zhang, 1999)) thus 
preventing inactivation of HIF-1α. This leads to the formation of the HIF-1 
transcription complex. Hypoxia-mimics have been shown to have beneficial 
effects on angiogenesis in a similar manner to hypoxia. DFO treatment has been 
shown to restore blood flow to ischemic tissues by promoting EC proliferation and 
reducing oxidative stress (Ikeda et al., 2011) and direct injection of DFO at a 
murine femur fracture site lead to a significant increase in both vessel number 
and volume of the developing vasculature in the resulting callus (Shen et al., 
2009). Similarly, CoCl2 pre-treated MSCs seeded on a collagen-based scaffold 
enhanced the vascularisation of an engineered periosteal model implanted in 
both a skull defect and subcutaneous murine model (Fan et al., 2010). However, 
despite these potential benefits that hypoxia-mimics offer, they also present their 
own unique set of disadvantages when compared to environmental O2 
manipulation; one of which is the requirement for continued application of an 
effective dosage to maintain HIF-1 activation. This dosage approach could 
potentially have a detrimental effect on cell viability due to toxicity. It has been 
found that high levels of CoCl2 and DFO can be toxic to certain cell types and can 
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negatively affect both viability and proliferation (Ren et al., 2006, Karovic et al., 
2007, Milosevic et al., 2009). There are also hypoxia mimics that do not rely on 
FE(II) sequestration for HIF-1 activation, for example, Insulin is capable of 
stimulating HIF-1α via the mitogen-activated protein kinase (MAPK) pathways 
necessary for expression of angiogenic genes in human vascular SMCs 
(Doronzo et al., 2004, Doronzo et al., 2006). Although each method of HIF-1 
activation has its own merits and drawbacks, the ideal artificial inducer of the HIF-
1 pathway is still debatable. 
1.9 The role of tissue engineering in cartilage repair 
The final chapter in this thesis focuses on the use of AFSCs in combination with 
collagen-HyA scaffolds as a TE solution for cartilage repair.  Articular cartilage is 
the highly specialised connective tissue that covers the diarthrodial joints. Adult 
articular cartilage is composed primarily of a dense extracellular matrix of 
collagen, proteoglycans, water and non-collagen proteins that is populated by 
chondrocytes (Bhosale and Richardson, 2008, Goldring and Marcu, 2009). The 
principal function of articular cartilage is to allow for unimpeded, low-friction 
movement whilst being able to bear high tensile forces and resist repetitive 
compressive stress and deformation throughout an individual’s lifetime. (Sophia 
Fox et al., 2009, Nelson et al., 2010). 
Articular cartilage is unable to heal even the most minor injuries due to its poor 
regenerative capacity. This is partly due to the avascular, aneural and alymphatic 
nature of the tissue and the poor migratory capacity of chondrocytes (Bora and 
Miller, 1987, Nelson et al., 2010). Defects in the tissue can be caused by both 
disease and trauma which can manifest in three main forms: superficial matrix 
disruption, partial thickness defects and full thickness defects. Superficial matrix 
disruption arises from blunt trauma whereby the ECM is damaged but viable 
chondrocytes aggregate into clusters and are still capable of synthesising new 
matrix (Caplan et al., 1997, Hunziker, 1999). However, the soft superficial zone 
is not only vulnerable to immediate structural damage but there is a predisposition 
of this damaged articular surface to further softening with an increased risk of 
developing secondary osteoarthritis (Rolauffs et al., 2010). Partial thickness 
defects are mechanical disruptions to the articular cartilage but the damage does 
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not extend into the underlying subchondral bone (Buckwalter, 2002). Unlike 
superficial matrix disruption, these defects are unable to self-repair (Shapiro et 
al., 1993, Hunziker and Rosenberg, 1996). Full thickness defects are similar to 
partial thickness injuries but the damage penetrates deep into the subchondral 
bone (Temenoff and Mikos, 2000). This disruption of subchondral bone 
stimulates cartilage and bone repair due to access to the cells of the bone 
marrow, but it rarely restores an articular surface that duplicates the biologic and 
mechanical properties of normal articular cartilage, and eventually degrades over 
a period of months (Buckwalter, 1998, Buckwalter, 2002). 
Osteoarthritis is the most common form of degenerative joint disease and is 
characterised by focal and progressive loss of hyaline cartilage eventually leading 
to bone sclerosis. In the USA alone, approximately 12% of adults over the age 
25 years were diagnosed with symptoms of osteoarthritis in 2008 (Lawrence et 
al., 2008) and it is predicted that one in four people may develop symptomatic 
osteoarthritis of the hip by age 85 (Murphy et al., 2010b).  
There are a number of conventional clinical treatments available which attempt 
cartilage regeneration – all of which have associated drawbacks. These include 
autologous chondrocyte implantation (ACI), microfracture and mosaicplasty. ACI 
relies on the use a patient’s own chondrocytes for the treatment of articular 
cartilage defects. A small portion of cartilage is harvested from a non-weight 
bearing part of the patient’s knee. Chondrocytes are harvested from this cartilage 
and subsequently expanded in vitro until a sufficient cell density is achieved. 
These cells are then implanted into the defect site. The defect site is exposed 
and debrided so that the defect is surrounded by circumferential vertical walls of 
normal articular cartilage (Detterline et al., 2005). A periosteal flap that is 
harvested from the ipsilateral tibial shaft is used to retain the cells within the 
defect and is either sewn in place or sealed with fibrin glue. However, the use of 
a periosteal flap may result in donor site morbidity and the flap itself is prone to 
hypertrophy leading to localised pain (Nehrer et al., 1999). Microfracture is a 
drilling technique in which a bed of small holes are made in the subchondral bone 
to create bleeding within the bone, allowing cells from the bone marrow to enter 
the avascular cartilage defect, differentiate into fibrocartilage producing cells, and 
fill the defect with fibrocartilage (Detterline et al., 2005). Microfracture is a 
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palliative technique and is therefore only used with patients with painful conditions 
with the aim of bringing symptomatic relief (Hunziker et al., 2001). Mosaicplasty 
involves obtaining small osteochondral cylindrical sections of autologous or 
allogeneic graft tissue from non-weight-bearing areas of the articular cartilage 
and transporting them to the prepared defect site. The graft plugs are 
transplanted by press-fit, along a convergent plane in recipient sockets the same 
depth. This process of harvesting, drilling and insertion is repeated until the region 
has been covered (Robert, 2011). Drawbacks associated with this procedure 
include donor site morbidity, chondrocyte death due to the harvesting procedure 
as well as mismatch of stiffness between recipient and transplant tissue causing 
abrasion on opposing surfaces (Beris et al., 2005).  
All of these procedures often fail to generate fully functional hyaline-like articular 
cartilage growth in the affected area as they encourage the growth of 
fibrocartilage within the defects. As a result, treatment tends to focus heavily of 
the management of symptoms rather than the long-term restoration of cartilage 
in the defect. Therefore, an alternative approach is required.  
TE has begun to show promise in the provision of a solution for cartilage repair 
(Cascio and Sharma, 2008, Getgood et al., 2009, Matsiko et al., 2013). The TE 
approach to cartilage repair typically employs the concept of the “TE triad”, 
(previously discussed in Section 1.1) which involves a scaffold that provides 
structure, cells that facilitate tissue formation and growth factors/ biophysical 
stimuli to direct the growth and differentiation of the cells. Therefore, this 
approach generally involves the use of scaffolds seeded with either chondrocytes 
or stem cells that are then implanted in a defect site in order to induce cartilage 
regeneration. Chondrocytes are the primary cell type in articular cartilage and 
have been previously utilised in cartilage TE for the treatment of defects, for 
example, Pereira et al. developed an injectable hydrogel seeded with human 
articular chondrocytes that was capable of regenerating articular cartilage 
damaged by an experimentally-induced lesion (Pereira et al., 2009). Multi- and 
pluripotent stem cells, which can be derived from a range of sources in the body, 
have also shown potential for use in cartilage repair due to their ability to 
differentiate down a chondrogenic lineage. For example, Cui et al. used 
chondrogenically differentiated ASCs on a fibrous PGA scaffold to generate 
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cartilage within a full thickness articular cartilage defect (Cui et al., 2009). AFSCs 
have also been previously differentiated down a chondrogenic lineage in vitro and 
therefore may present a promising new cell type for cartilage repair (Kolambkar 
et al., 2007, Rodrigues et al., 2012). Investigating their potential for cartilage 
repair is the focus of Chapter 5 of this thesis.  
As with angiogenesis, hypoxia is known to have potential to enhance 
chondrogenesis. Hypoxia and the HIF-1α pathway have been previously 
implicated in the development of cartilage (Schipani, 2005, Amarilio et al., 2007) 
and hypoxia also represents a physiologically accurate microenvironment for 
articular chondrocytes, which reside in a naturally hypoxic environment in the 
body where O2 concentration generally varies from about 1-6%  (Silver, 1975, Al-
Asmakh et al., 2007, Pfander and Gelse, 2007, Fermor et al., 2007). A number 
of studies have reported that the use of hypoxic conditions during chondrogenic 
differentiation can significantly enhance this process (Scherer et al., 2004, Robins 
et al., 2005, Kanichai et al., 2008, Krinner et al., 2009, Lee et al., 2013b), for 
example, it has been shown that hypoxic conditions for 14 days increased 
cartilage-like matrix accumulation and enhanced gene expression of 
chondrogenic markers (such as SOX9) in aggregates of stem cells derived from 
the intrapatellar fat pad (Khan et al., 2007). Hypoxic culture has previously been 
shown to delay hypertrophy in both stem cells exposed to chondrogenic stimuli 
(Gawlitta et al., 2012b, Lee et al., 2013b, Zhu et al., 2014) and chondrocytes 
cultured in vitro (Lafont et al., 2008, Markway et al., 2013). Hypertrophy involves 
terminal differentiation of chondrocytes to a more round, less proliferative 
phenotype, followed by cartilage matrix calcification, vascular invasion, and 
ossification (Bruckner et al., 1989, Pacifici et al., 1990, Goldring et al., 2006) and 
is an undesired outcome for a construct created for cartilage repair. Hypoxia and 
the HIF-1 pathway have been implicated the maintenance of normal chondrocyte 
function in vivo (Schipani, 2005, Amarilio et al., 2007, Provot et al., 2007). Overall, 
the use of hypoxic culture represents a potential means to improve current TE 
approaches to cartilage repair. 
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1.10 Thesis objectives 
The overall aim of the research presented in this thesis was to investigate the 
angiogenic potential of amniotic fluid-derived stem cells (AFSCs) in order to 
develop a novel co-culture system to engineer, in vitro, an inherent network of 
vessel-like structures within 3D, highly porous collagen-composite scaffolds. In 
order to potentially enhance this vessel-like structure formation, the effect of 
hypoxic culture on this co-culture system was also investigated. The final part of 
the research presented in this thesis aimed to investigate the chondrogenic 
potential of AFSCs, with and without hypoxia, with the aim of creating a novel 
construct consisting of AFSCs and a collagen-hyaluronic acid (CHyA) scaffold for 
use in cartilage tissue engineering (TE).  
The specific objectives of this thesis were: 
1. To determine if culture in either intermittent or continuous hypoxia could 
enhance the ability of AFSCs to differentiate down an endothelial lineage 
and enhance their potential for use in TE applications (Chapter 2). 
 
2. To investigate whether: 
a. An AFSC-human umbilical vein endothelial cell (HUVEC) co-culture 
could be used to pre-vascularise a collagen-chondroitin sulphate scaffold, 
with AFSCs acting as the pericyte source.  
b. Hypoxic culture could enhance vessel-like structure formation by this 
HUVEC- AFSC co-culture in order to elucidate the optimal O2 culture 
condition for pre-vascularisation (Chapter 3). 
 
3. To investigate the ability of the AFSC-HUVEC co-culture developed in 
Chapter 3 to pre-vascularise two different collagen-based scaffolds; 
namely, a collagen-hydroxyapatite (CHA) and CHyA scaffold. The effect 
of scaffold composition on the development of vessel-like structures was 
also assessed (Chapter 4).  
 
4. To determine the potential of AFSCs for use in cartilage TE by promoting 
differentiation down a chondrogenic lineage within a highly porous CHyA 
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scaffold, In addition, the potential of pre-culture in hypoxia to enhance this 
process was also assessed (Chapter 5). 
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Chapter 2: The effect of hypoxic culture on the 
endothelial differentiation of human amniotic 
fluid-derived stem cells 
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2.1 Introduction 
The successful post-implantation engraftment of tissue engineering (TE) 
constructs relies on the rapid formation of stable and functional vasculature 
(Laschke et al., 2006, Unger et al., 2010), especially those used for bone repair. 
If the formation of vasculature does not occur, it can result in core degradation 
and necrosis of the implant (Ko et al., 2007). Core degradation is a major concern 
for non-vascularised constructs implanted in vivo, as cells will deposit matrix 
around the periphery of the construct, reducing perfusion of oxygen (O2) and 
nutrients throughout. Therapeutic strategies to enhance vascularisation within TE 
constructs have involved a number of different approaches, including the delivery 
of growth factors to induce and enhance angiogenesis (Ehrbar et al., 2004, 
Epstein, 2011, Murphy et al., 2014) and the use of gene-activated matrices to 
manipulate gene expression to enhance vessel development (Kyriakides et al., 
2001, Geiger et al., 2005, Duffy et al., 2010). These strategies demonstrate 
varying degrees of success due to the fact that they are not target-specific and 
can lead to ectopic bone formation. An alternative, cell-based approach, involving 
the engineering of a vascular network within a TE construct, in vitro, prior to 
implantation has emerged as a potential solution to the issue of implant failure as 
a result of core degradation. This pre-vascularisation of constructs has been 
recently identified as a potential approach in the enhancement of engraftment 
post-implantation (Unger et al., 2010, Duffy et al., 2011, McFadden, 2013, 
Roubelakis et al., 2013).  
Primary endothelial cells are the most common cell type used in pre-
vascularisation of scaffolds due to their role in the formation and homeostasis of 
the vascular system. However, there is still no consensus for the ideal source of 
primary endothelial cells (Finkenzeller et al., 2009). Primary endothelial cells must 
be used at an early passage number as they begin to lose angiogenic potential 
and develop an increase in apoptotic tendency over time (Prasad Chennazhy and 
Krishnan, 2005, Prigozhina et al., 2011). However, the use of multi- and 
pluripotent stem cell types for the generation of endothelial-like cells is an area of 
TE that shows great potential for use in the pre-vascularisation of constructs 
(Levenberg et al., 2002, Oswald et al., 2004, Doan et al., 2014). Amniotic fluid-
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derived stem cells (AFSCs) are a cell source that has attracted recent attention 
due to their pluripotentiality (De Coppi et al., 2007a). AFSCs have previously 
shown angiogenic potential as they have been successfully differentiated into 
functional endothelial-like cells (Zhang et al., 2009, Benavides et al., 2012). They 
do not display any telomere shortening within the first 250 passages, allowing 
them to be maintained in culture for long periods of time (Miranda-Sayago et al., 
2011) which, along with their easy isolation, culture and maintenance (Shaw et 
al., 2011), potentially makes them an alternative cell source to primary endothelial 
cells. Therefore, the ability of AFSCs to undergo endothelial differentiation will be 
assessed in this study. 
In stem cell biology, there is a growing appreciation for the use of external stimuli 
to replicate biologically relevant culture conditions. Hypoxia and the associated 
HIF-1 pathway have been implicated in the induction of angiogenesis in a number 
of biological processes, including bone development (Liao and Johnson, 2007, 
Portal-Nunez et al., 2012). The early development of mammalian embryos takes 
place in hypoxic environments (Harvey, 2007) and deficiency of HIF-1α in 
knockout mice embryos has been shown to result in lethal disruptions to cardiac 
and vascular development (Iyer et al., 1998, Kotch et al., 1999). Upregulated HIF-
1α, however, has shown potential in the enhancement of endothelial 
differentiation in a number of stem cell types. For example, it been shown to 
restore the gene expression of pro-angiogenic factors in aged adipose derived 
stem cells (Efimenko et al., 2011) and to enhance the endothelial differentiation 
of both embryonic stem cells and CD133 positive human bone marrow cells 
(Prado-Lopez et al., 2010, Ong et al., 2010, Kusuma et al., 2014). The angiogenic 
growth factor VEGF is also known to be a downstream target of the HIF-1 
pathway (Namiki et al., 1995, Liu et al., 1995, Forsythe et al., 1996). For these 
reasons, in this study, hypoxia was chosen as a stimulus to direct endothelial 
differentiation of AFSCs.  
Two forms of exposure to hypoxia were utilised in this study: intermittent and 
continuous. Continuous hypoxia has previously been shown to negatively affect 
the proliferation of endothelial cells (Fasanaro et al., 2008, Decaris et al., 2009, 
Ulyatt et al., 2011). Therefore, intermittent hypoxia was used as an alternative to 
continuous hypoxia in order to investigate whether minimising hypoxic exposure 
72 
 
to shorter periods of time could still have a positive effect on endothelial 
differentiation. The use of intermittent hypoxia in stem cell differentiation has not 
been previously investigated and therefore represents a novel method of applying 
a hypoxic stimulus.  
In this study, it was hypothesised that culture in hypoxic conditions could enhance 
the endothelial differentiation of AFSCs to produce an endothelial-like cell 
suitable for use in pre-vascularisation. To date, little to no research has been 
carried out investigating the use of endothelial-like cells derived from AFSCs to 
pre-vascularise a TE biomaterial. With this in mind, the objective of this study was 
to investigate whether culture in in either intermittent or continuous hypoxia could 
enhance the ability of AFSCs to differentiate down an endothelial lineage and 
enhance their potential for use in TE applications. HUVECs were used as a 
positive control in order to allow for the assessment of the endothelial potential of 
the AFSCS. 
2.2 Methods 
2.2.1 Cell culture 
All cell culture work was carried out under sterile conditions in a laminar flow hood 
(SterilGard 111, MSC, Ireland). All cells were maintained at 37°C in a 5% CO2 
atmosphere in an incubator. 
Culture of AFSCs 
AFSCs were obtained from Professor Shay Soker’s group, Wake Forest 
University, North Carolina. The AFSCs had previously been isolated from pooled-
donor back up amniocentesis samples using magnetic-activated cell sorting 
(MACS) separation prior to their delivery. Cells were isolated on the basis of 
expression for C-kit (CD117) (De Coppi et al., 2007a). AFSCs were expanded in 
basic amniotic fluid cell (BAFC) growth media, which consisted of α-MEM 
medium (Invitrogen, California, USA) containing 15% embryonic stem cell 
qualified-fetal bovine serum (ES-FBS) (Invitrogen, California, USA), 1% L-
glutamine (Sigma-Aldrich, Arklow, Ireland), 2% penicillin/streptomycin (PenStrep) 
(Invitrogen, California, USA) and was supplemented with 18% Chang B and 2% 
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Chang C (Irvine Scientific, California, USA). Upon reaching 70% confluency, cells 
were washed using phosphate buffered saline (PBS) (Sigma-Aldrich, Arklow, 
Ireland) and detached using 0.25% trypsin ethylenediaminetetraacetic acid 
(EDTA) (Sigma-Aldrich, Arklow, Ireland). The cells were centrifuged at 1200 rpm 
for 5 min at 21°C. Cell pellet was then resuspended in 1 mL of fresh media and 
10 µL of the suspension was added to a haemocytometer in order to perform a 
cell count.  Cells were plated at a density of 3.5x103/cm2. All AFSCs used during 
the study were used prior to passage 25.  
Induction of endothelial differentiation of AFSCs 
In order to facilitate endothelial differentiation, AFSCs were cultured in 
EndoGro™- VEGF complete media supplemented with 50 ng/mL recombinant 
VEGF-165 (R&D systems, Oxfordshire, UK), 5 ng/mL human fibroblast growth 
factor-b, 5 ng/mL epidermal growth factor, 15 ng/mL insulin-like growth factor-1, 
1 µg/mL hydrocortisone hemisuccinate, 0.75 U/mL heparin sulphate, 50 µg/mL 
ascorbic acid, 1% L-glutamine and 2% fetal bovine serum (FBS) (Millipore, 
Massachusetts, USA). Media was changed every 3 days. AFSCs cultured in 
growth media were used as a negative control. 
AFSC hypoxic culture regime 
In order to assess the effect of hypoxia on endothelial differentiation, AFSCs were 
cultured in three O2 conditions: normoxia, intermittent hypoxia and continuous 
hypoxia (Table 2.1). 
 AFSCs cultured in normoxia were maintained in a standard incubator 
(20% O2, 5% CO2) at 37°C for the duration of the 14 day culture period.  
 AFSCs cultured in intermittent hypoxia were maintained in an 856-
HYPO/EXP model hypoxia chamber (Plas Labs, MI, USA) (Fig. 2.1) at 2% 
O2 (5% CO2) for 8 h every day. For the remaining 16 h, the cells were 
maintained in a standard incubator at 20% O2. 
 AFSCs cultured in continuous hypoxia were maintained in a hypoxia 
chamber at 2% O2 and 5% CO2 for the full 14 day culture period.  
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AFSCs were assessed for markers of endothelial differentiation and endothelial 
functionality at day 7 and 14.   
 
Table 2.1: Summary of culture conditions. 
Normoxia 20% O2 for 14 days 
Intermittent hypoxia 2% O2 for 8 h, followed by 20% O2 for 
16 h per day, for 14 days in total 
Continuous hypoxia 2% O2 for 14 days 
 
 
Figure 2.1: An 856-HYPO/EXP model hypoxia chamber in use. Samples are inserted through a 
transfer box on the side of the chamber which is subsequently deoxygenated and depressurised 
using a vacuum pump. The chamber is then pressurised and samples are then placed in the main 
chamber, in which O2 and CO2 levels are adjusted using nitrogen that is pumped through a valve 
in the back of the chamber and distributed using an internal circulation fan. O2 and CO2 levels are 
monitored using an electrochemical O2 sensor (0-25%) and infrared CO2 sensor (0-20%) located 
internally on the back wall of the chamber. Samples are maintained at identical temperature and 
humidity levels in both the hypoxia chamber and incubator in order to ensure that the only variable 
between groups is O2 level. 
Culture of human umbilical vein endothelial cells (HUVECs) 
HUVECs were used as a positive control to allow assessment of the endothelial 
potential of the AFSCS. Pooled-donor HUVECs were purchased from Lonza 
(Berkshire, UK) and cultured in EndoGro™ media supplemented with 5 ng/mL of 
VEGF (Millipore, Massachusetts, USA). Media was replaced every 3 days and 
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the cells were cultured until 90% confluency. When confluency was reached, the 
cells were washed using PBS and detached using 0.25% trypsin EDTA. HUVECs 
were split at a ratio of 1:4. All HUVECs in this experiment were used prior to 
passage 9.  
2.2.2 Assessing the effect of hypoxic culture on endothelial 
differentiation 
The effect of hypoxic culture on HIF-1α protein expression 
AFSCs were seeded in a 6 well culture plate (Greiner, Frickenhausen, Germany) 
at a density of 5x104 per well and maintained in EndoGro™ media supplemented 
with 50 ng/mL VEGF. AFSCs were cultured in normoxia, intermittent hypoxia or 
continuous hypoxia. At day 3 of culture, cells were lysed with RotiLoad-1 loading 
buffer 1x (80 µL per well) (Carl Roth, Karlsruhe, Germany), removed using 
Nunc™ Cell Scrapers (Thermo scientific, Massachusetts, USA), transferred to 
1.5 mL tubes and stored at -20°C.  
HIF-1 α expression was analysed using western blotting as described by Dohle 
et al. (Dohle et al., 2011). Briefly, protein extracts were separated by molecular 
weight using polyacrylamide gel (Laemmli, 1970). Protein extracts were 
incubated at 95°C for 5 min to allow for denaturation before sample loading. 
Separation of proteins was performed at 25 mA in SDS-running buffer (25 mM 
Tris, 192 mM Glycine, 0.1% SDS) (Sigma-Aldrich, Schnelldorf, Germany). 
Protein transfer from the gel onto a nitrocellulose membrane was performed at 
65 V in 1X transfer buffer (25 mM Tris, 190 mM glycine and 20% methanol) for 
30 min using Standard SD transfer protocol (25 V, 1.0 A) for a Trans-Blot Turbo 
Blotting System (Bio-Rad Laboratories, Munich, Germany). The membrane was 
blocked in 5% milk powder containing 0.2% Tween PBS (blocking solution) 
(Sigma-Aldrich, Schnelldorf, Germany) for 1 h at room temperature and was 
subsequently incubated with a mouse anti-human HIF-1α primary antibody (BD 
Biosciences, Oxford, United Kingdom) at a dilution of 1:250 in blocking solution. 
Blots were rinsed three times in wash buffer (0.2% Tween 20/PBS) and then 
incubated with an anti-mouse horseradish peroxidase (HRP)-conjugated 
secondary antibody (BD Biosciences) diluted 1:1000 in 5% milk powder in PBS 
for 2 h at room temperature. In order to detect unequal protein loading, ERK2 
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was detected on every membrane using a rabbit anti-human primary antibody 
(1:3000) (BD Biosciences) and an anti-rabbit secondary antibody (1:3000) (BD 
Biosciences) and used as reference protein in analysis.  For detection of antibody 
labelled target proteins, membranes were covered with Super Signal West Dura 
Extended Detection Substrate (Thermo scientific, Massachusetts, USA) for 
5 min, excess substrate was removed and chemifluorescence was recorded with 
a CHEMI-SMART 5100 (Peqlab, Erlangen, Germany). 
The effect of hypoxic culture on gene expression 
Cells were detached and centrifuged as described in Section 2.2.1 on day 7 and 
14. A lysis buffer composed of 1:100 β-mercaptoethanol (Sigma-Aldrich, Arklow, 
Ireland) in RLT buffer (Qiagen, Ireland) was added to the cell pellets which were 
then stored at -80°C. RNA was extracted using an RNeasy Mini Kit (Qiagen, 
Ireland) according to the manufacturer’s instructions. RNA quality and quantity 
was determined using an RNA nanodrop (Thermo scientific, Massachusetts, 
USA). Following RNA isolation, reverse transcription PCR was carried out using 
200 ng of RNA. Genomic DNA was removed, followed by reverse transcription of 
the RNA (Qiagen, Ireland) according to the manufacturer’s instructions. 
Quantitative real-time PCR (qRT-PCR) was carried out using the 7500 Real Time 
polymerase chain reaction system (Applied Biosystems, Paisley, UK). The 
QuantiTect SYBR Green PCR kit (Qiagen, Ireland) was used for this process 
according to the manufacturer’s instructions with the QuantiTect primers for 
Angiopoietin 1 (Hs_ANGPT1_1_SG), TIE-2 (Hs_TEK_2_SG), VEGFR2 
(Hs_KDR_1_SG), PECAM-1 (CD31) (Hs_PECAM1_1_SG) and von Willebrand 
factor (VWF) (Hs_VWF_1_SG). These genes were chosen due to their 
expression by endothelial cells and association with endothelial differentiation. All 
gene expression was normalised against 18s (Hs_RRN18S_1_SG), a 
housekeeping gene commonly used for this purpose. Expression of the 
endothelial marker genes studied was determined using the relative 
quantification ΔΔCt method (Livak and Schmittgen, 2001). 
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The effect of hypoxic culture on VEGF secretion 
VEGF concentration within the cell media after 7 and 14 days of culture was 
quantified using a DuoSet ELISA kit (R&D systems, Oxfordshire, UK) as per the 
manufacturer’s instructions. Cells were cultured in EndoGro™ media without 
supplemented VEGF for 2 days before each time-point in order to prevent 
interference with assay results. Samples were evaluated on a photometric plate 
reader (Varioskan Flash, Fisher Scientific, Dublin, Ireland) at 450 nm with 
corrections at 570 nm.  
The effect of hypoxic culture on CD31 cell-surface expression 
The cell-surface expression of CD31 in AFSCs was analysed as CD31 is a well-
known marker protein expressed in all endothelial cells and is commonly used as 
a criteria for their identification and isolation (Baldwin et al., 1994, Dong et al., 
1997). AFSCs were seeded in a µ-Slide 8 well (Ibidi, Martinsried, Germany) 
chamber slide at a density of 5x103 per well and maintained in EndoGro™ media 
supplemented with 50 ng/mL VEGF. AFSCs were cultured in normoxia, 
intermittent hypoxia or continuous hypoxia. At day 7 and 14 of culture, samples 
were fixed using 3.7% paraformaldehyde (PFA) (Sigma-Aldrich, Schnelldorf, 
Germany) and stored in PBS at 4°C. Fixed samples were washed in PBS and 
permeabilised in 0.002% Triton/PBS (Sigma-Aldrich, Schnelldorf, Germany) for 
10 min. Samples were washed in PBS and then incubated in a 1:50 dilution of 
monoclonal mouse anti-human CD31 antibody (Dako, Hamburg, Germany) in 1% 
bovine serum albumin (BSA)/PBS (Sigma-Aldrich, Schnelldorf, Germany). 
Samples were washed in PBS again and subsequently incubated in a 1:1000 
dilution of goat anti-mouse 488 (Life Technologies, Darmstadt, Germany) in 1% 
BSA/PBS for 1 h. Samples were then washed twice in PBS and cell nuclei were 
stained using a 1:10000 dilution of Hoechst stain solution in PBS (Sigma-Aldrich, 
Schnelldorf, Germany) for 5 min. AFSCs cultured in growth media were used as 
a negative control and HUVECs were used as a positive control. Media was 
changed every 3 days of culture.  
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2.2.3 Assessing the effect of hypoxic culture on endothelial-like 
functionality 
In order for AFSCs to be considered endothelial-like cells, they must be able to 
demonstrate that they possess abilities that are characteristic of functional 
endothelial cells. With this in mind, the ability of AFSCs to adopt functional 
endothelial cell characteristics was assessed using two standard tests for 
endothelial functionality: the uptake of acetylated low-density lipoprotein (ac-LDL) 
and tubule formation on Matrigel™.  
The effect of hypoxic culture on ac-LDL uptake 
The ability of AFSCs to uptake fluorescently-tagged ac-LDL was analysed at day 
7 and 14 of culture. Low-density lipoprotein (LDL) refers to a class of lipoprotein 
particles which carry cholesterol in the blood and around the body for use by cells. 
Endothelial cells from various sources in the body have previously been shown 
possess a higher affinity for ac-LDL rather than native LDL (Stein and Stein, 1980, 
Pitas et al., 1981). Therefore, uptake of ac-LDL is a well-recognised pre-requisite 
for cells to be considered to be differentiating down an endothelial lineage, as it 
is known to be a functional characteristic of mature endothelial cells (Voyta et al., 
1984). As a result, it is a well-established method for the assessment and 
validation of endothelial differentiation (Silva et al., 2005a, Wang et al., 2007b, 
Zhang et al., 2011b, Janeczek Portalska et al., 2012, Doan et al., 2014).   
AFSCs were seeded in a µ-Slide 8-well (Ibidi, Martinsried, Germany) chamber 
slide at a density of 5x103 per well and maintained in EndoGro™ media 
supplemented with 50 ng/mL VEGF. The AFSCs were cultured in normoxia, 
intermittent hypoxia or continuous hypoxia. At day 7 and 14 of culture, 10 ng/mL 
of Alexa Fluor 488-conjugated ac-LDL (Life Technologies, Darmstadt, Germany) 
diluted in EndoGro™ media was added to the cells. The cells were incubated with 
ac-LDL for 4 h, at which point they were fixed with 3.7% PFA (Sigma-Aldrich, 
Schnelldorf, Germany) and stored in PBS at 4°C. Uptake of ac-LDL was 
subsequently visualised using fluorescent microscopy (4x objective, Keyence BZ-
9000, Keyence, Neu-Isenburg, Germany) with BZ II viewer software (Keyence, 
Neu-Isenburg, Germany). AFSCs cultured in growth media were used as a 
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negative control and HUVECs were used as a positive control. Media was 
changed every 3 days of culture.  
The effect of hypoxic culture on tubule formation on Matrigel™ 
The ability of AFSCs to form tubules on Matrigel™ was analysed at day 7 and 14 
of culture. This is considered a functional characteristic of endothelial cells. 
Matrigel™ is generally used to study the effect of pro-angiogenic and anti-
angiogenic factors on endothelial cell function and to define endothelial cell 
populations (Browning et al., 2008, Arnaoutova et al., 2009). As a result, it is a 
well-established method for the assessment and validation of endothelial 
differentiation and has been used in a number of studies for this purpose 
(Thangarajah et al., 2009, Zhang et al., 2009, Roura et al., 2012, Portalska et al., 
2013). 
Growth Factor Reduced Matrigel™ (BD Biosciences, Oxford, United Kingdom) 
was defrosted on ice overnight before use. 120 μL of Matrigel™ was evenly 
distributed on the bottom of the wells of a 48 well plate (Greiner, Frickenhausen, 
Germany). The plate was then placed in an incubator at 37°C for 30 min in order 
to allow the Matrigel™ to set. 1 mL of EndoGro™ media (50 ng/mL VEGF) was 
gently added to the wells. Cells from each O2 group were seeded at a density of 
3x104 in their assigned wells. Tubule formation by cells on Matrigel™ was imaged 
at 6 h, 8 h, 12 h and 24 h post-seeding with a Leica DMIL microscope (10x 
objective, DFC420C digital camera). 5 images were taken per well at random 
positions. Total tubule length was calculated using “ImageJ” software (ImageJ, 
U. S. National Institutes of Health, Maryland, USA). Total tubule length was 
quantified using tubules over 30 µm in length. This was done in order to minimise 
the quantification of non-tubule cell structures. 
2.2.4 Statistical analysis 
To assess statistical difference between O2 groups, a one-way ANOVA with 
Tukey post-hoc analysis was performed. To calculate statistical difference in 
tubule formation on Matrigel™, a two-way ANOVA with Bonferroni post-test was 
performed.  Error is reported in figures as the standard deviation of the mean and 
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significance was determined using a probability value of p<0.05. All experiments 
were carried out with a sample size of 3 unless otherwise stated. 
2.3 Results 
2.3.1 Hypoxic culture enhances endothelial differentiation 
Hypoxic culture upregulates HIF-1α protein expression in AFSCs  
Western blotting was performed in order to confirm that culture in hypoxic 
conditions was leading to an upregulation of HIF-1α, a master regulator of hypoxic 
response. Protein expression of HIF-1α was observed in both intermittent hypoxia 
and continuous hypoxia by day 3 of culture (Fig. 2.2). Expression of HIF-1α in 
intermittent hypoxia indicates that even an 8 h period of hypoxic exposure every 
24 h was enough to activate the HIF-1α pathway. Little to no visible HIF-1α 
expression was observed in the normoxic group. Expression of ERK2, the loading 
control protein, was found to be at a similar level in each of the O2 conditions 
studied. 
 
Figure 2.2: The effect of hypoxia on HIF-1α protein expression in AFSCs after 3 days of culture 
as visualised using western blotting. Bands indicating the expression of HIF-1α protein were 
visible in intermittent hypoxia and continuous hypoxia. Little to no HIF-1α was visible in normoxia. 
ERK2 was used as the housekeeping/reference protein. Blot represents one independent 
experiment, n=1. 
Hypoxic culture enhances the endothelial gene expression profile of 
AFSCs  
Endothelial gene expression levels were analysed using qRT-PCR. Endothelial 
gene expression patterns of AFSCs in normoxia, intermittent hypoxia and 
continuous hypoxia were compared to those of AFSCs in growth media and 
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HUVECs, the negative and positive controls respectively, to assess the effect of 
hypoxia on endothelial differentiation. 
By day 7, it was clear that the AFSCs in all three O2 conditions were adopting an 
early stage endothelial gene expression profile (Fig. 2.3). A significant (p<0.001) 
four-fold decrease in Angiopoietin 1 expression was seen in AFSCs cultured in 
all O2 conditions (except for continuous hypoxia, which demonstrated a two-fold 
decrease) (Fig. 2.3 A) relative to AFSCs in growth media. HUVECs also displayed 
low expression levels of Angiopoietin 1 that were significantly (p<0.001) 
decreased relative to AFSCs in growth media and continuous hypoxia. TIE-2 
expression (Fig. 2.3 B) was significantly reduced in all three O2 conditions in 
comparison to HUVECs (p<0.001) and AFSCs in growth media (p<0.001 relative 
to normoxia and intermittent hypoxia, p<0.05 relative to continuous hypoxia). 
VEGFR2 and CD31 expression (Fig. 2.3 C and D) was significantly enhanced 
(p<0.001 and p<0.01 respectively) fifteen- and seven-fold respectively in 
continuous hypoxia relative to AFSCs in growth media and the other two O2 
conditions. Increases in the levels of expression of these two genes were also 
noted in normoxia and intermittent hypoxia, but these increases were non-
significant in comparison to AFSCs in growth media. vWF expression (Fig. 2.3 E) 
was also increased in all three O2 conditions in comparison to AFSCs in growth 
media, although this increase was non-significant. VEGFR2, CD31 and vWF 
expression was significantly (P<0.001) higher in HUVECs relative to all other 
groups.  
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Figure 2.3: qRT-PCR analysis investigating the expression of the endothelial markers (A) 
Angiopoietin 1, (B) TIE-2, (C) VEGFR2, (D) CD31 and (E) vWF by AFSCs at day 7 of culture. 
AFSCs in growth media were used as a negative control and HUVECs were used as a positive 
control. AFSCs in all O2 conditions adopted an early stage endothelial gene expression profile. 
Significant increases in VEGFR2 and CD31 in continuous hypoxia indicated that continuous 
hypoxia enhanced the endothelial gene expression profile of AFSCs relative to AFSCs in growth 
media and the other O2 conditions. Endothelial gene expression in AFSCs in all three O2 
conditions was significantly (p<0.001) lower than the baseline expression of HUVECs. Values are 
expressed as mean ± standard deviation, n=4. * denotes p<0.05 statistical significance 
differences relative to normoxia and intermittent hypoxia. ** denotes p<0.01 statistical significance 
differences relative to all other groups excluding HUVECs. *** denotes p<0.001 statistical 
significance differences relative to all other groups. # denotes p<0.001 statistical significance 
differences relative to HUVECs. ## denotes p<0.001 statistical significance differences relative to 
normoxia and intermittent hypoxia. ### denotes p<0.001 statistical significance differences 
relative to all other groups excluding HUVECs. 
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At day 14, an early stage endothelial gene expression profile similar to that of day 
7 was observed (Fig. 2.4) in AFSCs in all three O2 conditions. Angiopoietin 1 
expression (Fig. 2.4 A) was significantly downregulated by approximately 50% in 
all groups relative to AFSCs in growth media (p<0.01 relative to normoxia, 
p<0.001 relative to all other groups). Angiopoietin 1 expression in HUVECs was 
approximately ten-fold lower than AFSCs in growth media (p<0.001). TIE-2 
expression was significantly (p<0.001) reduced in all groups in comparison to 
HUVECs (Fig. 2.4 B). TIE-2 expression was significantly reduced (p<0.01) in 
intermittent and continuous hypoxia relative to AFSCs in growth media and 
normoxia. Expression of VEGFR2 (Fig. 2.4 C) was increased at least two-fold in 
continuous hypoxia relative to normoxia (p<0.05), intermittent hypoxia and 
AFSCs in growth media. CD31 (Fig. 2.4 D) was significantly (p<0.01) increased 
approximately five-fold in continuous hypoxia relative to normoxia, intermittent 
hypoxia and AFSCs in growth media, demonstrating that continuous hypoxia was 
enhancing endothelial gene expression. vWF expression (Fig. 2.4 E) was three-
fold higher in normoxia and continuous hypoxia in comparison to AFSCs in 
growth media, although this was not significant. VEGFR2, CD31 and vWF 
expression levels in HUVECs were significantly (p<0.001) higher than all other 
groups (Fig. 2.4 C, D and E). 
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Figure 2.4: qRT-PCR analysis investigating the expression of the endothelial markers (A) 
Angiopoietin 1, (B) TIE-2, (C) VEGFR2, (D) CD31 and (E) vWF by AFSCs at day 14 of culture. 
AFSCs in growth media were used as a negative control and HUVECs were used as a positive 
control. AFSCs in all O2 conditions adopted an endothelial gene expression profile as evidenced 
by CD31, vWF, VEGFR2 and Angiopoietin 1 expression, indicating early stage differentiation was 
occurring. Significant increases in CD31 (p<0.01) and VEGFR2 (p<0.05) expression in 
continuous hypoxia indicate that continuous hypoxia enhanced the endothelial gene expression 
profile of AFSCs. Endothelial gene expression was significantly (p<0.001) lower in AFSCs 
subjected to endothelial stimuli than that of the baseline expression of HUVECs, indicating that 
differentiating AFSCs were not as mature as HUVECs. Values are expressed as mean ± standard 
deviation, n=4. * denotes p<0.05 statistical significance differences relative to AFSCs in growth 
media. **denotes p<0.01 statistical significance relative to normoxia. *** denotes p<0.001 
statistical significance relative to all other groups. # denotes p<0.001 statistical significance 
differences relative to intermittent hypoxia, continuous hypoxia and HUVECs. ## denotes p<0.01 
statistical significance differences relative to normoxia. ### denotes p<0.01 statistical significance 
differences relative to HUVECs. $ denotes p<0.01 statistical significance differences relative to 
all other groups excluding HUVECs.  
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Table 2.2 shows the endothelial marker gene expression levels of the continuous 
hypoxia group from the previous two figures (Fig. 2.3 and 2.4) together with those 
of the HUVEC control at day 14, in order to allow for a comparison of changes in 
gene expression between day 7 and 14. Continuous hypoxia was chosen as it 
was the O2 condition which induced the greatest change in endothelial gene 
expression as seen in Fig. 2.3 and 2.4. Angiopoietin 1 expression decreased over 
the culture period, although the value observed in the HUVECs group was 
approximately seven-fold lower relative to day 14. TIE-2 expression decreased 
three-fold between day 7 and 14 and was approximately eighty five-fold lower 
than HUVECs. VEGFR2, CD31 and vWF expression remained at similar levels 
between day 7 and 14, although baseline expression in HUVECs was far higher 
at day 14, demonstrating that although continuous hypoxia may enhance 
endothelial gene expression relative to normoxia and intermittent hypoxia, it was 
still much lower than the baseline expression observed in the HUVEC control.  
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Table 2.2: Comparison of expression levels of endothelial markers in continuous 
hypoxia at day 7 and 14 compared to HUVECs at day 14. Endothelial marker 
expression in continuous hypoxia was similar at day 7 and 14 but was still low 
when compared to the baseline expression of HUVECS, the endothelial cell 
control. 
 
Taken together, the endothelial gene expression profile of AFSCs over a 14 day 
culture period indicates that differentiation is taking place in all three O2 
conditions. Continuous hypoxia enhanced endothelial gene expression to the 
greatest extent; however, HUVECs displayed significantly higher baseline gene 
expression levels of VEGFR2, CD31 and vWF than AFSCs in any of the three O2 
conditions. 
  
 Day 7 Day 14 HUVECs Day 14 
Angiopoietin 1 0.512 
 +/- 
0.05 
0.395 
 +/- 
0.22 
0.062 
+/- 
0.005 
TIE-2 0.651 
+/- 
0.29 
0.272 
+/- 
0.15 
23.36 
+/- 
2.80 
VEGFR2 13.24 
 +/- 
2.79 
12.73 
 +/- 
5.46 
384.2 
+/- 
39.26 
CD31 7.75 
+/- 
1.10 
6.61 
 +/- 
1.21 
6563.4 
+/- 
364.06 
vWF 2.36 
 +/- 
0.91 
3.29 
 +/- 
 2.70 
407.8 
 +/- 
112.38 
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Hypoxic culture enhances VEGF secretion by AFSCs  
VEGF protein secretion by AFSCs during culture in normoxia, intermittent 
hypoxia or continuous hypoxia at day 7 and 14 was quantified using ELISA (Fig. 
2.5). Low levels of VEGF secretion were observed in AFSCs in growth media and 
HUVECs after 14 days. Day 14 normoxia produced approximately five-fold higher 
levels of VEGF in comparison to AFSCs in growth media and HUVECs, although 
this was non-significant. Continuous hypoxia enhanced VEGF secretion at day 7 
and 14 with levels that were significantly higher (p<0.001) than all other groups. 
VEGF secretion in continuous hypoxia also significantly increased (p<0.001) 
between day 7 and 14, with a two-fold difference between the two time-points. 
Intermittent hypoxia was significantly (p<0.05) higher than AFSCs in growth 
media and normoxia at day 7. Overall, intermittent hypoxia produced the second 
highest levels of VEGF secretion after continuous hypoxia, implicating that length 
of exposure time to hypoxia could play a role in the enhancement of VEGF 
secretion by AFSCs. This is further corroborated by the two-fold increase in 
VEGF between intermittent hypoxia groups at day 7 and 14.  
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Figure 2.5: VEGF secretion by AFSCs over the course of 14 days in response to endothelial 
stimuli in various O2 conditions. VEGF secretion was significantly higher (p<0.001) in continuous 
hypoxia at day 7 and 14. VEGF secretion in intermittent hypoxia was significantly (p<0.05) higher 
relative to AFSCs in growth media and normoxia at day 7. AFSCs in growth media served as the 
negative control. HUVECs served as the positive control. Values are expressed as mean ± 
standard deviation, n=4. * denotes p<0.05 statistical significance differences relative to AFSCs in 
growth media and the normoxia group at day 7. *** denotes p<0.001 statistical significance 
differences relative to all other groups excluding continuous hypoxia at day 14.   
Hypoxic culture does not affect CD31 cell-surface expression in 
AFSCs 
The ability of AFSCs to express the cell-surface endothelial marker CD31 was 
assessed by fluorescent immunostaining at day 7 and 14 of culture (Fig. 2.6). No 
staining was detectable in AFSCs in growth media by day 14 of culture (Fig. 2.6 
i-ii). Strong staining was visible in the HUVECs group (Fig. 2.6 iii-iv). AFSCs 
displayed weak staining at both day 7 and 14 of in normoxia (Fig. 2.6 A-B, G-H), 
intermittent hypoxia (Fig. 2.6 C-D, I-J) and continuous hypoxia (Fig. 2.6 E-F, K-
L). This weak staining corroborates the CD31 gene expression seen using qRT-
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PCR (Fig. 2.3 and 2.4 respectively). There were no visible differences between 
AFSCs in any O2 condition in at either time-point. 
 
 
Figure 2.6: Fluorescent staining indicating CD31 expression by AFSCs in the presence of 
endothelial stimuli at day 7 and 14 of culture. No CD31 expression was visible in AFSC in growth 
media (i-ii). Strong CD31 expression was visible in HUVECs (iii-iv). AFSCs in normoxia (A-B and 
G-H), intermittent hypoxia (C-D and I-J) and continuous hypoxia (E-F and K-L) displayed weak 
expression of CD31 at both day 7 and 14. AFSCs in growth media and HUVECs were used as 
the negative and positive controls respectively. Images of AFSCs in growth media and of HUVECs 
were taken at day 14 of culture. Green represents CD31 positive staining, blue represents DAPI 
nuclear stain. Scale bar represents 100 µm.  
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2.3.2 Hypoxic culture does not enhance functional endothelial 
characteristics adopted by AFSCs 
Hypoxic culture does not affect the uptake of ac-LDL by AFSCs 
As previously mentioned in Section 2.2.3, the ability to uptake ac-LDL is known 
to be a functional characteristic of endothelial cells. For this reason, the ability of 
AFSCs to uptake fluorescently tagged ac-LDL was investigated. AFSCs in growth 
media were capable of little to no ac-LDL uptake at any point during the culture 
period (Fig. 2.7 i) as demonstrated by the weakness of green fluorescence in that 
group, therefore indicating that ac-LDL uptake is not an innate characteristic of 
AFSCs. HUVECs showed effective ac-LDL uptake, indicated by the visibility of 
strong green fluorescence within the boundaries of the cells. This was indicative 
of their mature endothelial cell type phenotype (Fig. 2.7 ii). AFSCs showed 
effective ac-LDL uptake in normoxia (Fig. 2.7 A-B), intermittent hypoxia (Fig. 2.7 
C-D) and continuous hypoxia (Fig. 2.7 E-F) at both day 7 and 14 of culture. Taken 
together, these data indicate that AFSCs in all of the three O2 conditions had 
acquired the ability to uptake ac-LDL.  
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Figure 2.7: Florescent imaging demonstrating ac-LDL uptake by AFSCs over the course of 14 
days in response to endothelial stimuli in all three O2 conditions. AFSCs cultured in normoxia (A-
B), intermittent hypoxia (C-D) and continuous hypoxia (E-F) were all capable of ac-LDL uptake at 
day 7 and 14 of culture. HUVECs were also capable of ac-LDL uptake (ii). AFSCs in growth media 
were capable of little to no uptake of ac-LDL at any point during the 14 day culture period (i). 
AFSCs in growth media and HUVECs were used as the negative and positive controls 
respectively. Images of AFSCs in growth media and of HUVECs were taken at day 14 of culture. 
Green represents ac-LDL uptake, blue represents DAPI nuclear stain. Scale bar represents 300 
µm. 
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Hypoxic culture does not affect the ability of AFSCs to form tubules 
on Matrigel™ 
As hypoxia was found to enhance endothelial gene expression and VEGF protein 
secretion, its effect on tubule formation on Matrigel™ was investigated. As 
previously mentioned in Section 2.2.3, the ability to form tubules on Matrigel™ is 
considered to be a functional characteristic of endothelial cells. At day 7 and 14 
of culture, AFSCs were seeded on Matrigel™ for up to 24 h and it was found that 
AFSCs in normoxia, intermittent hypoxia and continuous hypoxia were all 
capable of tubule formation (Fig. 2.8). There were no significant differences 
between O2 conditions at any time-point. HUVECs displayed significantly 
(p<0.001) higher tubule length that was approximately four-fold higher than all 
other groups at every time-point. This indicates that although the AFSCs are 
capable of tubule formation, they are not able to replicate the high levels of tubule 
formation seen by HUVECs. 
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Figure 2.8: Quantification of tubule formation by AFSCs on Matrigel™ after 7 days of culture in 
normoxia, intermittent hypoxia or continuous hypoxia. No significant differences were observed 
between the three O2 conditions at any time-point. However, HUVECs displayed significantly 
(p<0.001) higher tubule length than all other groups at all time-points. Quantitative analysis is 
accompanied by representative images of all three O2 conditions and the HUVEC control taken 
at the 6 h time-point. Values are expressed as mean ± standard deviation, n=3. *** denotes 
p<0.001 statistical significance differences relative to all other groups. Scale bar represents 200 
µm. 
Similar to the results seen at day 7, there were no significant differences between 
O2 conditions at any time-point (Fig. 2.9). HUVECs displayed significantly higher 
tubule formation at all time-points (p<0.001) relative to normoxia, intermittent 
hypoxia and continuous hypoxia. 
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Figure 2.9: Quantification of tubule formation by AFSCs on Matrigel™ after 14 days of culture in 
normoxia, intermittent hypoxia or continuous hypoxia. No significant differences were observed 
between the three O2 conditions at any time-point. HUVECs displayed significantly higher tubule 
length than all other groups at all time-points (p<0.001). Quantitative analysis is accompanied by 
representative images taken at the 6 h time-point. Values are expressed as mean ± standard 
deviation, n=3. *** denotes p<0.001 statistical significance differences relative to all other groups. 
Scale bar represents 200µm. 
Taken together, these results demonstrate the ability of AFSCs exposed to 
endothelial stimuli to adopt the functional endothelial-like characteristics of ac-
LDL uptake and tubule formation on Matrigel™ as early as day 7 of culture 
regardless of O2 culture conditions. 
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2.4 Discussion  
The objective of the data presented in this chapter was to investigate whether 
culture in hypoxia could enhance the ability of AFSCs to differentiate down an 
endothelial lineage in order to produce an endothelial-like cell type. The results 
demonstrated that AFSCs adopted an endothelial gene expression pattern and 
displayed the functional endothelial cell characteristics of ac-LDL uptake and 
tubule formation on Matrigel™. Culture in continuous hypoxia significantly 
enhanced both the endothelial gene expression profile and VEGF protein 
secretion relative to AFSCs in growth media, normoxia and intermittent hypoxia, 
although it had no beneficial effect on the adoption of functional endothelial 
characteristics. However, as expected, HUVECs presented a more advanced 
endothelial cell type as evidenced by its more mature endothelial gene 
expression profile, stronger CD31 expression and superior tubule forming ability 
on Matrigel™. Taken together, this study demonstrates the positive effect of 
continuous hypoxia on endothelial gene expression and VEGF secretion of 
AFSCs undergoing endothelial differentiation. 
The 14 day culture period caused the AFSCs in normoxia, intermittent hypoxia 
and continuous hypoxia to adopt a similar, albeit less mature, endothelial gene 
expression profile to HUVECs. This endothelial expression profile manifested in 
the form of decreased Angiopoietin 1 expression and increased CD31, VEGFR2 
and vWF expression in comparison to AFSCs in growth media at day 7 and 14. 
This increase in CD31 and vWF expression in AFSCs subjected to endothelial 
stimuli is consistent with the literature, for example, the work carried out by Zhang 
et al. demonstrated that a three-fold increase in CD31 expression and a four-fold 
increase in vWF expression was evident from week 1 to week 3 of a period of 
endothelial stimulation (Zhang et al., 2009). Similar increases in CD31, vWF and 
VEGFR2 have been noted in other stem cell types when differentiating down an 
endothelial lineage, for example, embryonic stem cells (Levenberg et al., 2002) 
and adipose-derived stem cells (Zhang et al., 2011b). AFSCs in continuous 
hypoxia demonstrated significantly increased expression levels of CD31 and 
VEGFR2 relative to AFSCs in growth media, normoxia and intermittent hypoxia 
at both day 7 and 14. This indicates that long-term continuous hypoxia may be a 
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potent stimulus in the enhancement of endothelial gene expression of AFSCs, a 
result that has not been demonstrated previously. Zhang et al. has previously 
shown that pre-culturing AFSCs in hypoxia for 48 h prior to a period of endothelial 
stimulation could increase the upregulation of a number of angiogenic genes like 
placental and hepatocyte growth factor (Zhang et al., 2009). However, that study 
did not investigate the effects of hypoxia on endothelial gene expression beyond 
a 48 h pre-culture period. The role of hypoxia in endothelial differentiation has 
been demonstrated in other stem cell types. For example, it has been shown that 
hypoxic preconditioning and culture can enhance angiogenic gene expression in 
both adipose-derived stem cells and human pluripotent stem cells (Efimenko et 
al., 2011, Kusuma et al., 2014). However, this is the first time that the positive 
effect of an extend period of continuous hypoxic culture on endothelial 
differentiation in AFSCs has been demonstrated.  
AFSCs in continuous hypoxia were shown to have the highest levels of VEGF 
protein secretion as demonstrated by ELISA at day 7 and 14. VEGF secretion 
has previously been used as an indicator of endothelial differentiation in stem 
cells (Zhang et al., 2009, Thangarajah et al., 2009, Bassaneze et al., 2010, Zhang 
et al., 2011b). HUVECs displayed a low level of VEGF secretion, although this is 
possibly due to the fact that as a mature endothelial cell, HUVECs are more likely 
to rely on the secretion of angiogenic growth factors from surrounding support 
cells for vessel formation (Mayer et al., 2005). Benavides et al. have previously 
shown that AFSCs differentiating down an endothelial lineage undergo an 
increase in VEGF secretion (Benavides et al., 2012). In the study presented in 
this chapter, it was observed that AFSCs in continuous hypoxia demonstrated 
significantly higher levels of VEGF secretion relative to all other groups. AFSCs 
in intermittent hypoxia showed the second highest level of VEGF secretion at day 
14, which implies that length of exposure time to hypoxia affects the level of 
VEGF secretion. VEGF is known to be a downstream target of HIF-1α (Neufeld 
et al., 1999) and hypoxia and the HIF-1α pathway have previously been linked to 
an increase in VEGF secretion by a number of different cell types, including 
endothelial cells, bone marrow-derived mesenchymal stem cells (MSCs) and 
adipose-derived stem cells (Namiki et al., 1995, Potier et al., 2007, Thangarajah 
et al., 2009). It was theorised that by using continuous hypoxia to increase VEGF 
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expression, the AFSCs could be directed further down an endothelial cell lineage 
as increased VEGF supplementation has been previously shown to enhance 
endothelial differentiation of AFSCs (Benavides et al., 2012). The increase in 
VEGF protein secretion by AFSCs in continuous hypoxia corresponds with 
increased CD31 and VEGFR2 gene expression seen in that group previously, 
indicating that potentially, the secreted VEGF is acting upon the AFSCs to 
enhance differentiation. The previously mentioned increase in VEGFR2 gene 
expression at day 7 and 14 in AFSCs in continuous hypoxia is likely a response 
to the increased VEGF protein secretion by the continuous hypoxia group. This 
is due to the fact that VEGFR2 is one of the primary receptors for VEGF (Neufeld 
et al., 1999), so the upregulation of this gene in response to increased VEGF is 
to be expected.  
AFSCs cultured in each of the three O2 conditions displayed CD31 cell-surface 
expression as evidenced by fluorescent immunostaining. This corroborates the 
data produced by qRT-PCR that suggests AFSCs subjected to endothelial stimuli 
were expressing CD31, but that this expression was weak relative to HUVECs. 
There were no visible differences in CD31 expression between AFSCs in any O2 
condition, which suggests that the increase in CD31 gene expression seen 
previously in continuous hypoxia was not high enough to translate into an 
enhanced CD31 cell-surface expression. Oswald et al. demonstrated that 
differentiating MSCs do not express CD31 after a 7-day differentiation period, 
and concluded that this marker was “later expressed in endothelial maturation” 
(Oswald et al., 2004).  Similarly, Janeczek Portalska et al. found that endothelial 
stimuli combined with shear force were not sufficient for the cell-surface 
expression of CD31 after 10 days, although the cells presented with an 
endothelial gene expression profile and were capable of tubule formation on 
Matrigel™ (Janeczek Portalska et al., 2012). In the study presented in this 
chapter, AFSCs in growth media displayed no visible expression of CD31, which 
suggests that there has been an acquisition of an endothelial phenotype by 
AFSCs in each of the three O2 conditions over the 14 day culture period. HUVECs 
displayed high levels of CD31 expression, with the highest expression rates at 
the gap junctions between cells, which is indicative of a healthy endothelial cell 
monolayer (Bazzoni and Dejana, 2004). This further suggests that the AFSCs, 
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while acquiring an early endothelial phenotype, are still immature in comparison 
to HUVECs. 
Having established that the AFSCs acquired an early stage endothelial gene 
expression profile and phenotype, the ability of these cells to adopt functional 
endothelial-like characteristics was assessed. Firstly, the ability of AFSCs to 
uptake fluorescently-tagged ac-LDL was analysed at day 7 and 14 of culture. 
AFSCs were found to be capable of uptaking ac-LDL when cultured for up to 14 
days in normoxia, intermittent hypoxia and continuous hypoxia, similar to the 
HUVEC control. Uptake of ac-LDL is a well-recognised pre-requisite for cells to 
be considered to be differentiated down an endothelial lineage, as it is known to 
be a functional characteristic of mature endothelial cells. As a result, it is a well-
established method for the assessment and validation of endothelial 
differentiation (Silva et al., 2005a, Wang et al., 2007b, Zhang et al., 2011b, 
Janeczek Portalska et al., 2012, Doan et al., 2014). The uptake of ac-LDL 
suggests that the AFSCs have acquired some functional endothelial 
characteristics as early as day 7, although functional characteristics by 
themselves are not indicative of full differentiation. Other studies have obtained 
similar results when attempting to differentiate AFSCs down an endothelial 
lineage, for example, Zhang et al. and Benavides et al. have both previously 
observed that AFSCs were capable of ac-LDL uptake after 14 days when 
subjected to endothelial stimuli (Zhang et al., 2009, Benavides et al., 2012). 
Similar to the results of the CD31 fluorescent immunostaining, there were no 
visible differences in ac-LDL uptake between AFSCs cultured in any of the three 
O2 conditions, which suggests that the increase in endothelial gene expression 
seen previously in continuous hypoxia was not high enough to translate into an 
enhanced uptake of ac-LDL. AFSCs in growth media were the only group 
analysed that were incapable of ac-LDL uptake. This indicates that AFSCs in 
growth media do not possess innate endothelial characteristics, which also 
demonstrates that the AFSCs changed towards an endothelial phenotype over 
the course of the differentiation period. Imaging of ac-LDL uptake also 
demonstrated that, at day 7 and 14, the cell morphology of the differentiating 
AFSCs was still markedly different to that of the HUVEC control, with the 
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HUVECs displaying a characteristic round, cobblestone-like appearance and the 
AFSCs maintaining a spindle-shaped, stretched morphology. 
Having now determined that the AFSCs subjected to endothelial stimuli were 
capable of ac-LDL uptake and that continuous hypoxia did not affect this process; 
the formation of tubule networks by the AFSCs in all three O2 conditions was 
investigated at day 7 and 14. The ability to form tubules on Matrigel™, like ac-
LDL uptake, is considered a functional characteristic of endothelial cells. The 
results indicated that AFSCs in all three O2 conditions were capable of tubule 
formation, demonstrating that all groups had indeed begun to undergo endothelial 
differentiation. However, total tubule length in the HUVECs group was found to 
be significantly higher at all time-points, indicating that although AFSCs in all 
three O2 conditions are capable of tubule formation, HUVECs are still possess a 
superior tubule-forming ability. Taken together, these results demonstrate that 
AFSCs in all three O2 conditions are capable of tubule formation, indicating their 
progress in differentiating down an endothelial lineage. 
Overall, these results suggest that AFSCs subjected to culture for 14 days in all 
of the three O2 conditions displayed a gene expression profile, phenotype and 
functional characteristics associated with endothelial differentiation. This 
endothelial gene expression profile was enhanced by culture in continuous 
hypoxia. Despite this, AFSCs in all three O2 conditions were also found to 
possess a less mature endothelial gene expression profile and phenotype than 
HUVECs, the endothelial cell control. This was evidenced by the elevated levels 
of endothelial gene expression, CD31 cell-surface expression and the superior 
tubule forming ability of HUVECs on Matrigel™. A school of thought in the 
literature concerning the endothelial differentiation of stem cells is that a number 
of studies fail to include a positive endothelial cell control. For example, a number 
of studies have compared the differentiation of their stem cell of choice to a 
negative control consisting of an undifferentiated form of that cell, without 
including a positive, endothelial cell control (Oswald et al., 2004, Zhang et al., 
2009, Bai et al., 2010b, Wingate et al., 2014). While this allows for visualisation 
of the progress that the cells have made in terms of differentiation, it fails to give 
an idea of how well this differentiated cell type compares to a typical endothelial 
cell standard. The results from this study suggest that differentiated AFSCs (even 
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those cultured in continuous hypoxia) may simply not be mature enough to 
present a viable source of endothelial cells for our desired purpose of 
vascularising TE scaffolds and that this role is more suited to a primary 
endothelial cell type. In addition to this, Rouwkema et al. has also shown 
previously that primary endothelial cells can fulfil the role of vessel-producing cell 
more effectively than endothelial cells derived from differentiated stem cells 
(Rouwkema et al., 2009). Based on the results in this study, the follow-on study, 
which is presented in Chapter 3, focused on using AFSCs in the role of 
perivascular support cell in a co-culture model with HUVECs in order to determine 
their ability to form a vascular network within a collagen-chondroitin sulphate 
(CCS) scaffold. 
2.5 Conclusion 
The results of this study demonstrated that AFSCs subjected to endothelial 
stimuli over a 14 day culture period display an early endothelial gene expression 
profile and acquired functional endothelial cell characteristics, indicating early 
endothelial differentiation had taken place. Culture in continuous hypoxia was 
found to enhance endothelial gene expression and VEGF protein secretion but 
did not enhance endothelial-like functionality. AFSCs subjected to endothelial 
stimuli demonstrated a less mature endothelial gene expression profile and 
phenotype when compared to HUVECs, the endothelial cell control. Overall, 
however, this study suggests that continuous hypoxia may enhance the 
differentiation of AFSCs into an endothelial-like cell type. 
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Chapter 3: The pre-vascularisation of a collagen-
chondroitin sulphate scaffold using human 
amniotic fluid-derived stem cells to enhance and 
stabilise endothelial cell-mediated vessel 
formation  
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3.1 Introduction 
The pre-vascularisation approach to overcoming core degradation in tissue 
engineering (TE) constructs focuses on the creation of cell-based, pre-
engineered vasculature within the TE construct/scaffold in vitro, prior to 
implantation in vivo. Pre-vascularisation is a multicellular co-culture approach 
which typically involves at least two different cell types; a pro-angiogenic 
endothelial cell type to produce nascent vessel-like structures and a smooth 
muscle/ pericytic cell to provide both the physical and paracrine support required 
for the stabilisation of these vessel-like structures (Darland and D'Amore, 1999, 
Gerhardt and Betsholtz, 2003, von Tell et al., 2006, Kirkpatrick et al., 2007, Rivron 
et al., 2008, Kirkpatrick et al., 2011a, Alekseeva et al., 2014). It is generally 
accepted that a TE construct with an inherent vascular network pre-engineered 
in vitro could accelerate anastomosis with the host vasculature when implanted 
in vivo and enhance tissue repair. A number of co-culture systems have been 
implemented for the pre-vascularisation of TE constructs. For example, Unger et 
al. used a co-culture consisting of human dermal microvascular endothelial cells 
(HDMECs) and human primary osteoblasts to pre-vascularise a range of porous 
biomaterials including hydroxyapatite, calcium phosphate, nickel–titanium and 
silk fibroin (Unger et al., 2007). Berthod et al. found success in pre-vascularising 
collagen sponges using a combination of human umbilical vein endothelial cells 
(HUVECs) and human fibroblasts (Berthod et al., 2006). However, despite 
numerous successes and failures, there is still no consensus on the ideal source 
for either the endothelial cell or pericyte component of co-cultures for use in the 
pre-vascularisation of TE constructs. 
The study presented in Chapter 2 demonstrated that differentiated amniotic fluid-
derived stem cells (AFSCs) displayed functional endothelial cell characteristics 
and a nascent endothelial gene expression pattern, but ultimately were unable to 
adopt the mature endothelial cell phenotype necessary for the formation of 
vessel-like structures required for pre-vascularisation. However, HUVECs 
already present a mature endothelial cell source and have previously been used 
in numerous pre-vascularisation studies (Rouwkema et al., 2006, Saleh et al., 
2011, Mendes et al., 2012, Strassburg et al., 2013). HUVECs were therefore used 
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in the role of the vessel forming endothelial cell in this study. Although very little 
research has been done on the ability of AFSCs to act as a pericyte in co-culture 
with endothelial cells, it has been previously demonstrated that AFSCs can 
support vessel formation by human umbilical cord blood endothelial cells 
(Roubelakis et al., 2013). Based on this and the results from Chapter 2, this study 
investigated the potential of AFSCs to act as pericytes and form stable vascular 
structures in co-culture with HUVECs.  
In this current study, the ability of an AFSC-HUVEC co-culture to pre-vascularise 
a collagen-chondroitin sulphate (CCS) scaffold was investigated. The CCS 
scaffold is highly porous collagen-based scaffold that has been used for a number 
of TE applications including skin, lung, nerve, conjunctiva and brain repair (Butler 
et al., 1999, Hsu et al., 2000, Chen et al., 2005, Yannas et al., 2011, Huang et 
al., 2012). Our group has worked on optimising this scaffold type for use in a 
number of applications including bone and cartilage repair – the focus of research 
in this thesis (Farrell et al., 2006, Tierney et al., 2009b, Keogh et al., 2010, Lyons 
et al., 2010). This CCS scaffold has previously been pre-vascularised by our 
group, for example, McFadden et al. produced a network of vessel-like structures 
within the scaffold using a delayed addition co-culture in which HUVECS were 
seeded onto the scaffold 72 h prior to the addition of mesenchymal stem cells 
(MSCs). These vessel-like structures were capable of anastomosing with host 
vasculature when implanted in vivo (Duffy et al., 2011, McFadden, 2013). Notably 
however, these vessel-like structures were found to regress (characterised by a 
disengagement of cells from tubule structures with a subsequent decrease in 
vessel number) by day 14 of culture so one focus of the current research was to 
determine whether vessel-like structures could be maintained in the scaffolds for 
longer periods in vitro using an alternative stem cell source. 
In order to enhance the potential of the AFSC-HUVEC co-culture to pre-
vascularise a CCS scaffold, and based on the results from Chapter 2, exposure 
to a hypoxic environment was chosen as a stimulus to mimic vessel formation in 
vivo. Hypoxia is a well-known physiological stimulus of angiogenesis (Loges et 
al., 2009) and has been implicated in processes ranging from structural 
development (Neufeld et al., 1999, Wan et al., 2010) to wound repair (Knighton 
et al., 1981, Shweiki et al., 1992). The implantation site for a pre-vascularised 
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construct in vivo is also likely to be hypoxic (Sinaasappel et al., 1999), implying 
that hypoxic culture could replicate the natural environment that the construct 
would encounter upon implantation. The manipulation of the HIF-1 pathway has 
been used previously to enhance vascularisation of constructs (Fan et al., 2010, 
Hadjipanayi et al., 2011, Stewart et al., 2011). For example, Hadjipanayi et al. 
found that angiogenic factors secreted from human fibroblasts seeded in a dense-
collagen depots pre-conditioned under physiological cell-generated hypoxia 
rapidly induced an angiogenic response within endothelial cell-seeded constructs 
in vitro and also encouraged infiltration by perfused vessels in acellular constructs 
one week after implantation in vivo (Hadjipanayi et al., 2011). Therefore, the pro-
angiogenic effects of hypoxic culture indicates that it could potentially be used as 
a tool for the enhancement of pre-vascularisation.   
The primary objective of the study presented in this chapter was to investigate 
whether an AFSC-HUVEC co-culture could be used to pre-vascularise a CCS 
scaffold, with AFSCs acting as the pericyte source. To achieve this, the ability of 
two different AFSC-HUVEC co-culture seeding techniques to form vessel-like 
structures were investigated. The secondary objective of this study was to 
investigate whether hypoxic culture could enhance vessel-like structure formation 
by the cells in the scaffold. In order to achieve this, AFSC-HUVEC co-cultures 
were subjected to culture in the same oxygen (O2) conditions that were used as 
Chapter 2 over the course of a 14 day culture period; normoxia, intermittent 
hypoxia or continuous hypoxia.  
3.2 Methods 
3.2.1 Cell culture 
All cell culture work was carried out under sterile conditions in a laminar flow hood 
(SterilGard 111, MSC, Ireland). All cells were maintained at 37°C in a 5% CO2 
atmosphere in an incubator. 
Culture of AFSCs 
AFSCs were cultured as previously outlined in Section 2.2.1 (Chapter 2). AFSCs 
used during this experiment did not exceed passage 24. 
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Isolation and culture of HUVECs 
HUVECs were isolated from fresh umbilical cord samples for use in this study as 
using recently harvested HUVECs at a low passage number is common practice 
for co-culture mediated vascularisation studies (Stahl et al., 2004, Rouwkema et 
al., 2006, Chen et al., 2009b, Verseijden et al., 2010). HUVECs were isolated 
from umbilical cord samples obtained from the Gesundheits- und Pflegezentrum 
Rüsselsheim (GPR) clinic in Russelsheim, Germany (Jaffe et al., 1973). After 
birth, the cord was severed from the placenta and placed in a sterile bottle 
containing cord buffer, which consisted of 900 mL distilled water, 100 mL 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid buffer (HEPES (10X)) (Sigma-
Aldrich, Schnelldorf, Germany), 1% penicillin/streptomycin (PenStrep) 
(Invitrogen, California, USA), 1% Ciprobay (Ciprofloxacin) (Bayer, Leverkusen, 
Germany) and 1% Fungizone (Gibco, Life Technologies, Darmstadt, Germany). 
The cord was kept at 4°C until processing. When harvesting the cells, areas of 
the umbilical cord damaged by clamping during delivery were removed. Drain 
tubes were placed in the umbilical vein on both ends and the cord was rinsed with 
HEPES. To assess the vein for defects, one of the drain tubes was sealed with a 
combi stopper (B. Braun Medical, Schweiz, Germany) and HEPES was syringed 
through. All defects were fixed with clamps. The HEPES solution was drained 
and 5 mL collagenase type 1 (0.1%) (Worthington Biochemical, NJ, USA) was 
mixed 1:1 (v/v) with HEPES and syringed into the vein. The second drain tube 
was then closed with a combi stopper and the vein was incubated with 
collagenase for 20 min at 37°C. To increase HUVEC detachment, the umbilical 
cord was lightly massaged for 1 min.  
 
Figure 3.1: A human umbilical cord clamped and filled with collagenase during the process of 
HUVEC isolation.  
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The collagenase was released into a 50 mL falcon tube (Greiner Bio-One, 
Frickenhausen, Germany) and the vein rinsed with 10 mL 199 medium (Gibco, 
Life Technologies, Darmstadt, Germany) containing 10% fetal calf serum (FCS) 
(Sigma-Aldrich, Schnelldorf, Germany), 1% PenStrep (Invitrogen, California, 
USA) and 0.34% GlutaMax (Life Technologies, Darmstadt, Germany). This rinse 
was collected in the falcon tube and centrifuged at 1200 rpm for 5 min (Heraeus 
Megafuge 1.0, Kendro Laboratory products, Connecticut, USA).  
The supernatant was discarded and the cell pellet resuspended in 5 mL of 199 
medium and seeded onto a 25 cm2 cell-culture flask (Greiner Bio-One, 
Frickenhausen, Germany) coated with 0.2% gelatin (Sigma-Aldrich, Schnelldorf, 
Germany). Sodium heparin solution (Sigma-Aldrich, Schnelldorf, Germany) (50 
µg/mL) was added to act as an endothelial cell growth supplement. The cells 
were maintained at 37°C, 20% O2, 5% CO2 until confluent, split at a ratio of 1:3 
and reseeded on gelatin-coated flasks (passage 1). After the HUVECs were fully 
attached, the media was changed to standard EndoGro™ endothelial cell media 
(Section 2.2.1, Chapter 2) (Millipore, Massachusetts, USA). HUVECs used during 
this experiment did not exceed passage 4.  
AFSC-HUVEC co-culture seeding techniques  
AFSCs and HUVECs were cultured, trypsinised and centrifuged as previously 
outlined in Section 2.2.1 (Chapter 2). The effect of two distinct co-culture seeding 
techniques on vessel-like structure formation was investigated during this study: 
HUVEC>AFSC co-culture: HUVECs were seeded 72 h prior to the addition of 
AFSCs. The cells were seeded at a final ratio of 4:1 HUVECs: AFSCs. This co-
culture technique was previously developed by our group and was shown to 
produce optimal vessel-like structure formation by a HUVEC-MSC co-culture on 
a CCS scaffold (McFadden, 2013). All samples were harvested at day 14 post-
seeding with HUVECs. 
AFSC>HUVEC co-culture: AFSCs were seeded 24 h prior to the addition of 
HUVECs. The cells were seeded at a final ratio of 1:4 HUVECs: AFSCs. This 
seeding technique was based on a ratio commonly employed for use with co-
cultures that have previously been used successfully in pre-vascularisation 
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(Melero-Martin et al., 2008, Roubelakis et al., 2013). All samples were ultimately 
harvested at day 7 and 14 post-seeding with AFSCs.  
3.2.2 Assessing the optimal AFSC-HUVEC co-culture seeding 
technique for vessel-like structure formation on a 2D monolayer 
In order to initially evaluate the ability of co-cultures to form vessel-like structures 
on a 2D monolayer, cells were seeded onto 35x10 mm cell culture dishes 
(Greiner, Frickenhausen, Germany) coated with 50 µg/mL rat tail collagen type 1 
(BD Biosciences, MA, USA). Collagen type 1 has previously been used as a 2D 
substrate for the analysis of vessel-like structure formation (Roubelakis et al., 
2013). Each co-culture seeding technique was seeded as follows: 
HUVEC>AFSC co-culture: Confluent cultures of HUVECs were washed with 
phosphate buffered saline (PBS) (Sigma-Aldrich, Schnelldorf, Germany), 
trypsinised and centrifuged as detailed previously in Section 2.2.1 (Chapter 2). 
1.2x105 HUVECs were seeded onto cell culture dishes and maintained in 2 mL 
of EndoGro™ media. HUVECs were cultured on the dishes for 72 h to facilitate 
cell attachment and proliferation. After 72 h, 3x104 AFSCs were added to the dish 
for a final cell ratio of 4:1 HUVECs: AFSCs and a final total cell number of 
approximately 1.5 x105. Media was replaced every 3 days. The cells were fixed 
on day 14 using 3.7% paraformaldehyde (PFA) (Sigma-Aldrich, Schnelldorf, 
Germany), washed and stored in PBS at 4°C. Collagen type 1 coated dishes were 
seeded with 1.2x105 HUVECs as an endothelial cell monoculture control. 
AFSC>HUVEC co-culture: Confluent cultures of AFSCs were washed with PBS, 
trypsinised and centrifuged as detailed previously in Section 2.2.1 (Chapter 2). 
1.2x105 AFSCs were seeded onto each cell culture dish and maintained in 2 mL 
of EndoGro™ media. AFSCs were cultured on the dish for 24 h to facilitate cell 
attachment and proliferation. After 24 h, 3x104 HUVECs were added to each dish 
for a final cell ratio of 1:4 HUVECs: AFSCs and a final total cell number of 
approximately 1.5 x105. Media was replaced every 3 days. The cells were fixed 
on day 7 or 14 using 3.7% PFA and stored in PBS at 4°C. Collagen type 1 coated 
dishes were seeded with 1.2x105 HUVECs as an endothelial cell monoculture 
control. 
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3.2.3 Assessing the optimal AFSC-HUVEC co-culture seeding 
technique for vessel-like structure formation on CCS scaffolds 
Fabrication of CCS scaffolds 
CCS scaffolds were fabricated using a previously described freeze-drying 
technique (O'Brien et al., 2004).  CCS scaffolds were composed of 0.5 % (w/v) 
micro-fibrillar type 1 bovine tendon collagen (Integra Life Sciences, Plainsboro, 
NJ) with chondroitin-6-sulfate, isolated from shark cartilage (Sigma-Aldrich, 
Schnelldorf, Germany). CCS suspensions were made by dissolving collagen and 
chondrotin-6-sulfate separately in 0.05 M (pH 3.2) glacial acetic acid and blending 
using an overhead blender (IKA Works Inc, Wilmington, NC, USA) at 15,000 
RPM. The blending process was carried out for 3.5 h at 4°C in a cooling system 
(Brinkman, Westbury, CT, USA) in order to prevent denaturation of the collagen. 
The final concentration of the slurry was 0.5% (w/v) collagen and 0.044% (w/v) 
chondroitin-6-sulfate. The slurry was then degassed in a vacuum desiccator to 
remove any air bubbles, which could disrupt the architecture of the scaffold during 
the freeze-drying process. 67.5 mL of slurry was pipetted into a steel pan (5 x 5 
in, grade 304 SS) and placed onto the shelf of the freeze dryer (Advantage EL, 
VirTis Co., Gardiner, NY) at room temperature. The chamber and the shelf of the 
freeze dryer were cooled at a constant rate to a final temperature of freezing (Tf) 
and held constant for 60 min. This creates a homogenous pore structure 
throughout the scaffold via homogenous ice crystal nucleation, provided by the 
constant cooling rate. The ice phase was then sublimated under vacuum 
(>100mTorr) at 0°C for 17 h. The scaffolds used for these experiments were 
ramped down to a Tf of -10°C creating a final mean pore size of 325μm (Murphy 
et al., 2010a, Haugh et al., 2011), which is within the previously determined 
optimal pore size range for vascularisation (Bai et al., 2010a). 
Scaffolds were then dehydrothermally (DHT) cross-linked for stabilisation and 
sterilisation (Haugh et al., 2011). DHT crosslinking was performed by placing the 
scaffolds within aluminium foil packets into a vacuum oven (VacuCell, MMM, 
Germany). The scaffolds were exposed to a vacuum of 50 mTorr at 105°C for 25 
h. After removal from the oven, the scaffolds were stored as before. The scaffolds 
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were cut using a disposable 6 mm biopsy punch (Kai Medical, Soligen, Germany) 
and stored in the dark at room temperature until use. Prior to use, scaffolds were 
hydrated in PBS. The scaffolds were then added to a mixture of 14 mM N-(3-
Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDAC) and 5.5 mM 
N-Hydroxysuccinimide (NHS) in distilled water (Sigma-Aldrich, Schnelldorf, 
Germany), for 2 h. Any remaining EDAC/NHS was removed by washing the 
scaffolds in PBS on an orbital shaker for 30 min. PBS was refreshed after 15 min. 
Scaffolds were then stored for a maximum of 10 days in fresh PBS at 4°C until 
ready for use. 
 
Scaffold seeding 
HUVEC>AFSC co-culture: Excess PBS was removed from the scaffolds and they 
were placed in cell suspension 24-well plates (Starstedt, Nümbrecht, Germany). 
A 25 μL cell suspension containing 2x105 HUVECs was seeded onto each side 
of the 6 mm diameter, 4 mm height scaffold with a 30 min incubation period at 
37°C between sides in order to facilitate cell attachment. HUVECs were cultured 
on the scaffold in 2 mL of EndoGro™ for 72 h to facilitate cell attachment and 
proliferation. After 72 h, 5x104 AFSCs were seeded onto each side of the scaffold 
for a final cell ratio of 4:1 HUVECs: AFSCs and a final total cell number of 
approximately 5x105. The scaffold was then incubated for a 30 min period at 37°C 
between sides in order to facilitate cell attachment. After this 30 min period, the 
scaffold was cultured in a fresh 2 mL of EndoGro™. Media was replaced every 3 
days. Scaffolds fixed on day 14 using 3.7% PFA and were washed and stored in 
PBS at 4°C.  Scaffolds seeded with 4x105 total HUVECs were used as an 
endothelial cell monoculture control. 
AFSC>HUVEC co-culture: A 25 μL cell suspension containing 2x105 AFSCs was 
seeded onto each side of the scaffold with a 30 min incubation period at 37°C 
between sides in order to facilitate cell attachment. AFSCs were cultured on the 
scaffold in 2 mL of EndoGro™ for 24 h to facilitate cell attachment and 
proliferation. After 24 h, 5x104 HUVECs were seeded onto each side of the 
scaffold for a final cell ratio of 1:4 HUVECs: AFSCs and a final total cell number 
of approximately 5x105. After the two 30 min incubation periods, a fresh 2 mL of 
EndoGro™ was added to the scaffold. Media was replaced every 3 days. 
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Scaffolds were fixed on day 7 and 14 using 3.7% PFA and washed and stored in 
PBS at 4°C. Scaffolds seeded with 4x105 total HUVECs were used as an 
endothelial cell monoculture control. 
Staining and imaging vessel-like structure formation on a 2D 
monolayer and on CCS scaffolds 
Fluorescent PECAM (CD31) staining was performed to allow for the detection of 
vessel-like structures on a 2D monolayer and on CCS scaffolds. Fixed samples 
were washed in PBS (Sigma-Aldrich, Schnelldorf, Germany) and permeabilised 
in 0.002% Triton/PBS (Sigma-Aldrich, Schnelldorf, Germany) for 10 min. 
Samples were washed in PBS and then incubated in a 1:50 dilution of monoclonal 
mouse anti-human CD31 antibody (Dako, Hamburg, Germany) in 1% bovine 
serum albumin (BSA)/PBS (Sigma-Aldrich, Schnelldorf, Germany). Samples 
were washed in PBS and subsequently incubated in a 1:1000 dilution of goat anti-
mouse 488 (Life Technologies, Darmstadt, Germany) in 1% BSA/PBS for 1 h. 
Samples were then washed twice in PBS and then the cell nuclei stained using a 
1:10000 dilution of Hoechst Stain solution in PBS (Sigma-Aldrich, Schnelldorf, 
Germany) for 5 min. Samples were washed and stored in PBS at 4°C until use. 
 
CD31-stained vessel-like structures on a 2D monolayer were imaged using 
epifluorescence microscopy (4x objective, Keyence BZ-9000, Keyence, Neu-
Isenburg, Germany) with BZ II viewer software (Keyence, Neu-Isenburg, 
Germany).  
 
CD31-stained vessel-like structures on CCS scaffolds were imaged using a 
confocal microscope (10x objective, Leica TCS SP2, Leica Microsystems, 
Wetzlar, Germany) and the resulting images were merged using ImageJ (ImageJ, 
U.S. National Institutes of Health, Maryland, USA).  
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3.2.4 Assessing the effect of hypoxic culture on the formation of 
vessel-like structures by an AFSC-HUVEC co-culture  
Hypoxic culture regime 
When the optimal AFSC-HUVEC co-culture was identified from the study above, 
it was then used in order to determine the effect of hypoxia on vessel-like 
structure formation. Samples were maintained for 14 days in one of three O2 
conditions: normoxia, intermittent hypoxia and continuous hypoxia. The hypoxic 
culture regime has been previously outlined in Section 2.2.1 (Chapter 2). Briefly, 
co-cultures in normoxia were maintained in an incubator (20% O2, 5% CO2) at 
37°C for the 14 day culture period. Co-cultures in intermittent hypoxia were 
maintained in a hypoxic incubator with adjustable O2 levels (Labotect C200, 
Labotect, Rosdorf, Germany) for 8 h every 24 h. For the remaining 16 h of the 
day, the scaffolds were maintained in a standard incubator at 20% O2. 
Continuous hypoxia groups were also maintained in the hypoxic incubator at 2% 
O2 but for the full 14 day culture period.   
Table 3.1: Summary of culture conditions. 
Normoxia 20% O2 for 14 days 
Intermittent hypoxia 2% O2 for 8 h, followed by 20% O2 for 
16 h per day, for 14 days in total 
Continuous hypoxia 2% O2 for 14 days 
 
The effect of hypoxic culture on the formation of vessel-like lumina 
in a CCS scaffold 
In order to allow for characterisation and quantification of vessel-like structure 
formation within the scaffold in all three O2 conditions, fixed scaffolds were 
embedded in paraffin wax using a tissue processor (ASP300, Leica, Germany) 
and sectioned at 4 µm thickness every 100μm using a microtome (Leica RM2255, 
Leica, Germany). Sections were collected on microscopy slides and used for 
histological analysis. Sections were then deparaffinised with xylene and 
rehydrated in descending grades of ethanol (100% to 50%), washed in dH2O 
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(Sigma-Aldrich, Schnelldorf, Germany) and incubated at 90°C with Target 
Retrieval Solution (diluted 1:10 with dH2O) (Dako, Hamburg, Germany) in order 
to increase staining intensity of the primary antibody. The sections were allowed 
to cool and were then placed into an Autostainer (Autostainer Plus, Dako, 
Hamburg, Germany)  
The autostainer carried out the following steps automatically: sections were 
incubated in peroxidase and Alkaline Phosphatase Blocking Reagent Plus (Dako, 
Hamburg, Germany) for 5 min in order to inhibit non-specific binding of the 
primary antibody. Sections were washed with EnVision FLEX Wash Buffer (Dako, 
Hamburg, Germany) and incubated with the mouse anti-human CD31 primary 
antibody (in EnVision™ FLEX Antibody Diluent) (Dako, Hamburg, Germany) for 
30 min. Sections were washed and incubated with a peroxidase labelled polymer, 
conjugated to goat anti-mouse immunoglobulin buffer (Dako, Hamburg, 
Germany) for 30 min. Sections were washed again and NovaRED Peroxidase 
Substrate Kit (Vector Laboratories Ltd, Peterborough, United Kingdom) was 
applied. The sections were then rinsed in water when a red colour change was 
achieved. Sections were lightly counterstained with Harris haematoxylin stain 
(Sigma-Aldrich, Schnelldorf, Germany). Finally, sections were dehydrated in 
ascending grades of ethanol ending with immersion in xylene. 
Digital images of all stained sections were obtained using an Eclipse 90i 
microscope, DS Ri1 digital camera and NIS Elements software (Nikon, Japan). 
For quantification, 3 slides from each sample were selected, one from the front, 
middle and back of the scaffold. 6 images were taken at 4x objective at random 
positions on each section for analysis. Sections were analysed using a blind 
scoring method to count the number of vessel-like luminal structures formed per 
scaffold.  
The effect of hypoxic culture on cell density  
Double stranded DNA (dsDNA) was quantified as a surrogate measure of cell 
density in the scaffold using the Quant-iT PicoGreen dsDNA assay (Molecular 
Probes, Invitrogen, UK). Scaffolds were flash frozen in liquid nitrogen and stored 
at -80°C until ready for use. A lysis buffer composed of 1:100 β-mercaptoethanol 
(Sigma-Aldrich, Arklow, Ireland): RLT buffer (Qiagen, Ireland) was added to the 
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thawed scaffolds which were then homogenised using a rotor-stator homogeniser 
(Omni International, Germany). Cell lysate was transferred to a QIA shredder Mini 
Spin Column (Qiagen, Ireland) and spun at 13,000 rpm. The filtered lysate was 
transferred to RNase-free tubes and stored at -20°C. The Quant-iT PicoGreen 
dsDNA assay was used according to the manufacturer’s instructions in order to 
calculate the concentration of dsDNA in the lysate. Samples were evaluated on 
a photometric plate reader (Varioskan Flash, Fisher Scientific, Dublin, Ireland) at 
485nm (excitation) and 538nm (emission). Scaffolds seeded with either a HUVEC 
or AFSC monoculture composed of 4x105 cells were used as cell control 
representing each cell component of the co-culture separately. 
The effect of hypoxic culture on VEGF and PDGF-BB secretion 
The concentration of VEGF and PDGF-BB was quantified in order to observe the 
effect of hypoxic culture on angiogenic growth factor secretion patterns. The 
concentration of VEGF and PDGF-BB secreted by cell-seeded scaffolds into the 
media was quantified using a DuoSet ELISA kit (R&D systems, Oxfordshire, UK) 
as per the manufacturer’s instructions. Media was collected at 4, 7, 10 and 14 
days of culture during cell feeding or sample harvesting. Samples were evaluated 
on a photometric plate reader (Tecan Genios Plus, Tecan Group, Männedorf, 
Germany) at 450 nm with corrections at 550 nm.  Scaffolds seeded with either 
4x105 HUVECs or AFSCs were used as a monoculture control representing each 
cell component of the co-culture.  
The effect of hypoxic culture on gene expression of VEGF, VEGFR1 
and VEGFR2 
RNA was extracted from the filtered lysate as previously detailed in Section 2.2.2 
(Chapter 2) using an RNeasy Mini Kit (Qiagen, Ireland) according to the 
manufacturer’s protocol. RNA quality and quantity was determined using an RNA 
nanodrop (Thermo scientific, Massachusetts, USA). Following RNA isolation, 
quantitative real-time PCR (qRT-PCR) was carried out as previously detailed in 
Section 2.2.2 (Chapter 2). The QuantiTect SYBR Green PCR kit (Qiagen, Ireland) 
was used for this process according to the manufacturer’s instructions with the 
QuantiTect primers for VEGF (Hs_VEGFA_6_SG), VEGFR1 (Hs_FLT1_1_SG) 
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and VEGFR2 (Hs_KDR_1_SG). These genes were chosen due to their 
involvement in the VEGF pathway and the theorised sequestration of soluble 
VEGF in hypoxia as outlined in a number of publications (Park et al., 1994, 
Jayasinghe et al., 2009, Ulyatt et al., 2011). All gene expression was normalised 
against 18s (Hs_RRN18S_1_SG), a housekeeping gene commonly used for this 
purpose. Expression of the genes studied was determined using the relative 
quantification ΔΔCt method (Livak and Schmittgen, 2001). Scaffolds seeded with 
either 4x105 HUVECs or AFSCs were used as monoculture controls representing 
each cell component of the co-culture. 
3.2.5 Statistical analysis 
To assess statistical difference between O2 groups, a two-way ANOVA with 
Bonferroni post-test was performed. Error is reported as the standard deviation 
of the mean and significance was determined using a probability value of p<0.05. 
All experiments were carried out with a sample size of 3 unless otherwise stated. 
3.3 Results 
3.3.1 Addition of AFSCs prior to HUVECs results in enhanced 
formation of vessel-like structures on both a 2D monolayer and on 
CCS scaffolds  
In order to determine the most effective seeding technique for the induction of 
vessel-like structure formation by HUVECs in co-culture with AFSCs, both the 
HUVEC>AFSC co-culture and the AFSC>HUVEC co-culture were evaluated on 
a 2D monolayer and on a CCS scaffold.  
When the ability of these two co-culture seeding techniques were assessed on a 
2D monolayer, it was found that the HUVEC>AFSC co-culture did not form 
vessel-like structures by day 14 (Fig. 3.2 A). The AFSC>HUVEC co-culture 
however, was found to be capable of forming vessel-like structures (Fig.3.2 B). 
The HUVEC monoculture was incapable of vessel-like structure formation (Fig. 
3.2 C). However, both the HUVEC>AFSC co-culture and monoculture displayed 
healthy endothelial cells as evidenced by typical cobblestone morphology and 
strong CD31-positive junctions between cells.  
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Figure 3.2: Representative images of fluorescent CD31 staining indicating vessel-like structure 
formation by the AFSC>HUVEC co-culture on a 2D monolayer at day 14. The HUVEC>AFSC co-
culture was incapable of producing vessel-like structures on a 2D monolayer (A). The 
AFSC>HUVEC co-culture, however, formed a network of vessel-like structures (B). The HUVEC 
monoculture (which served as a negative control) was incapable of vessel-like structure formation 
(C). Green represents CD31-positive staining, blue represents Hoechst nuclear stain. Red arrows 
indicate examples of vessel-like structure formation on the 2D monolayer. Scale bar indicates 100 
µm, Inset B scale bar represents 300 µm. 
The HUVEC>AFSC co-culture was also unable to form vessel-like structures on 
CCS scaffolds at day 14 of culture. However, this co-culture did present with a 
number of “pseudo” vessel-like structures due to CD31-positive cells forming 
vessel-shaped arrangements along the struts and around the pores of the 
scaffold (Fig. 3.3 A). In contrast, the AFSC>HUVEC co-culture formed a robust 
network of vessel-like structures on the CCS scaffold (Fig. 3.3 B). Similar to the 
HUVEC>AFSC co-culture, the HUVEC monoculture did not form vessel-like 
structures (Fig. 3.3 C).  
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Figure 3.3: Representative images of fluorescent CD31 staining indicating vessel-like structure 
formation by the AFSC>HUVEC co-culture on a CCS scaffold at day 14 of culture. The 
HUVEC>AFSC co-culture was incapable of producing vessel-like structures (A). The 
AFSC>HUVEC co-culture, however, generated a robust network of vessel-like structures (B). The 
HUVEC monoculture (which served as a negative control) was incapable of vessel-like structure 
formation (C). Green represents CD31-positive staining, blue represents Hoechst nuclear stain. 
Scale bar indicates 300 µm, Inset B scale bar represents 126 µm. 
Due to the lack of vessel-like structure formation by the HUVEC>AFSC co-culture 
on both a 2D monolayer and on a CCS scaffold, it was determined that this co-
culture seeding technique was unsuitable and its use was discontinued. As the 
AFSC>HUVEC co-culture successfully formed vessel-likes structures, this co-
culture seeding technique was used for the remainder of this thesis and will now 
be referred to as the “AFSC-HUVEC co-culture”. 
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3.3.2 Hypoxic culture exerts no beneficial effects on vessel-like 
structures formed by an AFSC-HUVEC co-culture 
Having established that the AFSC>HUVEC co-culture was the optimal cell-
seeding technique for the formation of vessel-like structures, the effect of hypoxic 
culture on vessel-like structure formation on a 2D monolayer was assessed. It 
was evident that as early as day 7 of culture that the co-culture displayed vessel-
like structure formation in normoxia, intermittent hypoxia and continuous hypoxia 
(Fig. 3.4 A,C,E). There appeared to be more vessel-like structures in normoxia 
relative to the other O2 conditions despite the appearance of large monolayer 
patches of CD31-positive HUVECs (Fig. 3.4 A). Culture in intermittent hypoxia 
led to an intermediate level of vessel-like structure formation with fewer patches 
of HUVECs (Fig. 3.4 C). Continuous hypoxia appeared to actively reduce vessel-
like structure growth in comparison to the other groups (Fig. 3.4 E). As expected, 
HUVEC monocultures in normoxia, intermittent hypoxia and continuous hypoxia 
did not form any vessel-like structures (Fig. 3.4 B, D, F). 
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Figure 3.4: Representative images of fluorescent CD31 staining demonstrating the formation of 
vessel-like structures by the AFSC-HUVEC co-culture on a 2D monolayer after 7 days in (A) 
normoxia, (C) intermittent hypoxia and (E) continuous hypoxia. Vessel-like structure formation 
appeared reduced in continuous hypoxia (E) in comparison to normoxia or intermittent hypoxia 
(A, C). HUVEC monocultures did not form vessel-like structures in any O2 condition. Red arrows 
indicate examples of vessel-like structure formation. Green represents CD31-positive staining, 
blue represents Hoechst nuclear stain. Images were taken at 4x objective, inset pictures are 10x. 
Scale bar represents 300 µm and 100 µm for inset pictures. 
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At day 14 of culture, it was observed in that vessel-like structure networks were 
still present in all three O2 conditions (Fig. 3.5 A, C, E). The normoxic group 
appeared to display a greater amount of vessel-like structures in comparison to 
the other two O2 groups. Once again, continuous hypoxia displayed the lowest 
amount of vessel-like structure formation (Fig. 3.5 E) while HUVEC monocultures 
again presented with no vessel-like structures in any of the culture conditions 
(Fig. 3.5 B, D, F). 
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Figure 3.5: Representative images of fluorescent CD31 staining indicating the formation of 
vessel-like structures by the AFSC-HUVEC co-culture on a 2D monolayer after 14 days in (A) 
normoxia, (C) intermittent hypoxia and (E) continuous hypoxia. Vessel-like structure formation 
appeared reduced in intermittent hypoxia and continuous hypoxia in comparison to normoxia. 
HUVEC monocultures did not form vessel-like structures in any O2 condition (B, D, F). Red arrows 
indicate examples of vessel-like structure formation. Green represents CD31 positive staining, 
blue represents Hoechst nuclear stain. Images were taken at 4x objective, inset pictures are 10x. 
Scale bar represents 300 µm and 100 µm for inset pictures. 
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When the effect of hypoxic culture on vessel-like structure formation on a CCS 
scaffold was assessed, fluorescent staining for CD31 demonstrated that as early 
as day 7 of culture, the co-culture generated a robust network of vessel-like 
structures within the porous architecture of the CCS scaffold in all three O2 
conditions (Fig. 3.6 A-C). This is further supported by the inability of the HUVEC 
monoculture to produce vessel-like structures in any O2 condition, although there 
were a large number of pseudo vessel-like structures present due to cells 
arranging on the pores of the scaffold (Fig. 3.6 D-F). Vessel-like structure 
formation in normoxia and intermittent hypoxia appeared to be at similar levels 
throughout the scaffold (Fig. 3.6 A-B). This indicates that continuous hypoxia had 
a more pronounced effect on vessel-like structure formation than intermittent 
hypoxia, as continuous hypoxia displayed a more sparsely distributed network of 
vessel-like structures in comparison to the other O2 conditions (Fig. 3.6 C). 
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Figure 3.6. Confocal microscopy demonstrating the ability of the AFSC-HUVEC co-culture to form 
networks of vessel-like structures within a CCS scaffold after 7 days of culture. Images 
demonstrate that the co-culture formed vessel-like structures in all three O2 conditions (A-C). 
However, vessel-like structure formation was visibly weaker in co-cultures in continuous hypoxia 
(C). The HUVEC monoculture was incapable of any vessel-like structure formation in any O2 
condition but displayed pseudo vessel-like structures due to the porous nature of the scaffold (D-
F). Green represents CD31-positive staining, blue represents Hoechst nuclear stain. Scale bar 
represents 300 µm. 
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It was observed that there were still vessel-like structures present in the CCS 
scaffold after 14 days in culture (Fig. 3.7 A-C). There also appeared to be more 
vessel-like structures present in each O2 condition relative to their day 7 
counterpart (Fig. 3.6 A-C). Intermittent hypoxia appeared to have a less dense 
vessel-like structure network than normoxia (Fig. 3.7 B) further suggesting that 
there was no beneficial of hypoxic culture on vessel-like structure formation. 
Similar to day 7, vessel-like structures in continuous hypoxia displayed a more 
sparse distribution with fewer vessels present than the other two O2 conditions 
(Fig. 3.7 C). At day 14, the HUVEC monoculture did not produce vessel-like 
structures in any O2 condition, further reinforcing the importance of a pericytic 
support cell type in the process of inducing the formation of a vascular network in 
a CCS scaffold (Fig. 3.7 D-F). 
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Figure 3.7: Confocal microscopy demonstrating the ability of the AFSC-HUVEC co-culture to 
form networks of vessel-like structures within a CCS scaffold after 14 days of culture. Images 
demonstrate that the co-culture formed vessel-like structures in all three O2 conditions (A-C). 
Vessel-like structure formation was more complex than that seen at day 7 (Fig. 3.6). Vessel-like 
structure formation appeared weaker in intermittent hypoxia and continuous hypoxia relative to 
normoxia. The HUVEC monoculture did not form vessel-like structures in any O2 condition (D-F). 
Green represents CD31-positive staining, blue represents Hoechst nuclear stain. Scale bar 
represents 300 µm. 
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Hypoxic culture reduces formation of vessel-like lumina by an 
AFSC-HUVEC co-culture in CCS scaffolds 
To allow for characterisation and quantification of vessel-like structure formation 
within the scaffold in all three O2 conditions, lumina present in the centre of the 
vessel-like structures were quantified using CD31 positive histological sections 
(Fig. 3.8). At day 7 and 14 of culture, CD31-positive lumina surrounded by CD31-
positive cells were present throughout the scaffold in all three O2 conditions (Fig. 
3.8 A-F). The lumina were located in the middle of the annular shape of the 
scaffold pores, confirming that they are not just cellular aggregates caused by 
CD31-positive cells lining the scaffold struts. These CD31-positive cellular 
aggregations present along the porous structure of the scaffold made 
identification of genuine lumina difficult. However, these aggregations generally 
manifested as larger and looser round structure in comparison to the smaller, 
genuine lumina.  
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Figure 3.8: Representative images of CD31 immunostaining for lumina within CCS scaffolds. 
CD31-positive cells are stained red. Images demonstrate the presence of lumina produced by the 
AFSC-HUVEC co-culture at day 7 and 14 in all three O2 conditions. Examples of identified luminal 
structures are indicated by blue arrows. Scale bar indicates 100 µm. 
Blind scoring of lumina within the CCS scaffold demonstrated that normoxia 
displayed a two-fold increase in lumina at day 7 relative to the other O2 conditions, 
although this was only significant relative to continuous hypoxia (p<0.05) (Fig. 
3.9).  
127 
 
Culture in intermittent hypoxia induced a non-significant reduction in the number 
of luminal structures relative to normoxia at day 7 (p=0.052) and 14, suggesting 
that even intermittent exposure to hypoxia was enough to negatively affect 
vessel-like structure formation.  
Continuous hypoxia displayed a reduced number of lumina at both time-points 
but this was non-significant at day 14 compared to the other O2 conditions. These 
results corroborate previous data obtained using confocal microscopy that 
suggests that continuous hypoxia reduces levels of vessel-like structure 
formation in CCS scaffolds (Fig. 3.6 and Fig 3.7).  
 
Figure 3.9: Quantification of lumina formed within CCS scaffolds using CD31 immunostaining. 
Blind scoring indicated that the normoxia displayed a significant (p<0.05) two-fold increase in the 
number of lumina in comparison to continuous hypoxia at day 7. The number of lumina was non-
significantly higher in normoxia relative to the other O2 groups at day 14. Values are expressed 
as mean ± standard deviation, n=3. * denotes p<0.05 statistical significance relative to continuous 
hypoxia.  
Overall, quantitative assessment of luminal structures demonstrated that 
although lumina formation by the AFSC-HUVEC co-culture was observed in all 
three O2 conditions, hypoxic culture reduced the number of enclosed vessel-like 
structures present in the CCS scaffold, an effect that was more pronounced in 
continuous hypoxia.  
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Hypoxic culture negatively affects the cell density of the AFSC-
HUVEC co-culture 
Analysis of dsDNA concentration was used as an indicator of the cell density of 
the AFSC-HUVEC co-culture and HUVEC and AFSC monocultures in all three 
O2 conditions (Fig. 3.10). Continuous hypoxia significantly reduced dsDNA 
concentration of the co-culture relative to normoxia and intermittent hypoxia at 
day 7 (p<0.01) and 14 (p<0.001 and p<0.05 respectively) (Fig. 3.10 A). Normoxia 
displayed 25% higher dsDNA concentration compared to intermittent hypoxia at 
day 14 (p<0.05). 
There were no significant differences between HUVEC monocultures maintained 
in normoxia, intermittent hypoxia or continuous hypoxia at day 7 (Fig. 3.10 B). 
There was a significant 25% decrease in dsDNA concentration at day 14 in 
continuous hypoxia (p<0.05) relative to the normoxia.  
In the AFSC monoculture (Fig. 3.10 C), continuous hypoxia displayed a 
significant (p<0.01) 15% decrease in dsDNA concentration relative to normoxia 
at day 7. There were no significant differences between O2 conditions at day 14. 
Overall, both intermittent and continuous hypoxia led to a reduction in dsDNA 
concentration in the co-culture and the HUVEC monoculture at day 7 and 14 and 
in the AFSC monoculture at day 7.  
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Figure 3.10: The effect of hypoxic culture on the dsDNA concentration of an (A) AFSC-HUVEC 
co-culture, (B) HUVEC monoculture and (C) AFSC monoculture seeded on CCS scaffolds. 
Continuous hypoxia significantly decreased the dsDNA concentration of AFSC-HUVEC co-
cultures relative to normoxia and intermittent hypoxia at day 7 (p<0.01) and 14 (p<0.01 and 
p<0.001 respectively). Continuous hypoxia significantly reduced dsDNA concentration two-fold 
relative to intermittent hypoxia at day 14 (p<0.05) (A). Culture in continuous hypoxia induced a 
significant decrease in dsDNA concentration relative to normoxia in the HUVEC monoculture at 
day 14 (p<0.05) (B) and in the AFSC monoculture at day 7 (p<0.01) (C). Values are expressed 
as mean ± standard deviation, n=3. * denotes p<0.05 statistical significance relative to intermittent 
hypoxia. **denotes p<0.01 statistical significance relative to continuous hypoxia. *** denotes 
p<0.001 statistical significance relative to continuous hypoxia. # denotes p<0.01 statistical 
significance relative to continuous hypoxia. ## denotes p<0.05 statistical significance relative to 
continuous hypoxia. ### denotes p<0.01 statistical significance relative to continuous hypoxia. 
Hypoxic culture enhances VEGF and PDGF-BB protein secretion  
In order to observe the effect of hypoxic culture on the secretion pattern of 
angiogenic growth factors VEGF and PDGF-BB, concentration was analysed 
using ELISA (Fig. 3. 11). It was observed that continuous hypoxia induced a 
significant (p<0.001) two-fold increase in VEGF concentration at day 4 relative to 
normoxia and intermittent hypoxia in the AFSC-HUVEC co-culture group (Fig. 
3.11 A). There were no significant differences in VEGF concentration between 
any O2 condition at day 7 or 10. VEGF concentration was significantly higher in 
continuous hypoxia relative to normoxia at day 14 (p<0.05).  
Culture in continuous hypoxia had a similar effect on VEGF secretion in the 
HUVEC monoculture, significantly increasing VEGF concentration two-fold 
relative to normoxia and intermittent hypoxia at day 4 (p<0.001) (Fig. 3.11 B). 
Similar to the results seen in the co-culture, there were no significant differences 
in VEGF concentration between any O2 condition at day 7 or 10. VEGF 
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concentration was also significantly higher in continuous hypoxia relative to 
normoxia at day 14 (p<0.05).  
There were no significant differences in VEGF concentration detected in the 
AFSC monoculture at day 4 or 7 of culture (Fig. 3.11 C). VEGF concentration was 
significantly increased in continuous hypoxia relative to normoxia at day 10 
(p<0.05) and 14 (p<0.001). VEGF concentration was also significantly (p<0.01) 
increased in intermittent hypoxia relative to normoxia at 14. 
Overall, VEGF concentration in the HUVEC monoculture was in a similar range 
to that of the co-culture (approximately 1,500 pg/mL-3,000 pg/mL) over the 
course of the 14 day culture period. VEGF concentration in the AFSC 
monoculture was higher than the other two cell groups with a range of 
approximately 3,000-4,000 pg/mL indicating AFSCs were capable of elevated 
VEGF production, a characteristic that could be beneficial to the formation of 
vessel-like structures by HUVECs in co-culture.  
Figure 3.11: The effect of hypoxic culture on VEGF protein secretion by an (A) AFSC-HUVEC 
co-culture, (B) HUVEC monoculture and (C) AFSC monoculture seeded on a CCS scaffold. VEGF 
secretion by the AFSC-HUVEC co-culture was significantly increased in continuous hypoxia 
relative to normoxia and intermittent hypoxia at day 4 (p<0.001) and relative to normoxia at day 
14 (p<0.05) (A). Continuous hypoxia significantly increased VEGF at day 4 (p<0.01) and 14 
(p<0.05) relative to the other O2 conditions in the HUVEC monoculture (B). In the AFSC 
monoculture, VEGF concentration in continuous hypoxia was significantly increased at day 10 
(p<0.05) and 14 (p<0.001) relative to normoxia. Intermittent hypoxia also significantly (p<0.01) 
increased VEGF concentration relative to normoxia at day 14 (C). Values are expressed as mean 
± standard deviation, n=3. * denotes p<0.05 statistical significance relative to normoxia. **denotes 
p<0.01 statistical significance relative to normoxia. *** denotes p<0.001 statistical significance 
relative to normoxia and intermittent hypoxia. # denotes p<0.001 statistical significance relative 
to intermittent hypoxia. ### denotes p<0.001 statistical significance relative to normoxia. 
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There were no significant differences in PDGF-BB concentration between any of 
the O2 conditions at day 4, 7 or 10 in the AFSC-HUVEC co-culture (Fig. 3.12 A). 
At day 14 of culture, continuous hypoxia significantly (p<0.05) increased PDGF-
BB concentration 30% relative to normoxia.  
Continuous hypoxia significantly enhanced PDGF-BB concentration relative to 
the other O2 conditions at day 4 (p<0.05) and 7 (p<0.001) in the HUVEC 
monoculture (Fig. 3.12 B). PDGF-BB concentration was also significantly 
(p<0.05) higher in continuous hypoxia relative to normoxia at day 10 (p<0.05) and 
14 (p<0.05).  
There were no significant differences between O2 conditions in PDGF-BB 
concentration detected in the AFSC monoculture at any time-point (Fig. 3.12 C). 
Overall, PDGF-BB concentrations detected in the HUVEC monoculture (Fig. 3.12 
B) were ten-fold higher than those observed in the co-culture (Fig. 3.12 A) and 
AFSC monoculture (Fig. 3.12 C), with the co-culture ranging between 1000-3000 
pg/mL and the HUVEC monoculture ranging between 10,000-40,000 pg/mL. The 
AFSC monoculture had the lowest range of PGDF-BB concentration at 
approximately 400-600 pg/mL. This indicates that AFSCs do not secrete high 
levels of PDGF-BB but that HUVECs do. However, when these cell types were 
co-cultured together, the PDGF-BB secretion by HUVECs was reduced, 
suggesting that low PDGF-BB levels in a co-culture may be an indicator that 
stable vessel-like structure formation is taking place as endothelial cells normally 
produce PDGF-BB in order to facilitate pericyte migration to nascent vessels for 
the purpose of stabilisation and maturation. These data suggests that the AFSCs 
behave as pericytes while interacting with HUVECS to form vessel-like structures.  
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Figure 3.12: The effect of hypoxic culture on the PDGF-BB protein secretion by the (A) AFSC-
HUVEC co-culture, (B) HUVEC monoculture and (C) AFSC monoculture seeded on a CCS 
scaffold. PDGF-BB secretion by the AFSC-HUVEC co-culture (A) was significantly (p<0.05) 
increased by culture in continuous hypoxia at day 14. PGDF-BB secretion by the HUVEC 
monoculture (B) displayed significant increases in continuous hypoxia at all time-points. There 
were no significant differences between O2 conditions in PDGF-BB concentration detected in the 
AFSC monoculture at any time-point (C). PGDF-BB secretion levels by the HUVEC monoculture 
ranged between approx. 10,000-40,000 pg/mL, ten-fold higher than that secretion seen by the 
co-culture (A) and AFSC monoculture (C). Values are expressed as mean ± standard deviation, 
n=3. * denotes p<0.05 statistical significance relative to normoxia. *** denotes p<0.001 statistical 
significance relative to normoxia and intermittent hypoxia. # denotes p<0.001 statistical 
significance relative to normoxia and intermittent hypoxia. 
Hypoxic culture upregulates gene expression of VEGF and VEGFR1 
but downregulates VEGFR2  
In order to elucidate why hypoxic culture led to an increase in the secretion of the 
angiogenic growth factors VEGF and PDGF-BB but had a negative effect on 
vessel-like structure formation, gene expression of VEGF, VEGFR1 and 
VEGFR2 was assessed in all three O2 conditions using qRT-PCR (Fig. 3.13).  
In the AFSC-HUVEC co-culture (Fig. 3.13 A-C), continuous hypoxia induced a 
significant (p<0.001) four-fold increase in VEGF gene expression relative to 
normoxia and intermittent hypoxia at day 7 and 14 (Fig. 3.13 A). Continuous 
hypoxia induced a significant (p<0.001) increase in VEGFR1 expression relative 
to the other O2 conditions at day 14 (Fig. 3.13 B). VEGFR2 expression was 
significantly reduced in continuous and intermittent hypoxia relative to normoxia 
(p<0.001 and p<0.05 respectively) at day 7. At day 14, VEGFR2 expression was 
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reduced two-fold relative to intermittent hypoxia (p<0.001) and normoxia (Fig. 
3.13 C).  
In the HUVEC monoculture (Fig. 3.13 D-F), continuous hypoxia induced a 
significant two-fold increase in VEGF expression relative to the other O2 
conditions (p<0.001) at day 14 (Fig. 3.13 D). There was a significant increase in 
VEGFR1 expression in continuous hypoxia relative to normoxia (p<0.001) and 
intermittent hypoxia (p<0.05) at day 14 (Fig. 3.13 E). Continuous hypoxia and 
intermittent hypoxia caused a significant (p<0.05) increase in VEGFR2 
expression relative to normoxia at day 7. At day 14, VEGFR2 expression was 
significantly enhanced two-fold in continuous hypoxia relative to normoxia 
(p<0.001) (Fig. 3.13 F). 
In the AFSC monoculture (Fig. 3.13 G-I), VEGF expression was significantly 
increased five-fold in continuous hypoxia relative to normoxia at day 7 and 14 
(p<0.001) (Fig. 3.13 G). VEGFR1 expression (Fig. 3.13 H) was significantly 
increased three-fold relative to the other O2 conditions at day 7 and 14 (p<0.001). 
Normoxia displayed a significantly (p<0.001) higher level of VEGFR2 than either 
intermittent or continuous hypoxia at day 14 (Fig. 3.13 I). 
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Figure 3.13: qRT-PCR analysis investigating the expression of the angiogenic growth factor 
VEGF and its receptors VEGFR1 and VEGFR2. Expression of these genes was investigated 
using three different cell formulations: AFSC-HUVEC co-culture (A-C), HUVEC monoculture (D-
F) and AFSC monoculture (G-I). An overall trend was observed, in which continuous hypoxia 
upregulated VEGFR1 while simultaneously down-regulating VEGFR2 in all three cell groups. 
Values are expressed as mean ± standard deviation, n=3. * denotes p<0.05 statistical significance 
relative to intermittent hypoxia. **denotes p<0.01 statistical significance relative to continuous 
hypoxia. *** denotes p<0.001 statistical significance relative to continuous hypoxia. # denotes 
p<0.05 statistical significance relative to intermittent and continuous hypoxia. ## denotes p<0.01 
statistical significance relative to normoxia. ### denotes p<0.001 statistical significance relative 
to normoxia. 
Taken together, these data reveal a trend in which continuous hypoxia led to an 
upregulation of VEGF and VEGFR1 in all three cell groups. Continuous hypoxia 
significantly down-regulated VEGFR2 expression in both the AFSC-HUVEC co-
culture and the AFSC monoculture. This indicates that hypoxic culture has an 
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effect on the balance of the expression of VEGF and its receptors, which in turn 
could explain why hypoxic culture negatively effects vessel-like structure 
formation as VEGFR1 may sequester soluble VEGF while the capacity of 
VEGFR2 to interact with VEGF would be reduced along with its expression.  
3.4 Discussion  
The primary objective of the study presented in this chapter was to investigate 
whether an AFSC-HUVEC co-culture could be used to pre-vascularise a CCS 
scaffold, with AFSCs acting as the pericyte source. The secondary objective of 
this study was to investigate whether hypoxic culture could enhance this process. 
The results of this study demonstrated that seeding HUVECs prior to AFSCs in a 
ratio of 4:1 HUVECs: AFSCs did not result in the formation of vessel-likes 
structures on either a 2D monolayer or a CCS scaffold. However, when AFSCs 
were added first, followed by HUVECs at an inverted 1:4 ratio, it resulted in the 
formation of a robust network of vessel-like structures. This is first time that a 
porous scaffold has been successfully pre-vascularised using a co-culture 
containing AFSCs and demonstrates the potential of AFSCs to act as a pericyte 
in newly formed vessels. It was found that intermittent and continuous hypoxia 
reduced vessel-like structure formation despite increasing secretion of the 
angiogenic growth factors VEGF and PDGF-BB. This is possibly due to the 
upregulation of VEGFR1 and an accompanying downregulation of VEGFR2 gene 
expression observed in hypoxia, as increased VEGFR1 has previously been 
associated with the inhibition of VEGF-mediated angiogenesis due to its 
sequestration of soluble VEGF, leading to its inactivation (Munaut et al., 2008). 
Taken together, these results demonstrate that the AFSC-HUVEC co-culture can 
be used to successfully pre-vascularise a CCS scaffold by producing a robust 
network of vessel-like structures and that of the three O2 conditions studied, 
normoxia promoted the highest level of vessel-like structure formation.  
In order to assess the optimal co-culture seeding technique for the production of 
vessel-like structures, the effectiveness of seeding HUVECs prior to AFSCs at 
ratio of 4:1 HUVECs: AFSCs was investigated. This was compared to AFSCs 
seeded prior to HUVECs at an inverted ratio of 1:4. The results demonstrated 
that HUVECs did not arrange into vessel-like structures when seeded first on 
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either a 2D monolayer or on CCS scaffolds. This “HUVEC>AFSC” co-culture 
seeding technique was based on a delayed addition co-culture previously 
developed in our lab that was shown to form vessel-like structures within a CCS 
scaffold using a HUVEC-MSC co-culture (McFadden et al., 2013). As a different 
cell type (MSCs) was used as a pericyte in the co-culture in that study, it was not 
a certainty that it could successfully produce vessel-like structures when applied 
to a co-culture of HUVECs and AFSCs. As the HUVECs outnumbered the AFSCs 
by 4:1 in this seeding technique, the AFSCs may not have been numerous 
enough to provide the necessary structural and functional integrity to be effective 
as a pericyte. However, it was found that when AFSCs were seeded first, the 
HUVECs that were added subsequently (at ratio of 1:4 HUVECs: AFSCs) were 
capable of producing a robust network of vessel-like structures on both a 2D 
monolayer and a CCS scaffold, indicating that this seeding technique allowed 
AFSCs to function effectively as a pericyte. The previous study that pre-
vascularised the CCS scaffold (using a HUVEC-MSC co-culture) found that the 
vessel-like structures began regress and deteriorate by day 14 of culture 
(McFadden, 2013). However, this was not the case with the AFSC-HUVEC co-
culture as there were still vessel-like structures present in the scaffold at day 14 
of culture. 
According to Kirkpatrick et al., a lower proportion of the more proliferative and 
less fastidious cell type is usually necessary for a successful co-culture 
(Kirkpatrick et al., 2011a). This is why the seeding ratio was inverted to 1:4 when 
AFSCs were added first. This ratio of endothelial cell to perivascular cell has 
previously been implemented for the purpose of vascularisation in a number of 
studies (Melero-Martin et al., 2008, Gawlitta et al., 2012a, Roubelakis et al., 
2013). In order to produce the optimal conditions for co-culture mediated vessel-
like structure formation, endothelial and perivascular cells must interact. 
Perivascular cells are known to envelope endothelial cells in both arterial and 
microvascular structures (von Tell et al., 2006, da Silva Meirelles et al., 2008, 
Crisan et al., 2009), demonstrating the importance of a balance between the two 
cell types. It has also been demonstrated that the extracellular matrix produced 
by pericytes is vital for vessel-like structure formation in vitro (Berthod et al., 2006, 
Stratman et al., 2009) so it is also possible that a low number of AFSCs seeded 
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with a high number of HUVECs would be unable to provide the necessary matrix 
deposition to facilitate vessel-like structure formation. Overall, this study is the 
first time that a CCS scaffold (or any porous scaffold) has been successfully pre-
vascularised using a co-culture containing AFSCs. Therefore, this study has 
resulted in the development of a novel co-culture suitable for the purpose of pre-
vascularisation. 
Having determined the optimal seeding technique for the formation vessel-like 
structures by the AFSC-HUVEC co-culture, the effect of hypoxic culture on these 
structures was assessed. It was found that vessel-like structure formation 
appeared to be reduced in both intermittent and continuous hypoxia relative to 
normoxia on both a 2D monolayer and a CCS scaffold. Intermittent hypoxia 
appeared to have a less deleterious effect on vessel-like structure formation than 
continuous hypoxia, suggesting that length of exposure to hypoxia played a role 
in the severity of this effect. Hypoxia has previously been shown to negatively 
affect the proliferation of endothelial cells (Fasanaro et al., 2008, Ulyatt et al., 
2011), for example, Decaris et al. found that the proliferative ability of endothelial 
colony forming cells was significantly reduced when cultured at 4% and 1% O2 
(Decaris et al., 2009). It is a possibility that reduced proliferation of HUVECs in 
hypoxia was disrupting the cellular balance of the co-culture and contribuing to 
the poor vessel-like structure formation seen in continuous hypoxia. Continuous 
hypoxia was also found to significantly decrease dsDNA concentration in the 
AFSC monoculture at day 7. This result was unexpected as fetal stem cells such 
as AFSCs are known to naturally reside in a low O2 environment in vivo (Al-
Asmakh et al., 2007, Ivanovic, 2009). Chronic exposure to hypoxia has also been 
shown to positively affect the proliferation of a number of different stem cell types 
(Grayson et al., 2007, Lee et al., 2009, Lavrentieva et al., 2010, Hung et al., 2012, 
Fotia et al., 2014). However, dsDNA concentration in the AFSC monoculture 
group at day 14 was observed to be at a similar level in all O2 conditions so the 
negative effect of hypoxia on the cell density of the AFSC monoculture was 
temporary.  
Although the importance of hypoxia and the HIF-1α pathway in angiogenesis is 
well documented (Shweiki et al., 1992, Maxwell and Ratcliffe, 2002, Pugh and 
Ratcliffe, 2003, Wang et al., 2007a, Wan et al., 2010), studies have demonstrated 
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that hypoxic culture can have a negative effect on biomaterial-based vessel 
formation (Gawlitta et al., 2012a), for example, Griffith et al. found that hypoxic 
culture degraded a preformed capillary network generated by a co-culture of 
HUVECs and human lung fibroblasts embedded in fibrin within 4 days (Griffith 
and George, 2009) and Athanassopoulos et al. found that lowering O2 tension 
during culture from 21% to 1.5% O2 significantly reduced vascular tubule 
formation in 2D co-cultures of endothelial colony forming cells and MSCs 
(Athanassopoulos et al., 2012). Although these studies observed a negative 
effect of hypoxic culture on vessel formation, there was no prevailing theory to 
explain why this was the case. As a result, this study sought to investigate a 
possible explanation for the negative effect of hypoxic culture on vessel-like 
structure formation. 
In order to elucidate effect of hypoxic culture on the secretion pattern of the pro-
angiogenic growth factors VEGF and PDGF-BB, the concentration of both factors 
was analysed using ELISA. It was found that continuous hypoxia led to a 
significant increase in VEGF concentration in the co-culture and the HUVEC and 
AFSC monocultures relative to normoxia and intermittent hypoxia at a number of 
time-points. This result was expected, as hypoxia has previously been shown to 
increase expression of VEGF in a number of cell types (Namiki et al., 1995, 
Neufeld et al., 1999, Potier et al., 2007). It is possible that there were lower levels 
of VEGF in normoxia and intermittent hypoxia due to its consumption by the cells 
as VEGF is known to be one of the most important growth factors in vessel 
formation (Kaigler et al., 2005, Kasper et al., 2007, Laschke et al., 2009, Laschke 
and Menger, 2012). Furthermore, VEGF acts as a mitogen and a migration 
stimulant to pericytes (Yamagishi et al., 1999) and has been shown to enhance 
the proliferation and complexity of vessel networks in in vitro culture (Geiger et 
al., 2005, Koch et al., 2006, Nillesen et al., 2007). Therefore, one would expect 
that increased VEGF secretion in continuous hypoxia would correspond with an 
increase in vessel-like structure formation in the co-culture. However, similar to 
the data presented in this study, Griffith et al. observed a degradation in vessel 
network formation despite an increase in endogenous VEGF secretion induced 
by hypoxia (Griffith and George, 2009), which indicates that increased VEGF 
does not correlate with increase vessel-structure formation in hypoxic conditions.  
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Continuous hypoxia had a similar effect on PDGF-BB production in the co-culture 
and the HUVEC monoculture, inducing significant increases at a number of time-
points. PDGF-BB and its receptors play a critical role in the recruitment of 
pericytes to newly formed blood vessels by triggering cells’ migratory and 
proliferative responses (Hirschi et al., 1998, von Tell et al., 2006). It has 
previously been demonstrated that HUVECs cultured in 1% O2 undergo a 
significant up-regulation of PDGF-BB protein expression (Kourembanas et al., 
1990, Semenza, 1998). In this study, it was also observed that PDGF-BB 
concentration in the HUVEC monoculture was ten-fold higher than that observed 
in the co-culture and the AFSC monoculture, which is indicative of the lack of 
vessel-like structure formation taking place in the HUVEC monoculture as 
endothelial cells produce PDGF-BB in order to facilitate pericyte migration to 
nascent vessels for the purpose of stabilisation and maturation (Hellstrom et al., 
2001, Armulik et al., 2005a). AFSCs secrete low concentrations of PDGF-BB as 
they are more likely to be attracted by the PDGF-BB secreted by endothelial cells, 
rather than secrete it themselves. These data also suggest that AFSCs were 
acting as a pericyte by interacting with HUVECs to form vessel-like structures, 
which could explain the low PDGF-BB levels observed in the co-culture group, 
as endothelial cells do not need to produce PDGF-BB if vessels have already 
been stabilised. This is consistent with PDGF-BB levels observed in a number of 
other studies (Lee and Niklason, 2010b, Pedersen et al., 2014), for example, a 
study by McFadden et al. demonstrated PDGF-BB secretion by a HUVEC 
monoculture up until the addition of MSCs using a delayed-addition co-culture 
technique (McFadden et al., 2013).  
The effect of continuous hypoxia on VEGF-mediated signalling and angiogenic 
responses in human endothelial cells is not yet fully understood. In order to 
elucidate why the increased levels of VEGF in continuous hypoxia did not 
correlate with enhanced vessel-like structure formation, the expression of the 
VEGF gene and its two main receptors (VEGFR1 and VEGFR2) was 
investigated. Overall, it was observed that continuous hypoxia induced an 
upregulation of VEGF and VEGFR1 while simultaneously downregulating 
VEGFR2. VEGF binding to VEGFR1 and VEGFR2 has been shown to stimulate 
intracellular signalling and cell migration, proliferation and angiogenesis (Hoeben 
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et al., 2004, Takahashi and Shibuya, 2005). However, it has been found that 
chronic exposure to hypoxia causes an increase in the expression of VEGFR1, 
while simultaneously causing a decrease in the expression of VEGFR2 (Gerber 
et al., 1997, Ulyatt et al., 2011, Nevo et al., 2013). Recent studies have suggested 
that VEGFR1 may function as an angiogenic control by sequestering VEGF in 
order to “dampen” VEGFR2-mediated angiogenic signalling (Dvorak, 2002, Pan 
et al., 2010), possibly to prevent VEGF-stimulated and VEGFR2-regulated 
endothelial responses in order  to maximise cell viability and recovery in response 
to stress (Ulyatt et al., 2011). For example, Munaut et al. observed that soluble 
VEGFR1 directly abolished VEGF-induced angiogenesis in a rat aortic ring 
angiogenic assay (Munaut et al., 2008). Therefore, it was theorised that this 
increase in VEGFR1 expression may be a contributing factor in the inhibition of 
vessel-like structure formation seen in intermittent and continuous hypoxia. Long 
term exposure to hypoxia has also previously been shown to decrease VEGF-
stimulated endothelial cell migration, proliferation, and capillary tube formation by 
specific downregulation of VEGFR2 expression (Olszewska-Pazdrak et al., 
2009). Overall, the expression pattern presented in this study is consistent with 
the literature. However, the intermittent hypoxia group did not display consistent 
expression patterns, likely due to the variable nature of its culture conditions, 
although this may explain why this group displayed less inhibition of vessel-like 
structure formation than continuous hypoxia.  
Conclusively, this study shown that AFSCs can function in the role of pericyte 
and that the AFSC-HUVEC co-culture that can be used to generate a network of 
vessel-like structures within a CCS scaffold in vitro. No beneficial effect of hypoxia 
culture on this vessel-like structure formation was found. Based on these results, 
the follow-on study presented in Chapter 4 aimed to assess whether the vessel-
like structure forming ability of the co-culture could be implemented in the pre-
vascularisation of both a collagen-hydroxyapatite and a collagen hyaluronic acid 
scaffold, two scaffolds commonly used by our group for a number of TE 
applications. 
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3.5 Conclusion 
The results of this study demonstrate that the AFSC-HUVEC co-culture was 
capable of successfully pre-vascularising a CCS scaffold, confirming the potential 
of AFSCs as a source of pericytes. Hypoxic culture reduced vessel-like structure 
formation on both a 2D monolayer and a CCS scaffold. Despite the reduction in 
vessel-like structure formation, hypoxia was found to increase secretion of VEGF 
and PDGF-BB and upregulate VEGFR1 gene expression while decreasing 
VEGFR2, providing a possible explanation for the reduced vessel-like structure 
formation i.e. VEGFR1 may sequester soluble VEGF while the capacity of 
VEGFR2 to interact with VEGF would be reduced along with its expression. 
Overall, however, these results demonstrate the potential of this newly developed 
co-culture system for the pre-vascularisation of TE constructs. 
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4.1 Introduction 
In Chapter 3, the ability of a human umbilical vein endothelial cell (HUVEC) and 
amniotic fluid-derived stem cell (AFSC) co-culture to pre-vascularise a collagen-
chondroitin sulphate (CCS) scaffold was demonstrated for the first time. Our lab 
has previously developed a number of other collagen-based composite scaffolds 
for use in a range of tissue engineering (TE) applications including bone (Farrell 
et al., 2006, Al-Munajjed et al., 2009, Cunniffe et al., 2010) and cartilage repair 
(Matsiko et al., 2012, Almeida et al., 2014, Levingstone et al., 2014). These 
scaffolds, like all non-cell seeded biomaterials, do not possess an inherent 
vasculature, which, as outlined in Chapter 3, is a major limiting factor in cell 
survival and implant success in vivo. Further investigation into the ability of the 
AFSC-HUVEC co-culture to pre-vascularise other collagen-based biomaterials 
will potentially allow for the creation of a suite of vascularised TE constructs that 
have the ability to rapidly anastomose with the host vasculature and may have 
potential for a range of clinical applications. 
This chapter focuses on the pre-vascularisation of two collagen-composite 
scaffold types that are the closest to clinical translation in our lab: a collagen-
hydroxyapatite (CHA) and collagen-hyaluronic acid (CHyA) scaffold. 
The CHA scaffold is a patented scaffold type (W02008/096334) which is licensed 
to the RCSI spin-out company SurgaColl Technologies (commercialised under 
the trade name HydroxyColl™). It was developed by our group by incorporating 
osteoinductive hydroxyapatite (HA) particles into a porous, biocompatible 
collagen scaffold with the aim of creating a construct with enhanced mechanical 
properties and osteogenic potential for use in bone repair. This scaffold 
subsequently exhibited significantly improved bioactivity and mineralisation in 
vitro and was capable of healing a critical-sized bone defect in vivo (Gleeson et 
al., 2010). Given bone’s native composition of predominantly collagen type 1 and 
HA, these materials are an obvious choice as the basis for a composite scaffold 
capable of supporting and promoting bone regeneration (Wahl and Czernuszka, 
2006). McFadden et al. previously generated a network of vessel-like structures 
within this scaffold type using a delayed addition co-culture consisting of HUVECs 
and bone marrow derived mesenchymal stem cells (MSCs). However, this study 
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observed delayed and generally poor vessel-like structure formation in the CHA 
scaffold over the course of a 21 day culture period. Despite this, it was found that 
the CHA scaffold could better facilitate mineralisation and osteogenesis relative 
to a CCS scaffolds, further demonstrating the potential of these scaffolds for use 
in bone repair (McFadden, 2012). 
The importance of pre-vascularising a CHA scaffold cannot be understated as 
proximity to vessel networks has also been shown to enhance bone formation in 
HA constructs in vivo. Akita et al. found that a synthetic, porous HA biomaterial 
implanted in vivo with a vascular insertion of superficial epigastric vessels 
developed a number of large blood vessels derived from these inserted vascular 
bundles. A large amount of newly formed bone was observed around the pores 
of the construct in close proximity to the vascular bundles. Porous HA that was 
implanted without a vascular bundle showed poor bone formation in comparison 
(Akita et al., 2004). This further reinforces the importance of a readily available 
vessel network in TE constructs for bone repair. 
The CHyA scaffold was previously developed by our group by incorporating 
hyaluronic acid (HyA) in place of chondroitin sulphate into a porous, 
biocompatible collagen scaffold with the aim of creating a construct for use in 
cartilage repair. The presence of HyA in this scaffold was shown to improve the 
cellular infiltration and migration of MSCs, as well as accelerate chondrogenic 
gene expression and matrix production in comparison to CCS scaffolds (Matsiko 
et al., 2012). HyA is a non-sulphated GAG that functions as a ‘backbone’ 
component in the binding and retention of other GAGs to form aggregating 
proteoglycans. It is found primarily in the extracellular matrix in connective tissues 
and plays an important structural role in a number of tissues in the body. HyA-
based biomaterials have also previously been used for a variety of TE 
applications including soft tissue extracellular matrix regeneration (Tuin et al., 
2012, Dahiya and Kamal, 2013) and the repair of vascular (Pandis et al., 2011), 
bone (Angele et al., 1999, Aslan et al., 2006) and corneal tissues (Gomes et al., 
2004). Therefore, a pre-vascularised CHyA scaffold could have potential in a 
range of TE applications. For example, a pre-vascularised CHyA construct could 
potentially utilise the innate pro-chondrogenic characteristics of this scaffold-type 
in order to provide a new approach to bone repair by mimicking the process of 
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endochondral ossification. This endochondral ossification-centric approach to 
bone repair has been more prominent in recent years, as it offers an alternative, 
more biologically relevant approach to bone repair as seeks to replicate the steps 
of embryological long bone development (Thompson et al., 2014). This approach 
involves facilitating the deposition of cartilaginous matrix within the construct and 
facilitating the mineralisation of this matrix, commonly through the in-growth of 
host vessels in vivo (Farrell et al., 2009, Oliveira et al., 2009). The pre-
vascularisation of the CHyA scaffold provides the vessel-like structures required 
for endochondral ossification without the need host vessel invasion, potentially 
simplifying this approach to bone repair. However, the CHyA scaffold has never 
before been vascularised as it has been solely used in the repair of cartilage, an 
avascular tissue.  
In this study, it was hypothesised that the AFSC-HUVEC co-culture developed in 
Chapter 3 could be adapted for use in the pre-vascularisation of two collagen-
composite scaffolds previously developed by our group; CHA and CHyA. 
Therefore, the primary objective of this study was to investigate the ability of the 
AFSC-HUVEC co-culture to form a network of vessel-like structures within CHA 
and CHyA scaffolds over the course of a 14 day culture period. The secondary 
objective of this study was to investigate whether the development of these 
vessel-like structures was affected by scaffold composition.  
4.2 Methods 
4.2.1 Scaffold fabrication 
Fabrication of CHA scaffolds 
CHA scaffolds were fabricated using a previously described freeze-drying 
technique (O'Brien et al., 2004, Gleeson et al., 2010). A collagen suspension was 
made by dissolving 0.5% (w/v) bovine-derived collagen type 1 (Collagen Matrix, 
USA) in 0.1 M glacial acetic acid and blended at 15,000 rpm (IKA Works Inc, 
Wilmington, NC, USA) for 90 min in a cooling system (Brinkman, Westbury, CT, 
USA) at 4°C in order to prevent denaturation of the collagen. 3.6 g (200% wt) of 
HA was combined with 40 mL acetic acid.  This suspension was added to the 
collagen slurry in 10 mL aliquots every 30 min. The blending process was 
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continued for an additional 60 min after the final 10 mL of HA suspension was 
added (total blending time of 5.5 h). The slurry was then degassed in a vacuum 
desiccator to remove any air bubbles, which could disrupt the architecture of the 
scaffold during the freeze-drying process. 67.5 mL of slurry was pipetted into a 
steel pan (5 x 5 in, grade 304 SS) and placed onto the shelf of the freeze dryer 
(Advantage EL, VirTis Co., Gardiner, NY) at room temperature. The CHA 
suspension was freeze-dried (Virtis Genesis 25EL, Biopharma, Winchester, UK) 
at a constant cooling rate of 1°C/min to a final temperature of -40°C, resulting in 
a scaffold with a mean pore size of ~120 μm. Following freeze-drying, scaffolds 
were dehydrothermally (DHT) cross-linked for both stabilisation and sterilisation 
(Haugh et al., 2011). DHT crosslinking was performed by placing the scaffolds 
within aluminium foil packets into a vacuum oven (VacuCell, MMM, Germany). 
The scaffolds were exposed to a vacuum of 50 mTorr at 105°C for 25 h. After 
removal from the oven, the scaffolds were stored as before. The scaffolds were 
cut using a disposable 6 mm biopsy punch (Kai Medical, Soligen, Germany) and 
stored in the dark at room temperature until use. Prior to use, scaffolds were 
hydrated in phosphate buffered saline (PBS). The scaffolds were then added to 
a mixture of 14 mM N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (EDAC) and 5.5 mM N-Hydroxysuccinimide (NHS) in distilled water 
(Sigma-Aldrich, Arklow, Ireland) for 2 h. Any remaining EDAC/NHS was removed 
by washing the scaffolds in PBS on an orbital shaker for 30 min. PBS was 
refreshed after 15 min. Scaffolds were then stored for a maximum of 10 days in 
fresh PBS at 4°C until ready for use. 
Fabrication of CHyA scaffolds 
CHyA scaffolds were fabricated using a freeze-drying method that has been 
previously described (O'Brien et al., 2004, Matsiko et al., 2012).  CHyA scaffolds 
were composed of bovine-derived collagen type 1 (Collagen Matrix, USA) and 
HyA sodium salt derived from streptococcus equi (Sigma-Aldrich, Arklow, 
Ireland). CHyA suspensions were made by dissolving collagen and HyA in 0.5 M 
(pH 3.2) glacial acetic acid separately and blending at 15,000 rpm (IKA Works 
Inc, Wilmington, NC, USA). The blending process was carried out for 3.5 h in a 
cooling system (Brinkman, Westbury, CT, USA) at 4°C in order to prevent 
denaturation. The final concentrations of the suspensions were composed of 
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0.5% (w/v) collagen and 0.05% (w/v) HyA.  The slurry was then degassed in a 
vacuum desiccator to remove any air bubbles, which could disrupt the 
architecture of the scaffold during the freeze-drying process. 67.5 mL of slurry 
was pipetted into a steel pan (5 x 5 in, grade 304 SS) and placed onto the shelf 
of the freeze dryer (Advantage EL, VirTis Co., Gardiner, NY) at room 
temperature. The slurry was then freeze-dried (Virtis Genesis 25EL, Biopharma, 
Winchester, UK) at a constant cooling rate of 1°C/min to a final temperature of -
20°C with an additional annealing step (-10°C held for 24 h) resulting in a scaffold 
with a mean pore size of 300 μm. Following freeze-drying, the scaffolds were cut 
using a disposable 6mm biopsy punch (Kai Medical, Soligen, Germany) and 
stored in the dark at room temperature until use. Prior to use, scaffolds were 
hydrated in PBS.  The scaffolds were cross-linked using DHT and EDAC 
treatment as described in the previous section. 
4.2.2 Cell culture 
All cell culture work was carried out under sterile conditions in a laminar flow hood 
(SterilGard 111, MSC, Ireland). All cells were maintained at 37°C in a 5% CO2 
atmosphere in an incubator. 
Culture of AFSCs 
AFSCs were cultured as previously outlined in Section 2.2.1 (Chapter 2). All 
AFSCs used during this experiment did not exceed passage 24. 
Culture of HUVECs 
HUVECs were isolated and cultured as previously outlined in Section 3.2.1 
(Chapter 3). All HUVECs used during this experiment did not exceed passage 4. 
Scaffold seeding 
CHA and CHyA scaffolds were seeded with an AFSC-HUVEC co-culture as 
previously as outlined in Section 3.2.3 (Chapter 3). Confluent cultures of AFSCs 
were washed with PBS, trypsinised and centrifuged as detailed previously. Co-
cultures were seeded at a ratio of 1:4 HUVECs: AFSCs. Excess PBS was 
removed from the scaffolds and they were placed in cell suspension 24-well 
plates (Starstedt, Nümbrecht, Germany). A 25 μL cell suspension containing 
2x105 AFSCs was seeded onto each side of the 6 mm diameter, 4 mm high 
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scaffold with a 30 min incubation period at 37°C between sides in order to 
facilitate cell attachment. AFSCs were cultured on the scaffold for 24 h to facilitate 
cell attachment and proliferation. After 24 h, 5x104 HUVECs were seeded onto 
each side of the scaffold. After this 30 min period, the scaffold was cultured in a 
fresh 2 mL of EndoGro. Media was replaced every 3 days. Scaffolds seeded with 
4x105 HUVECs were used as an endothelial cell monoculture control. 
4.2.3 Assessing the ability of CHA and CHyA scaffolds to support 
vessel-like structure formation 
CD31 staining for vessel–like structure formation in cell-seeded 
scaffolds 
Scaffolds were stained for CD31 to allow for the detection of vessel-like structures 
as previously outlined in Section 3.2.3 (Chapter 3). Briefly, fixed samples were 
washed in PBS and permeabilised in Triton X/ PBS (Sigma-Aldrich, Arklow, 
Ireland) for 10 min. Samples were washed in PBS and then incubated in 
monoclonal mouse anti-human CD31 antibody (Dako, Hamburg, Germany) for 1 
h. Samples were washed again and subsequently incubated in goat anti-mouse 
488 secondary antibody (Dako, Hamburg, Germany) for 1 h. Samples were then 
washed twice in PBS and cell nuclei were stained using a 1:2000 dilution of 4',6-
diamidino-2-phenylindole (DAPI) in PBS for 5 min. The scaffolds were washed 
and stored in PBS at 4°C until use. 
Confocal imaging of CD31 stained cell-seeded scaffolds  
For representative images of vessel-like structures, scaffolds were imaged using 
a confocal microscope (Carl Zeiss LSM 710, Carl Zeiss, Jena, Germany). All 
images were taken using a 10x water dipping objective (W N-Achroplan 10x W 
(DIC) M27).  The resulting Z-projections were created using ImageJ (ImageJ, U. 
S. National Institutes of Health, Maryland, USA). A fixed laser power, pinhole, 
detector gain and dwell time were used to ensure that images were comparable. 
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VEGF and PDGF-BB protein secretion by AFSC-HUVEC co-cultures 
and HUVEC monocultures seeded on CHA and CHyA scaffolds 
The concentration of VEGF and PDGF-BB released by cell-seeded scaffolds into 
the media was quantified using a DuoSet ELISA kit (R&D systems, Oxfordshire, 
UK) as per the manufacturer’s instructions. Media was collected at day 4, 7, 10 
and 14 of culture. Samples were evaluated on a photometric plate reader 
(Varioskan Flash, Fisher Scientific, Dublin, Ireland) at 450 nm with corrections at 
570 nm. 
Cell density of AFSC-HUVEC co-cultures and HUVEC monocultures 
seeded on CHA and CHyA scaffolds 
Double stranded DNA (dsDNA) was quantified as a surrogate measure of cell 
density in the scaffold using the Quant-iT PicoGreen dsDNA assay (Molecular 
Probes, Invitrogen, UK). Scaffolds were flash frozen in liquid nitrogen and stored 
at -80°C until ready for use. A lysis buffer composed of 0.2 M carbonate buffer 
(Sigma-Aldrich, Arklow, Ireland) containing 1% Triton X was added to thawed 
scaffolds which were then subjected to three freeze thaw cycles at -80°C before 
the assay was performed. A Quant-iT PicoGreen dsDNA Assay Kit (Invitrogen, 
California, USA) was used according to the manufacturer’s instructions in order 
to calculate the concentration of dsDNA in the lysate. Samples were evaluated 
on a photometric plate reader (Varioskan Flash, Fisher Scientific, Dublin, Ireland) 
at 485nm (excitation) and 538nm (emission). Scaffolds seeded with 4x105 
HUVECs were used as an endothelial cell monoculture control. 
Quantifying vessel-like structure formation in CHA and CHyA 
scaffolds 
Similar to representative images of vessel-like structures, scaffolds were imaged 
using a confocal microscope (Carl Zeiss LSM 710, Carl Zeiss, Jena, Germany). 
Identical detection and scan settings were used across all scaffolds replicates. 
Four Z-stacks from each sample were collected, starting at the upper surface of 
the scaffold.  Each Z-stack was comprised of 25 optical sections of 6.663 μm to 
yield a total volume of 0.115 mm3.  
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Three dimensional renderings were created using Volocity 64 bit, Version 3.7.0, 
Build 146 (Improvision Ltd, PerkinElmer Inc., Waltham, Massachusetts, USA). 
Staining of vessel-like structures was quantified using image processing 
functions found in ImageJ. A macro was used to ensure that all images were 
processed in the same manner and to minimise the introduction of human bias. 
The CD31 channel was first separated from the stack and a threshold defined. A 
two dimensional ‘Smooth’ was used to simplify the image and the threshold set 
to produce a binary image. Basic 3D Gaussian noise removal was then performed 
before using "3D Objects Counter" to calculate surface area of vessel-like 
structure networks. The binary image and resultant data was saved and compiled 
in excel. A visual comparison with the original images was then made to ensure 
consistency and accuracy. Total surface area was used as a surrogate measure 
of vessel-like structure network density. 
4.2.4 Statistical analysis 
To assess statistical difference between time-points in the VEGF and PDGF-BB 
analysis, a one-way ANOVA with Tukey post-test was performed. To assess 
statistical difference in cell density and total vessel-like structure surface area 
between scaffold types, a two-way ANOVA with Bonferroni post-test was 
performed. Error is reported as the standard deviation of the mean and 
significance was determined using a probability value of p<0.05. All experiments 
were carried out with a sample size of 3 unless otherwise stated. 
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4.3 Results 
4.3.1 The AFSC-HUVEC co-culture forms vessel-like structures within 
CHA scaffolds  
Confocal imaging demonstrated that the AFSC-HUVEC co-culture had formed 
vessel-like structures within the CHA scaffold as early as day 7 of culture (Fig. 
4.1 A). This network of vessel-like structures was still present at day 14, indicating 
network stability (Fig. 4.1 B). The HUVEC monoculture was incapable of vessel 
formation at day 7 or 14 of culture (Figure 4.1 C and D). 
 
Figure 4.1: Vessel-like structure formation by the AFSC-HUVEC co-culture within a CHA scaffold 
at day 7 and 14 of culture as demonstrated by confocal microscopy. The HUVEC monoculture 
did not form any vessel-like structures (C-D). Green represents CD31 positive staining, blue 
represents DAPI nuclear stain. Scale bar represents 300µm. 
152 
 
AFSC-HUVEC co-cultures seeded on CHA scaffolds display VEGF 
and PDGF-BB secretion patterns indicative of vessel-like structure 
formation 
VEGF protein secretion by an AFSC-HUVEC co-culture and HUVEC 
monoculture seeded on a CHA scaffold was quantified using ELISA at day 4, 7, 
10 and 14 of culture (Fig. 4.2).  
A gradual increase in VEGF concentration was observed over the 14 day culture 
period in the co-culture (Fig. 4.2 A). VEGF concentration at day 10 was found to 
be significantly increased two-fold relative to day 4 (p<0.01) and day 7 (p<0.05). 
VEGF levels at day 14 were significantly increased two-fold relative to day 4 
(p<0.05). It was found that VEGF concentration levels in the co-culture remained 
within the range of 1000-2000 pg/mL. 
A similar increase in VEGF concentration over the course of the culture period 
was observed in the HUVEC monoculture (Fig. 4.2 B). VEGF concentration at 
day 10 was significantly increased two-fold relative to day 4 (p<0.01) and day 7 
(p<0.05). VEGF concentration at day 14 was significantly increased two-fold 
relative to day 4 (p<0.05). VEGF concentration levels in the monoculture group 
were found to be within the range of 1000-3500 pg/mL, similar to the VEGF 
concentration range observed in the co-culture.  
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Figure 4.2: VEGF protein secretion by an (A) AFSC-HUVEC co-culture and (B) HUVEC 
monoculture seeded on a CHA scaffold at day 4, 7, 10 and 14 of culture. In the co-culture (A), 
VEGF concentration at day 10 was found to be significantly increased two-fold relative to day 4 
(p<0.01) and day 7 (p<0.05). VEGF levels at day 14 were significantly increased two-fold relative 
to day 4 (p<0.05). In the HUVEC monoculture (B), VEGF concentration at day 10 was significantly 
increased two-fold relative to day 4 (p<0.01) and day 7 (p<0.05). VEGF levels at day 14 were 
significantly increased two-fold relative to day 4 (p<0.05). Values are expressed as mean ± 
standard deviation, n=3. * denotes p<0.05 statistical significance relative to day 4. ** denotes 
p<0.01 statistical significance relative to day 4. # denotes p<0.05 statistical significance relative 
to day 7. ## denotes p<0.01 statistical significance relative to day 4. 
PDGF-BB protein secretion by an AFSC-HUVEC co-culture and HUVEC 
monoculture seeded on a CHA scaffold was quantified using ELISA at day 4, 7, 
10 and 14 of culture (Fig. 4.3).  
There were no significant differences observed between time-points during the 
14 day culture period in the AFSC-HUVEC co-culture (Fig. 4.3 A). PDGF-BB 
concentration in the co-culture group remained between 2000-3000 pg/mL. 
In a HUVEC monoculture, an increase in PDGF-BB concentration was observed 
over the course of the culture period. There was an approximate seven-fold 
increase in PDGF-BB expression at day 10 relative to day 4 (p<0.001) and 7 
(p<0.01) (Fig. 4.3 B). This significant seven-fold difference was still present at day 
14 relative to day 4 (p<0.001) and 7 (p<0.01). Overall, PDGF-BB concentration 
in the monoculture group reached approximately 15,000 pg/mL, approximately 
five-fold higher than the highest value observed in the co-culture (approximately 
3000 pg/mL). 
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Figure 4.3: PDGF-BB protein secretion by an (A) AFSC-HUVEC co-culture and (B) HUVEC 
monoculture seeded on a CHA scaffold at day 7 and 14 of culture. There were no significant 
differences observed between time-points during the 14 day culture period in the co-culture (A). 
In the HUVEC monoculture (B), there was a seven-fold increase in PDGF-BB expression at day 
10 relative to day 4 (p<0.001) and 7 (p<0.01). There was also a seven-fold increase in at day 14 
relative to day 10 (p<0.001) and 14 (p<0.01). Values are expressed as mean ± standard deviation, 
n=3. ** denotes p<0.01 statistical significance relative to day 4. *** denotes p<0.001 statistical 
significance relative to day 7.  
4.3.2 The AFSC-HUVEC co-culture forms vessel-like structures within 
CHyA scaffolds  
The AFSC-HUVEC co-culture also formed a network of vessel-like structures 
within the CHyA scaffold the as early as day 7 of culture (Fig. 4.4 A). This vessel-
like structure network was also present day 14 of culture, indicating its stability 
(Fig. 4.4 B). The HUVEC monoculture did not form vessel-like structures at either 
time-point (Figure 4.4 C and D). 
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Figure 4.4: Vessel-like structure formation by the AFSC-HUVEC co-culture within a CHyA 
scaffold at 7 and 14 days of culture as demonstrated by confocal microscopy. The HUVEC 
monoculture was incapable of formation any vessel-like structures (C-D). Green represents CD31 
positive staining, blue represents DAPI nuclear stain.  Scale bar represents 300µm. 
AFSC-HUVEC co-cultures seeded on CHyA scaffolds display VEGF 
and PDGF-BB secretion patterns indicative of vessel-like structure 
formation 
VEGF protein secretion by an AFSC-HUVEC co-culture and HUVEC 
monoculture seeded on a CHyA scaffold was quantified using ELISA at day 4, 7, 
10 and 14 of culture (Fig. 4.5).  
Similar to CHA scaffolds, VEGF levels in the co-culture gradually increased over 
the course of the culture period (Fig. 4.5 A). VEGF concentration at day 10 and 
14 was significantly (p<0.05) increased two-fold relative to day 4. VEGF 
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concentration levels in the co-culture group remained within the range of 1000-
2000 pg/mL. 
VEGF concentration was significantly (p<0.05) increased one and a half-fold at 
day 7 relative to day 4 in the HUVEC monoculture (Fig. 4.5 B). There were no 
significant differences between any other time-points during the culture period. 
VEGF concentration levels in the monoculture remained within the range of 1000-
2000 pg/mL, similar to the VEGF concentration range observed in the co-culture 
group. 
Figure 4.5: VEGF protein secretion by an (A) AFSC-HUVEC co-culture and (B) HUVEC 
monoculture seeded on a CHyA scaffold at day 4, 7, 10 and 14 of culture. In the co-culture (A), 
VEGF concentration at day 10 and 14 was significantly (p<0.05) increased two-fold relative to day 
4. In the monoculture (B), VEGF concentration was significantly (p<0.05) increased one and a 
half-fold at day 7 relative to day 4. * denotes p<0.05 statistical significance relative to day 4. ** 
denotes p<0.01 statistical significance relative to day 4. 
Similar to the pattern observed in CHA scaffolds, there were no significant 
differences in PDGF-BB observed between time-points during the culture period 
in an AFSC-HUVEC co-culture seeded on a CHyA scaffold (Fig. 4.6 A). PDGF-
BB concentration in the co-culture group ranged between 2000-5000 pg/mL. 
In the HUVEC monoculture, an increase in PDGF-BB concentration, similar to 
the one observed in CHA scaffolds, was observed over the course of the culture 
period (Fig. 4.6 B). There was a significant (p<0.05) two-fold increase in PDGF-
BB concentration at day 10 relative to day 4. At day 14, PDGF-BB levels were 
157 
 
significantly higher than day 4 (p<0.001), 7 (p<0.001) and 10 (p<0.05). Overall, 
PDGF-BB concentration in the monoculture reached 30,000 pg/mL for CHyA 
scaffolds, approximately six-fold higher than the highest value observed in the 
co-culture (approximately 5000 pg/mL). 
Figure 4.6: PDGF-BB protein secretion by an (A) AFSC-HUVEC co-culture and a (B) HUVEC 
monoculture seeded on CHyA scaffolds at day 7 and 14 of culture. There were no significant 
differences observed between time-points during the 14 day culture period in the co-culture (A). 
In the HUVEC monoculture (B), there was a significant (p<0.05) two-fold increase in PDGF-BB 
concentration at day 10 relative to day 4. At day 14, PDGF-BB levels were significantly higher 
than day 4 (p<0.001), 7 (p<0.001) and 10 (p<0.05). * denotes p<0.05 statistical significance 
relative to day 4. *** denotes p<0.001 statistical significance relative to day 4 and day 7. # denotes 
p<0.05 statistical significance relative to day 10. 
4.3.3 CHA and CHyA scaffolds maintain consistent cell density over 
a 14 day culture period  
Analysis of dsDNA concentration using a PicoGreen assay demonstrated that 
when seeded with the AFSC-HUVEC co-culture or HUVEC monoculture, both 
CHA and CHyA scaffolds maintained similar dsDNA concentrations over the 
course of the 14 day culture period (Fig. 4.7). There were no significant 
differences in dsDNA concentration at day 7 or 14 between scaffold types seeded 
with the AFSC-HUVEC co-culture (Fig. 4.7 A). Similarly, there were also no 
significant differences between scaffold types seeded with the HUVEC 
monoculture at either day 7 or 14 of culture (Fig. 4.7 B). 
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Figure 4.7 dsDNA concentration of an (A) AFSC-HUVEC co-culture and (B) HUVEC monoculture 
seeded on CHA and CHyA scaffolds at day 4, 7, 10 and 14 of culture. Levels of dsDNA 
concentration indicate that both scaffold types were capable of maintaining similar dsDNA 
concentrations when seeded with either the AFSC-HUVEC co-culture or HUVEC monoculture. 
There were no significant differences in dsDNA concentration between scaffold types at either 
time point. Values are expressed as mean ± standard deviation, n=3.  
4.3.4 CHA and CHyA scaffolds support similar levels of vessel-like 
structure formation  
3D renderings of vessel-like structure networks within CHA (Fig. 4.8 A-B) and 
CHyA (Fig. 4.8 C-D) scaffolds were captured using confocal microscopy, 
generated using Volocity and quantified using ImageJ. Total surface area was 
used as a surrogate for vessel-like structure network density. It was found that 
the total surface area of vessel-like structure networks was similar at day 7 and 
14 with no significant differences between the two groups (Fig. 4.8 E). Total 
surface area increased between day 7 and 14 in both CHA and CHyA scaffolds, 
indicating that the vessel-like structure networks were developing over time, 
although this was also non-significant. 
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Figure 4.8. Representative 3D renderings of vessel-like structure networks in CHA (A-B) and 
CHyA (C-D) scaffolds at day 7 and 14 and the quantification of total surface area of these 
renderings (E). Images were captured using confocal imaging. Renderings were generated using 
Velocity and quantified using ImageJ. It was found that, at day 7 and 14 of culture, the total surface 
area of the vessel-like structure networks were similar in both CHA and CHyA scaffolds, with no 
significant differences between the two groups. Total surface area increased between day 7 and 
14 in both CHA and CHyA scaffolds, although this was also non-significant. Green represents 
CD31-positive staining. 1 unit represents 85.2 µm. Values are expressed as mean ± standard 
deviation, n=3. 
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4.4 Discussion 
The primary objective of this chapter was to investigate the ability of the AFSC-
HUVEC co-culture to pre-vascularise CHA and CHyA scaffolds over the course 
of a 14 day culture period. The secondary objective of this study was to 
investigate how the composition of each scaffold affected the development of 
these vessel-like structures. The results demonstrated that the AFSC-HUVEC co-
culture formed networks of vessel-like structures within both CHA and CHyA 
scaffolds as early as day 7 of culture and were still present in both scaffold types 
at day 14. AFSC-HUVEC co-cultures seeded on CHA and CHyA scaffolds 
presented with PDGF-BB concentration levels that were five-fold lower than 
those observed in the HUVEC monoculture, a pattern that is indicative of vessel-
like structure formation. Both scaffolds demonstrated similar levels of dsDNA 
concentration at day 7 and 14, indicating that both scaffold types facilitated similar 
levels of cell retention. Quantification of vessel-like structure networks 
demonstrated that both scaffolds supported a similar total network surface area 
at both time-points. It was also observed that total surface area in both CHA and 
CHyA scaffolds increased between time-points, indicating that the networks of 
vessel-like structures were developing over time. Taken together, this study 
demonstrates the potential of the AFSC-HUVEC co-culture as an adaptable cell-
based approach for the pre-vascularisation of collagen-based biomaterials. This 
study also demonstrates the ability of both of these scaffold types to support the 
formation of a network of vessel-like structures, which could potentially be used 
for a number of applications in regenerative medicine. 
The most important finding of this study was that both the CHA and CHyA 
scaffolds facilitated pre-vascularisation by the AFSC-HUVEC co-culture as 
evidenced by the presence of vessel-like structures by day 7 and 14 of culture. 
Co-cultures in both scaffold types displayed expression patterns of PDGF-BB that 
were similar to those seen in vessel-like structure forming co-cultures in CCS 
scaffolds in Chapter 3. This expression pattern was characterised by the high 
levels of PDGF-BB observed in the HUVEC monoculture in both scaffold types 
(approximately 15,000 pg/mL in CHA scaffolds and 30,000 pg/mL in CHyA 
scaffolds) compared to the low levels observed in the co-culture (approximately 
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3000 pg/mL in CHA scaffolds and 5000 pg/mL in CHyA scaffolds). For 
comparison, in Chapter 3, PDGF-BB levels in the CCS scaffold were 
approximately 2,000 pg/mL in the co-coculture and 20,000 pg/mL in the HUVEC 
monoculture. As previously mentioned in Chapter 3, endothelial cells produce 
PDGF-BB in order to facilitate pericyte migration to nascent vessels for the 
purpose of stabilisation and maturation, as an absence of pericytes causes 
vessels to leak and rupture (Hellstrom et al., 2001, Armulik et al., 2005a). The 
low levels of PDGF-BB concentration in the co-culture group in both scaffold 
types indicate successful vessel-like structure formation, as the endothelial cells 
no longer need to produce PDGF-BB to attract pericytic cells once vessel 
formation and stabilisation has taken place. This decrease in PDGF-BB has been 
previously observed in co-cultures in other studies, for example, Pedersen et al. 
found that a HUVEC monoculture displayed significantly increased PDGF-BB 
expression levels in comparison to a vessel-forming HUVEC-MSC co-culture 
after 1 week in culture (Pedersen et al., 2014). 
Having determined that the AFSC-HUVEC co-culture formed vessel-like 
structures in both CHA and CHyA scaffolds, the next stage was to analyse how 
the different composition of each scaffold affected the network of vessel-likes 
structures generated within them. At day 7 and 14 of culture, CHA and CHyA 
scaffolds were found to maintain similar concentrations of dsDNA. This 
demonstrated that both scaffold types maintained similar levels of cell density 
over the course of the culture period. The advantage of using collagen-based 
scaffolds over other available biomaterials is that they act as bio-mimetic 
constructs providing the cells with an environment similar to that of native ECM 
to which they can attach and proliferate within. These constructs are highly 
biocompatible, have a high porosity, high pore interconnectivity and present a 
large internal surface area for cellular attachment, allowing them to easily retain 
cells, thus making them highly suitable for bone TE and other clinical applications 
(O'Brien et al., 2005, Lyons et al., 2008b, Murphy and O'Brien, 2010). It was found 
that CHA and CHyA scaffolds supported similar levels of vessel-like structure 
formation. These vessel-like structure networks developed over the course of the 
14 day culture period, as evidenced by the increase in total surface area between 
time-points. Overall, these data indicate that both scaffold types had been 
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successfully pre-vascularised and that both types supported similar levels of 
vessel-like structure formation. 
The ability of the CHA scaffold to support the development of vessel-like 
structures is not surprising as HA-composite scaffolds have previously been 
shown to support co-culture based pre-vascularisation, for example, silk/ HA 
filaments fabricated via direct-write assembly have been pre-vascularised using 
human MSCs in co-culture with human mammary microvascular endothelial cells 
(Sun et al., 2012). HA-coated substrates have also been shown to promote 
superior attachment and proliferation of a co-culture of bone marrow derived 
endothelial cells and fibroblasts in comparison to non-coated polycaprolactone 
(PCL) substrates (Choong et al., 2006). The pro-angiogenic qualities of HA have 
also been previously documented, for example, Pezzatini et al. found that 
crystallized HA could induce endothelial cell migration in a concentration-
dependent manner, similar to the effects elicited by VEGF (Pezzatini et al., 2006). 
Chang et al. found that the implantation of HA particles into a tibiae defect in a 
canine model encouraged the invasion of organised and abundant vasculature 
(Chang et al., 1999). As previously stated, McFadden et al. previously generated 
a network of vessel-like structures within the CHA scaffold using a delayed 
addition co-culture consisting of HUVECs and bone marrow-derived MSCs. 
However, this study found poor vessel-like structure formation in the CHA scaffold 
over the course of a 21 day culture period. This HUVEC-MSC co-culture has also 
displayed signs of regression (disengagement of cells from tubule structures with 
a subsequent decrease in vessel size and vessel numbers) by day 14 of culture 
in CCS scaffolds (McFadden, 2012). In the current study, vessel-like structure 
formation was observed at day 7 and 14 of culture with an increase in total surface 
area of the vessel-like structure networks between time-points, indicating that 
there was no regression of vessel-like structures. This indicates that the AFSC-
HUVEC co-culture may be a more suitable method for the pre-vascularisation of 
this scaffold type than the delayed addition HUVEC-MSC co-culture used 
previously. 
The pre-vascularised CHA scaffold developed in this study presents a potential 
new construct for use in bone defect repair. In two studies from our group, the 
osteogenic potential of the CHA scaffold has been previously demonstrated in 
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vivo, as it has been shown to be capable of almost completely bridging a critical 
sized rat calvarial defect as early as 28 days post-implantation (Gleeson et al., 
2010) and has also been shown to improve bone healing in a rabbit radius 
osteotomy defect model compared to a CCS scaffold (Lyons et al., 2014). 
However, the CHA scaffolds used in both of these studies were unseeded and 
the potential of a cell-seeded (or pre-vascularised) CHA scaffold has yet to be 
assessed in vivo. The CHA scaffold also has previously been used in the creation 
of a biomimetic, multi-layered osteochondral construct (trade name 
ChondroColl™) (Patent WO2010/084481, licensed to the SurgaColl 
Technologies). This multi-layered scaffold is composed of three integrated layers: 
a CHA bottom layer, an intermediate suspension layer composed of collagen type 
1 and 2 with a low level of HA and an upper layer composed of CHyA. The unique 
composition of this multi-layered scaffold allows for the regeneration of both the 
osteochondral bone (via the CHA layer) and the overlying cartilage (via the CHyA 
layer) as it mimics the gradient structure of natural osteochondral tissue 
(Levingstone et al., 2014). As the ability of the AFSC-HUVEC co-culture to pre-
vascularise the CHA scaffold has been demonstrated in this chapter, it could 
potentially be used to pre-vascularise the CHA-based osteochondral bone portion 
of this construct. This portion of the construct would not have to rely on the in-
growth of host vessels and would be protected against encapsulation and core 
degradation, thereby enhancing its potential in vivo.  
HyA-based constructs have also previously been shown to be capable of 
facilitating vessel formation in vitro and in vivo, for example, dextran-HyA 
composite hydrogels were shown to support a branching network of capillary-like 
structures formed by a co-culture of bone-marrow derived-endothelial cells and 
MSCs that was capable of facilitating the in-growth of host vessels in vivo 
(Portalska et al., 2014). Hydrogels composed of  HyA and preloaded with VEGF 
have been demonstrated to encourage microvessel growth in vivo when 
surgically implanted in the ear pinnas of mice, inducing significantly more 
microvessel density than then empty defect controls (Peattie et al., 2004). 
Successfully pre-vascularised CHyA scaffolds show potential in a number of TE 
applications. For example, the transplantation of pancreatic islet cells is a 
promising upcoming treatment for type 1 diabetes. This treatment requires a 
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vascularised TE construct to allow for the survival and function of these islet cells 
upon implantation in vivo (Ellis et al., 2013). Previous constructs have included 
Matrigel™ and CCS-based biomaterials seeded with islets (Dufour et al., 2005, 
Knight et al., 2008, Ellis et al., 2013). These constructs, however, were not pre-
vascularised and relied on vessel infiltration from the host vasculature. HyA is a 
critical component of pancreatic ECM (Bollyky et al., 2012) and therefore a pre-
vascularised CHyA scaffold shows great potential as a construct for use in the 
implantation of islets in vivo as it could provide an well-vascularised environment 
that also mimics their natural environment. Another potential application of this 
pre-vascularised CHyA scaffold is in the area of cellular delivery for the neo-
vascularisation of ischemic tissue (caused by, for example, peripheral artery 
disease). Collagen-based scaffolds have been previously used for this purpose, 
Wang et al. seeded a scaffold with bone marrow-derived MSCs and implanted it 
in a chronic ischemia hindlimb rabbit model. This construct was found to improve 
ischemic hindlimb function and increase angiogenesis in comparison to injected 
MSCs alone (Wang et al., 2012). Scaffolds used for the purpose of therapeutic 
angiogenesis are often not pre-vascularised prior to implantation (Zhou et al., 
2012, Wang et al., 2012, Mima et al., 2012). Pre-vascularised CHyA scaffolds 
could potentially provide the inherent vasculature necessary to resupply O2 and 
nutrients to the ischemic tissue faster than a non-vascularised equivalent while 
also facilitating the infiltration of host cells for regeneration of the surrounding 
tissue.  
Taken together, this study has produced two pre-vascularised TE constructs that 
have the potential for use in a range of TE applications. 
4.5 Conclusion 
The results of this study have demonstrated the ability of an AFSC-HUVEC co-
culture to facilitate the generation of a network of vessel-like structures within 
CHA and CHyA scaffolds for the first time. This is also the first time that a CHyA 
scaffold has been shown to be capable of successfully supporting a network of 
vessel-like structures in vitro. CHA and CHyA scaffolds are also capable of 
facilitating similar levels of vessel-like structure formation. Overall, this study has 
led to the creation of two new pre-vascularised TE constructs that have the 
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potential to anastomose with the host vasculature independent of the final tissue 
being repaired and has proven the adaptability of the AFSC-HUVEC co-culture 
for use in the pre-vascularisation of TE biomaterials. 
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5.1 Introduction 
Articular cartilage is unable to heal even the most minor injuries due to its poor 
regenerative capacity. This is partly due to the avascular, aneural and alymphatic 
nature of the tissue (Bora and Miller, 1987). There are a number of conventional 
treatments available to regenerate cartilage including autologous chondrocyte 
implantation (ACI), microfracture and mosaicplasty, but these procedures often 
fail to generate fully functional hyaline-like articular cartilage growth in the 
affected area. As a result, treatment tends to focus on the management of 
symptoms rather than the long-term restoration of cartilage in the defect. 
Therefore, an alternative approach is required.  
Tissue engineering (TE) may offer an alternative solution in the form of a cell-
based approach to cartilage repair. However, there is no consensus on the ideal 
source for the cells required. Chondrocytes are the primary cell type in articular 
cartilage and were originally thought to be the ideal cell type for the repair of 
cartilage defects. As a result, ACI is often proposed as a suitable method for the 
repair of these defects. However, the suitability of chondrocytes as a cell source 
for TE is limited, partly due to the low availability of chondrocytes within articular 
cartilage, their poor migratory capacity and their limited potential for intrinsic 
repair (Mayhew et al., 1998). Another drawback associated with chondrocytes is 
their tendency to lose chondrocytic phenotype resulting in progression towards a 
hypertrophic phenotype with an alteration to extracellular matrix (ECM) 
production (Schulze-Tanzil, 2009). However, multi- and pluripotent stem cells, 
which can be derived from a range of sources in the body, have also shown 
potential for use in cartilage repair due to their ability to differentiate down a 
chondrogenic lineage. These sources include adipose tissue (Malladi et al., 2006, 
Wang et al., 2014), umbilical cord blood (Kao et al., 2008, Zheng et al., 2013) and 
placenta (Koo et al., 2012). Of the multipotent stem cells types available, bone 
marrow-derived mesenchymal stem cells (MSCs) have been the most 
extensively investigated and have shown great potential for use as a 
chondrocytic-like cell (Yoo et al., 1998, Barry et al., 2001, Solchaga et al., 2011). 
However, these MSCs have a limited self-renewal capacity that is characteristic 
of most primary cell types, their capacity to differentiate becomes limited with 
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increased donor age and these cells also have a predisposition towards a 
hypertrophic phenotype (Wagner et al., 2008, Stolzing et al., 2008, Mueller and 
Tuan, 2008, Zaim et al., 2012).  
Embryonic stem cells (ESCs) are another alternate cell-source that have shown 
potential in cartilage TE (Kramer et al., 2000, Hwang et al., 2008, Gong et al., 
2010). Although these cells show great potential for chondrogenic differentiation 
due their pluripotentiality, they also present with a number of disadvantages, for 
example, there are ethical concerns associated with the method by which these 
cells are obtained, the availability of these cells is limited and they are technically 
difficult to culture (Rippon and Bishop, 2004, Schwartz et al., 2011). Human 
amniotic fluid-derived stem cells (AFSCs), studied extensively in the previous 
chapters, are another a pluripotent stem cell type but do not have any of the 
ethical concerns associated with ESCs and are also relatively simple to culture. 
AFSCs have also been previously differentiated down a chondrogenic lineage in 
vitro and therefore may present a promising new cell type for cartilage repair 
(Kolambkar et al., 2007, Rodrigues et al., 2012). However, the area of AFSC 
chondrogenic differentiation is one that has not been thoroughly investigated and 
therefore, the potential of AFSCs for use in cartilage TE was the main focus of 
this study. 
3D biomaterials are an important part of the TE approach to cartilage repair as a 
biomimetic scaffold can promote the growth of stem cells in vitro, facilitate their 
chondrogenic differentiation, and encourage the production of cartilage-specific 
ECM components. In addition, the composition of a scaffold can exert control 
over the shape and volume of the engineered cartilage construct (Freed et al., 
1994, Tanaka et al., 2010). The collagen-hyaluronic acid (CHyA) scaffold 
developed in our group and used in the previous chapter has previously been 
shown to enhance both chondrogenic gene expression and cartilaginous matrix 
deposition by bone marrow-derived MSCs in comparison to collagen-chondroitin 
sulphate (CCS) scaffolds (Matsiko et al., 2012), thereby identifying it as the 
optimal choice for cartilage TE of all the scaffold types developed by our group. 
For this reason, it was utilised as the scaffold of choice in this study, in order to 
investigate the potential of the AFSCs to differentiate down a chondrogenic 
lineage. 
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The use of external stimuli such as hypoxia is known to enhance chondrogenesis. 
Hypoxia and the HIF-1α pathway have been previously implicated in the 
development of cartilage (Schipani, 2005, Amarilio et al., 2007). Hypoxia also 
represents a more physiologically accurate microenvironment for both AFSCs 
and articular chondrocytes, both of which naturally reside in hypoxic 
environments in the body (Silver, 1975, Al-Asmakh et al., 2007, Pfander and 
Gelse, 2007). Chondrocytes are typically exposed to hypoxic conditions that 
generally vary from about 1-6% oxygen (O2) (Zhou et al., 2004, Fermor et al., 
2007). The normoxic environmental O2 levels commonly employed in cell culture 
have also been shown previously to be inherently detrimental to stem cell 
proliferation (Wang et al., 2005a), whereas hypoxia has been shown to increase 
stem cell proliferation (Grayson et al., 2006, Grayson et al., 2007, Yew et al., 
2012). A number of studies have reported that the use of hypoxic conditions 
during chondrogenic differentiation significantly enhances chondrogenic gene 
expression and cartilage-like matrix deposition (Scherer et al., 2004, Robins et 
al., 2005, Khan et al., 2007, Krinner et al., 2009, Lee et al., 2013b), for example, 
Kanichai et al. demonstrated that culture in a 2% O2 environment could 
significantly increase both collagen type 2 expression and sulphated 
glycosaminoglycan (GAG) deposition in bone marrow-derived MSCs in 
comparison to those cultured in 20 % O2 (Kanichai et al., 2008). There have been 
no previous studies on the effect of hypoxic culture on the chondrogenic 
differentiation of AFSCs, therefore, the use of hypoxic culture to enhance AFSC 
chondrogenic differentiation was another focus of the current study.  A recent 
study has demonstrated that long term hypoxic culture does not stimulate greater 
chondrogenesis in comparison to short term culture. It was found that MSCs 
exposed to a 1 week hypoxic pre-culture period underwent enhanced 
chondrogenesis relative to a 2 week pre-culture period (Ghone and Grayson, 
2012) suggesting that long term culture in hypoxia may not be conducive to 
enhanced chondrogenic differentiation. For this reason, a 7-day hypoxia pre-
culture period was used in this study.  
The primary objective of this chapter was to investigate the potential of AFSCs 
for use in cartilage TE by investigating their ability to differentiate down a 
chondrogenic lineage within a highly porous CHyA scaffold. The secondary 
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objective of this study was to determine whether pre-culture of AFSCs in hypoxia 
could enhance this process. In order to achieve this, AFSCs were cultured on 
CHyA scaffolds and exposed to a 7 day culture period in either normoxia (20% 
O2) or hypoxia (2% O2). The cells were then cultured for a further 21 days in 
normoxia and the effect of pre-culture on chondrogenic gene expression and 
cartilage-like matrix deposition was assessed. 
5.2 Materials and methods 
5.2.1 Scaffold fabrication 
CHyA scaffolds were fabricated using a freeze-drying method as previously 
described in Section 4.2.1 (Chapter 4) (Matsiko et al., 2012). Briefly, the CHyA 
suspension was freeze-dried (Advantage EL, VirTis Co., Gardiner, NY) at a 
constant cooling rate of 1°C/min to a final temperature of -20°C with an additional 
annealing step (-10°C held for 24 hours) resulting in a scaffold with a mean pore 
size of 300 μm. Following freeze-drying, the scaffolds were cut using a metal 
punch to a diameter of 9.5 mm and a height of 4 mm and stored in the dark at 
room temperature until use. Prior to use, scaffolds were hydrated in phosphate 
buffered saline (PBS).  The scaffolds were cross-linked using dehydrothermal 
(DHT) treatment as previously described in Section 4.2.1 (Chapter 4). 
5.2.2 Cell culture  
All cell culture work was carried out under sterile conditions in a laminar flow hood 
(SterilGard 111, MSC, Ireland). All cells were maintained at 37° C in a 5% CO2 
atmosphere in an incubator. 
Culture of AFSCs 
AFSCs were cultured as previously outlined in Section 2.2.1 (Chapter 2). AFSCs 
used during this experiment did not exceed passage 24.  
Scaffold seeding 
Confluent cultures were washed with PBS, trypsinised and centrifuged as 
detailed previously in Section 2.2.1 (Chapter 2). A 50 μL cell suspension 
containing 2.5x105 AFSCs was seeded onto each side of the scaffold with a 30 
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min incubation period at 37°C between sides in order to facilitate cell attachment. 
AFSCs were cultured on the scaffold in 2 mL of basic amniotic-fluid cell (BAFC) 
growth media for 3 days at 37°C in order to further facilitate cell attachment and 
infiltration. After this 3 day attachment period was complete, growth media was 
replaced with chondrogenic medium composed of Dulbecco's Modified Eagle 
Medium (DMEM) media (Sigma-Aldrich, Arklow, Ireland) supplemented with 10% 
fetal bovine serum (FBS), 1% L-glutamine, 2% penicillin/streptomycin 
(PenStrep), 20 ng/mL human TGF-β3 (Prospec, Rehovot, Israel), 50 μg/mL 
ascorbic acid (Sigma-Aldrich, Arklow, Ireland), 40 μg/mL proline (Sigma-Aldrich, 
Arklow, Ireland), 100 nM dexamethasone (Sigma-Aldrich, Arklow, Ireland), 1x ITS 
(Insulin, Transferrin, Selinium) (BD Biosciences, Oxford, UK), and 0.11 mg/mL 
sodium pyruvate (Sigma-Aldrich, Arklow, Ireland).  
Hypoxic pre-culture regime 
After the initial 3 day cell attachment culture period, the seeded scaffolds were 
transferred to chondrogenic medium as detailed in the previous section and 
separated into normoxic or hypoxic pre-culture groups (which will be referred to 
as the normoxia or hypoxia group respectively) in order to assess the effect of 
hypoxic pre-culture on chondrogenic differentiation.  
The normoxia group was cultured in normoxic conditions in an incubator (20% 
O2, 5% CO2) at 37°C. The hypoxia group was maintained in hypoxic conditions 
(2% O2, 5% CO2) in an 856-HYPO/EXP model hypoxia chamber (Plas Labs, MI, 
USA) as previously described in Section 2.2.1 (Chapter 2). Both the normoxia 
and hypoxia group were maintained in their respective O2 conditions for a 7 day 
culture period (which will be referred to as the pre-culture period). The final day 
of this pre-culture period was referred to as day 0. After day 0, both groups were 
maintained in normoxia for a further 21 days. Scaffolds were harvested for 
analysis at day 0, 7, 14 and 21 post pre-culture period.  
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Table 5.1: Summary of culture conditions. 
Normoxia group 3 day cell attachment period at 20% 
O2.  
20% O2 for a further 28 days.  
31 days of culture in total. 
Hypoxia group 3 day cell attachment period at 20% 
O2.  
2% O2 for 7 days followed by 20% O2 
for 21 days. 
 31 days of culture in total. 
 
5.2.3 Analysis of cell density 
Scaffolds were flash frozen in liquid nitrogen and stored at -80°C until ready for 
use. A lysis buffer composed of 1:100 β-mercaptoethanol (Sigma-Aldrich, Arklow, 
Ireland) in RLT buffer (Qiagen, Ireland) was added to the thawed scaffolds which 
were then homogenised and the lysate was filtered as previously described in 
Section 3.2.3 (Chapter 3). A Quant-iT PicoGreen dsDNA Assay Kit (Invitrogen, 
California, USA) was used according to the manufacturer’s instructions in order 
to calculate the concentration of double-stranded DNA (dsDNA) in the lysate. 
Samples were evaluated on a photometric plate reader (Varioskan Flash, Fisher 
Scientific, Dublin, Ireland) at 485 nm (excitation) and 538 nm (emission). DsDNA 
quantification was carried out to normalise levels of sulphated GAG to dsDNA 
present in the scaffold. 
5.2.4 Analysis of gene expression 
RNA was isolated from the same filtered lysate used for dsDNA quantification in 
Section 5.2.3. RNA was isolated as previously described in Section 3.2.3 
(Chapter 3). Following RNA isolation, quantitative real-time PCR (qRT-PCR) was 
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carried out as previously detailed in Section 2.2.2 (Chapter 2). The QuantiTect 
SYBR Green PCR kit (Qiagen, Manchester, UK) was used for this process 
according to the manufacturer’s instructions with QuantiTect primers for early-
stage chondrogenic marker SOX9 (Hs_SOX9_1_SG), intermediate-stage 
markers collagen type 2 (COL2) and aggrecan (ACAN) (Hs_ACAN_1_SG) 
(Hs_COL2A1_1_SG), the late-stage chondrogenic marker collagen type X 
(COLX) (Hs_COLL10A_1_SG) and the pro-angiogenic marker VEGF 
(Hs_VEGFA_1_SG). These target genes were chosen as they are known to be 
characteristically expressed in cells undergoing chondrogenic differentiation. All 
gene expression was normalised against 18s (Hs_RRN18S_1_SG), a 
housekeeping gene commonly used for this purpose. Expression of the 
chondrogenic marker genes was determined using the relative quantification 
ΔΔCt method (Livak and Schmittgen, 2001). AFSCs seeded on a CHyA scaffold 
and cultured for three days in growth media were used as a negative control. 
5.2.5 Analysis of cartilage-like matrix production 
Analysis of sulphated GAG production 
Scaffolds were digested in a solution prepared from papain enzyme solution 
containing 0.5 M ethylenediaminetetraacetic acid (EDTA), cysteine- 
hydrochloride and 1 mg/mL papain enzyme (Carica papaya, Sigma-Aldrich, 
Arklow, Ireland) at 37°C over 12 h. Sulphated GAG content was quantified using 
a Blyscan Kit (Accurate Chemical, Westbury, NY) as per the manufacturer’s 
instructions. Samples were evaluated on a photometric plate reader (Varioskan 
Flash, Fisher Scientific, Dublin, Ireland) at 656 nm. The sulphated GAG 
concentration of each sample was normalised to dsDNA concentration of that 
specific sample in order to produce a more accurate representation of sulphated 
GAG production. 
Analysis of cartilage-like matrix deposition 
Deposition of cartilage-like matrix was analysed using histology. The samples 
were fixed in 10% formalin (Sigma-Aldrich, Arklow, Ireland) and dehydrated using 
an automatic tissue processor (ASP300, Leica, Germany). Samples were then 
embedded in paraffin wax and sectioned into 10 µm slices using a microtome 
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(Leica RM2255, Leica, Germany). Sections were mounted on polysine-coated 
glass slides (Fisher-Scientific, Dublin, Ireland). Samples were left in an oven at 
60°C overnight to melt the paraffin wax. Samples were then deparaffinised with 
xylene and rehydrated in descending grades of alcohol (100% to 50%). 
Specimens were then washed in dH2O (Sigma-Aldrich, Arklow, Ireland) and 
stained with safranin-O (Sigma-Aldrich, Arklow, Ireland) in order to visualise 
sulphated GAG deposition. Sections were counterstained with Harris 
haematoxylin (Sigma-Aldrich, Arklow, Ireland) in order to stain DNA and RNA rich 
cell nuclei and eosin (Sigma-Aldrich, Arklow, Ireland) in order to stain the cell 
cytoplasm. Fast green (Sigma-Aldrich, Arklow, Ireland) was used as a light 
counter stain to identify the structure of the scaffold itself. Sections of unseeded 
CHyA scaffold were used as a negative control. 
Analysis of collagen type 2 and aggrecan deposition 
Deposition of collagen type 2 and aggrecan was identified using 
immunohistochemical analysis using sections obtained as described in the 
previous section. Antigen retrieval was carried out using Proteinase K (Sigma-
Aldrich, Arklow, Ireland) for 1 h at 37°C. Endogenous peroxidase activity was 
inhibited using a peroxidase suppressor and sections were incubated in 1% 
bovine serum albumin (BSA) (Sigma-Aldrich, Arklow, Ireland) and 10% goat 
serum (Sigma-Aldrich, Arklow, Ireland) for 1 h at room temperature. This was 
done in order to inhibit non-specific binding. The sections were then incubated 
with rabbit anti-human collagen type 2 (Abcam, Cambridge, UK) or rabbit anti-
human aggrecan (Abcam, Cambridge, UK) at a dilution of 1:50 or 1:20 
respectively at room temperature for 1 h. The sections were subsequently 
washed in PBS and incubated with a goat polyclonal anti-rabbit IgG secondary 
antibody (Abcam, Cambridge UK) at a dilution of 1:200 at room temperature for 
1 h. The samples were incubated in Vectastain ABC reagent (Vector 
Laboratories, Peterborough, UK) for 1 h. The sections were then treated with a 
peroxidase DAB substrate kit (Vector Laboratories) for 2-5 min until a colour 
change was achieved, at which point cold water was used to stop the reaction. 
The sections were subsequently dehydrated and mounted using DPX (Sigma-
Aldrich, Arklow, Ireland). Sections of unseeded CHyA were used as a negative 
control. 
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5.2.6 Statistical analysis 
To assess statistical difference in gene expression levels between the normoxia 
and hypoxia groups, a one-way ANOVA with Tukey post-test was performed. To 
assess statistical difference in sulphated GAG content between O2 groups, a two-
way ANOVA with Bonferroni post-test was performed. Error is reported in figures 
as the standard deviation of the mean and significance was determined using a 
probability value of P<0.05. All experiments were carried out with a sample size 
of 3 unless otherwise stated. 
5.3 Results 
5.3.1 AFSCs adopt a chondrogenic gene expression pattern that is 
accelerated by hypoxic pre-culture 
Expression levels of the early-stage chondrogenic gene marker SOX9 were 
analysed using qRT-PCR at day 0 and 7 (Fig. 5.1). At day 0, it was found that 
SOX9 expression in the normoxia group was similar to AFSCs in growth media, 
the negative control. SOX9 expression was significantly up-regulated by three-
fold in the hypoxia group relative to AFSCs in growth media (p<0.01) and the 
normoxia group (p<0.05) (Fig. 5.1 A).  
At day 7, SOX9 expression in the normoxia and hypoxia group was significantly 
(p<0.01 and p<0.05 respectively) increased by approximately 50% relative to 
AFSCs in growth media. There was no significant difference in SOX9 expression 
between normoxia and hypoxia groups (Fig. 5.1 B).  
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Figure 5.1: qRT-PCR analysis investigating the expression of the early-stage chondrogenic 
marker SOX9 by AFSCs pre-cultured in either normoxia or hypoxia at day 0 (A) and 7 (B) of 
culture. At day 0, SOX9 expression in the hypoxia group was significantly increased by three-fold 
relative to AFSCs in growth media (p<0.01) and the normoxia group (p<0.05) (A). At day 7, SOX9 
expression in the normoxia and hypoxia group was  significantly increased by 50% relative to 
AFSCs in growth media (p<0.01 and p<0.05 repectively) (B). AFSCs in growth media were used 
as a negative control. Values are expressed as mean ± standard deviation, n=4. * denotes p<0.05 
statistical significance relative to hypoxia. ** denotes p<0.01 statistical significance relative to 
hypoxia. ## denotes p<0.01 statistical significance relative to AFSCs in growth media. 
Expression levels of the intermediate-stage chondrogenic gene markers COL2 
and ACAN were analysed using qRT-PCR at day 14 and 21 (Fig. 5.2). At day 14, 
COL2 expression was at a similar level in normoxia and hypoxia groups relative 
to AFSCs in growth media (Fig. 5.2 A). ACAN expression also was similar in all 
three groups (Fig. 5.2 B). There were no significant differences in gene 
expression levels of COL2 or ACAN between normoxia and hypoxia groups at 
day 14 (Fig. 5.2 A, B). 
At day 21, the normoxia group displayed a non-significant, approximate two-fold 
increase in expression of COL2 relative to AFSCs in growth media and the 
hypoxia group (Fig. 5.2 C). ACAN expression was similar in all three groups at 
day 21 (Fig. 5.2 D).  
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Figure 5.2: qRT-PCR analysis investigating the expression of intermediate-stage chondrogenic 
markers COL2 (A, C) and ACAN (B, D) by AFSCs pre-cultured in either normoxia or hypoxia at 
day 14 and 21 of culture. At day 14, COL2 expression was similar in both the normoxia and 
hypoxia group to AFSCs in growth media (A). ACAN expression was also at a similar level in all 
three groups (B). At day 21, COL2 expression was increased by approximately two-fold in the 
normoxia group relative to AFSCs in growth media and the hypoxia group, although this was non-
significant (C). ACAN expression was similar in all three groups at day 21 (D). AFSCs in growth 
media were used as a negative control. Values are expressed as mean ± standard deviation, n=4. 
Late-stage chondrogenic marker gene expression was also analysed using qRT-
PCR at day 14 and 21. At day 14, it was found that COLX expression levels in 
normoxia and hypoxia groups were similar to those in AFSCs in growth media 
(Fig. 5.3 A). VEGF expression was found to be significantly (p<0.001) five-fold 
lower in both normoxia and hypoxia groups relative to AFSCs in growth media 
(Fig. 5.3 B). There were no significant differences in expression of COLX or VEGF 
between normoxia and hypoxia groups (Fig. 5.3 A, B).  
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At day 21, COLX expression in the normoxia group was significantly increased 
approximately three-fold relative to both AFSCs in growth media and the hypoxia 
group (p<0.01 and p<0.05 respectively) (Fig. 5.3 C). VEGF expression levels in 
the normoxia and hypoxia groups were similar to that of AFSCs in growth media 
(Fig. 5.3 D).  
Figure 5.3: qRT-PCR analysis investigating the expression of the late-stage chondrogenic 
marker COLX (A, C) and the endothelial growth factor VEGF (B, D) by AFSCs pre-cultured in 
either normoxia or hypoxia at day 14 and 21 of culture. At day 14, it was found that COLX 
expression in normoxia and hypoxia groups was similar to AFSCs in growth media (Fig. 5.3 A). 
VEGF expression was found to be significantly (p<0.001) five-fold lower in both normoxia and 
hypoxia groups relative to AFSCs in growth media (B). At day 21, COLX expression in the 
normoxia group was significantly increased three-fold relative to both AFSCs in growth media 
(p<0.01) and the hypoxia group (p<0.05) (C). There were no significant differences in VEGF 
expression between groups at day 21 (D). AFSCs in growth media were used as a negative 
control. Values are expressed as mean ± standard deviation, n=4. * denotes p<0.05 statistical 
significance relative to normoxia. ** denotes p<0.01 statistical significance relative to normoxia. 
*** denotes p<0.001 statistical significance relative to AFSCs in growth media. 
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5.3.2 AFSCs produce cartilage-like matrix in both normoxic and 
hypoxic pre-culture groups 
 
AFSCs deposit sulphated GAG in both normoxic and hypoxic pre-
culture groups 
Overall, sulphated GAG content gradually increased over the course of the 
culture period with the highest values observed at day 21 in both normoxia and 
hypoxia groups (Fig. 5.4). Sulphated GAG rose approximately two-fold between 
day 7 and 14 and approximately 50% between day 14 and 21 in both groups. 
There was a significant two and a half-fold increase in sulphated GAG between 
day 7 and day 21 in the hypoxia group (p<0.01). There was a similar increase in 
sulphated GAG between day 7 and day 21 in the normoxia group, however, this 
was not significant (p=0.06). Sulphated GAG was found to be at similar levels in 
normoxia and hypoxia groups at all time-points with no significant differences 
between O2 groups.  
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Figure 5.4: The effect of hypoxic pre-culture on sulphated GAG production. A gradual increase 
in sulphated GAG content was observed over the course of the 21 day culture period with the 
highest values seen at day 21 in both normoxia and hypoxia groups. There was a significant two 
and a half-fold increase in sulphated GAG between day 7 and day 21 in the hypoxia group 
(p<0.01). There was a similar increase in sulphated GAG between day 7 and day 21 in the 
normoxia group, however, this was not significant (p=0.06). There were no significant differences 
between normoxia and hypoxia groups at any time-point. Values were normalised to dsDNA 
concentrations from the corresponding time-points and groups. Values are expressed as mean ± 
standard deviation, n=3. ** denotes p<0.01 statistical significance relative to day 7 hypoxia. 
Histological analysis revealed that CHyA scaffolds displayed sulphated GAG 
distribution throughout the construct at all time-points (Fig. 5.5 A-F) which was 
consistent with the previous sulphated GAG content data. Safranin-O staining 
(pink) revealed that AFSCs were capable of synthesising and depositing 
sulphated GAG throughout the CHyA scaffold as early as day 7 in both normoxia 
and hypoxia groups. At day 7, sulphated GAG deposition was visible 
predominantly around the periphery of the scaffolds (Figure 5.5 A, D). However, 
deposition became visible towards the centre of the scaffolds at day 21 (Fig. 5.5 
C, F). Sulphated GAG deposition increased over the course of the culture period 
with the highest levels of deposition visible at day 21. Visually, sulphated GAG 
deposition was indistinguishable between normoxia and hypoxia groups at all 
time-points. An unseeded CHyA scaffold was used as the negative control and 
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the lack of staining present indicated that the sulphated GAG was being produced 
by the AFSCs and was not a result of non-specific staining (Figure 5.5 G).  
                                
                                                     
Figure 5.5: Safranin-O staining of histological sections of AFSC-seeded CHyA scaffolds for the 
detection of sulphated GAG deposition by AFSCs in normoxia and hypoxia groups. Safranin-O 
stained deposited sulphated GAG pink. There was positive staining for sulphated GAG in both 
normoxia and hypoxia groups as early as day 7 (A, D). Deposition was present throughout the 
scaffold in both normoxia and hypoxia groups. Deposition increased at subsequent time-points. 
Levels of deposition were visually indistinguishable between normoxia and hypoxia groups. No 
deposition was detected on the unseeded scaffold, which acted as a negative control (G). Fast 
green, haematoxylin and eosin were used as counterstains. Scale bar represents 100 μm. 
AFSCs deposit collagen type 2 and aggrecan in both normoxic and 
hypoxic pre-culture groups 
Having established that AFSCs were capable of sulphated GAG production in 
both normoxia and hypoxia groups, collagen type 2 deposition was assessed 
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using immunohistochemical staining (Fig. 5.6). The results showed that there was 
homogenously distributed collagen type 2 deposition present in normoxia and 
hypoxia groups at day 7 (Fig. 5.6 A, D). Deposition in normoxia and hypoxia 
groups was visually indistinguishable at all time-points. Collagen type 2 
deposition increased over the course of the culture period. An unseeded CHyA 
scaffold was used as a negative control and the lack of staining present indicates 
that the collagen type 2 was being produced by the AFSCs and that deposition 
was not the result of non-specific staining of the scaffold (Fig. 5.6 G). 
 
                       
Figure 5.6: Immunohistochemical staining of CHyA scaffolds for collagen type 2 indicating 
deposition by AFSCs over the course of 21 days in normoxia and hypoxia groups. There were no 
differences in deposition between normoxia and hypoxia groups at any time-point. Collagen 2 
deposition increased over the course of culture period. No deposition was detected on the 
unseeded scaffold, which acted as a negative control (G). Haematoxylin and eosin were used as 
counterstains. Scale bar represents 100 μm. 
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The deposition of aggrecan within the CHyA scaffold was also assessed using 
immunohistochemical staining (Fig. 5.7). It was evident that by day 7 that there 
was aggrecan deposition around the periphery of the scaffold in both normoxia 
and hypoxia groups (Fig. 5.7 A, D). This deposition around the periphery 
gradually became denser over the course of the culture period in both groups. 
Aggrecan deposition was visible towards the centre of the scaffold by day 21 (Fig. 
5.7 C, F). Similar to the deposition pattern of sulphated GAG and collagen type 
2, normoxia and hypoxia groups were visually indistinguishable at each time-
point. An unseeded CHyA scaffold was used as a negative control and the lack 
of staining present indicates that the aggrecan was being produced by the AFSCs 
and was not the result of non-specific staining of the scaffold (Fig. 5.7 G). 
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Figure 5.7: Immunohistochemical staining of CHyA scaffolds for aggrecan indicating the level of 
matrix deposition by AFSCs over the course over 21 days in normoxia and hypoxia groups. At 
day 7, aggrecan deposition was limited to the periphery of the scaffold in both normoxia and 
hypoxia groups (A, D), although it began to move towards the centre of the scaffold by day 21 (C, 
F). There were no visible differences in the level of deposition between normoxia and hypoxia 
groups. No deposition was detected on the unseeded scaffold, which acted as a negative control 
(G). Haematoxylin and eosin were used as counterstains. Scale bar represents 100 μm. 
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5.4 Discussion 
The primary objective of this chapter was to investigate the potential of AFSCs 
for use in cartilage TE by differentiating them down a chondrogenic lineage within 
a highly porous CHyA scaffold. The secondary objective of this study was to 
investigate whether hypoxic pre-culture could enhance this process. AFSCs were 
exposed to a 7-day pre-culture in either normoxia (21% O2) or hypoxia (2% O2) 
and assessed for gene expression and cartilage-like matrix deposition. The 
results of this study demonstrated that AFSCs were capable of differentiating 
down a chondrogenic lineage on a CHyA scaffold. Hypoxic pre-culture showed 
some tendency to accelerate early stage chondrogenic differentiation as 
evidenced by a significant increase in SOX9 expression. Hypoxic pre-culture also 
led to a significant two-fold decrease in COLX gene expression relative to 
normoxia at day 21, indicating that it was also inhibiting late stage differentiation 
and hypertrophy. The CHyA scaffolds supported production of cartilage-like 
matrix by AFSCs in both normoxic and hypoxic pre-culture. Taken together, this 
study demonstrates that AFSCs seeded on a CHyA scaffold have potential as a 
TE construct for cartilage repair and that hypoxic pre-culture may enhance this 
process and inhibit the potential for hypertrophy- a limiting step with many cell-
based cartilage TE strategies.  
The results of this study found that AFSCs were capable of SOX9 expression in 
both normoxia and hypoxia groups. SOX9 is a chondrogenic master transcription 
factor that is responsible for the differentiation of chondrocytes (Goldring and 
Marcu, 2009) and there is an intrinsic relationship between SOX9 expression and 
the HIF-1α pathway. HIF1α-depleted mouse limb buds have been observed to 
form abnormal cartilage, attributed to the reduced expression of SOX9 (Amarilio 
et al., 2007).  SOX9 is also an essential regulator of the initial steps of cartilage 
formation (Bi et al., 1999) and is required for the expression of a number of 
cartilage-specific matrix proteins (Goldring et al., 2006). Hypoxic pre-culture 
induced a significant three-fold increase in SOX9 gene expression relative to the 
normoxia group at day 0 indicating accelerated early-stage chondrogenic 
differentiation. It was also demonstrated that there was a significant 50% increase 
in SOX9 expression in both normoxia and hypoxia groups relative to AFSCs in 
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growth media (the negative control) at day 7, indicating that early stage 
chondrogenic differentiation was taking place in both pre-culture groups. It is 
likely that the presence of TGF-β3 in the chondrogenic media used to culture the 
AFSCs also enhanced expression of SOX9 in both pre-culture groups, as it has 
previously shown to induce the up-regulation of a range of chondrogenic genes, 
including SOX9 (Chung and Burdick, 2009, Park et al., 2011, Wei et al., 2014) 
and is commonly utilised for the stimulation of chondrogenic differentiation 
(Mackay et al., 1998, Barry et al., 2001, Mauck et al., 2006, Tang et al., 2009).  
When the gene expression of COLX was assessed, it was found that, at day 14, 
expression levels in both normoxia and hypoxia groups were similar to AFSCs in 
in growth media. At day 21, however, there was a significant three-fold increase 
in COLX gene expression in the normoxia group relative to AFSCs in growth 
media and the hypoxia group. Pre-hypertrophic chondrocytes begin to express 
the late-stage chondrogenic marker COLX as they exit the terminal differentiation 
phase and enter the hypertrophic phase (Gannon et al., 1991, Chen et al., 1995, 
Goldring et al., 2006). It has been previously shown that hypoxic culture inhibits 
COLX gene expression in embryonic (Hirao et al., 2006) and adipose stem cells 
(Betre et al., 2006) undergoing chondrogenic differentiation. Therefore, it is 
possible that hypoxic pre-culture has an inhibitory effect on late stage 
chondrogenic differentiation (and by extension, hypertrophy). This may be an 
important finding in the use of these cells for cartilage repair, as the acquisition 
of a hypertrophic phenotype is a common problem for the cells used in cartilage 
TE (particularly for bone-marrow derived MSCs and chondrocytes), due to the 
fact that it results in widespread apoptosis and ossification, reducing the overall 
therapeutic potential of the construct (Pelttari et al., 2006, Mueller and Tuan, 
2008, Schulze-Tanzil, 2009). 
The results of this study demonstrated that VEGF expression was significantly 
five-fold higher in AFSCs in growth media relative to both normoxia and hypoxia 
groups at day 14. VEGF expression was similar to AFSCs in growth media at day 
21. There were also no differences in VEGF gene expression between normoxia 
and hypoxia groups at either day 14 or 21. The expression of the pro-angiogenic 
growth factor VEGF has also been implicated in the hypertrophic phenotype of 
chondrocytes, coupled with the eventual vascular ingrowth and angiogenesis that 
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is associated with mineralisation via endochondral ossification (Gerber et al., 
1999, Carlevaro et al., 2000). For this reason, the expression of VEGF in a 
construct for cartilage repair is undesirable. Although hypoxia is known to 
increase VEGF expression in a number of cell types (Namiki et al., 1995, Potier 
et al., 2007, Thangarajah et al., 2009), it is possible that the low level of VEGF 
expression by AFSCs was due to the presence of TGF-β3 in the chondrogenic 
media. A previous study within our group demonstrated that MSCs differentiated 
down a chondrogenic lineage using a hypoxic pre-culture demonstrated 
significantly higher VEGF gene expression relative to normoxia after 3 days in 
the absence of TGF-β3. However, this expression of VEGF was subsequently 
down-regulated in the presence of TGF-β3 (Matsiko, 2012).  
AFSCs seeded on CHyA scaffolds were capable of producing sulphated GAG 
regardless of the O2 condition they were pre-cultured in. Overall, sulphated GAG 
content gradually increased over the course of the culture period with the highest 
values observed at day 21 in both normoxia and hypoxia groups. The majority of 
GAGs in the body are linked to core proteins, forming proteoglycans (aggrecan 
is the major proteoglycan in cartilage). Proteoglycans have an anionic charge and 
therefore attract water molecules, maintaining the osmotic pressure of the tissue, 
which is fundamental for providing the compressive strength of articular cartilage 
(Dudhia, 2005). Therefore, the production of sulphated GAG is a necessary 
characteristic of a TE construct for cartilage repair.  The levels of sulphated GAG 
produced by AFSCs seeded on CHyA scaffolds after 21 days is comparable to 
other studies that have focused on the chondrogenic differentiation of AFSCs. 
For example, Kolambkar et al. used a pellet culture system to facilitate 
chondrogenic differentiation in AFSCs and saw low levels of sulphated GAG 
content after three weeks of culture (approximately 4 µg/µg) (Kolambkar et al., 
2007). Park et al. seeded AFSCs in a fibrin hydrogel containing TGF-β3 and 
found that the sulphated GAG content after 3 weeks of culture was approximately 
3 µg/µg (Park et al., 2011). These values are approximately eight-fold lower than 
those observed in CHyA scaffolds in this current study as sulphated GAG content 
was found to be approximately 24 µg/µg in the normoxia group and 23 µg/µg in 
the hypoxia group at day 21. Sulphated GAG production by AFSCs on CHyA 
scaffolds also compares well to a study that has induced the chondrogenic 
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differentiation of MSCs on the CHyA scaffold. In this study, Matsiko et al. seeded 
MSCs on a CHyA scaffold and cultured them in chondrogenic media containing 
TGF-β3. It was found that after 14 days of culture, the CHyA scaffolds had a 
sulphated GAG content of approximately 32 µg/µg (Matsiko et al., 2012). These 
studies, however, all used different seeding densities and culture media and are 
therefore not directly comparable but overall, the level of sulphated GAG content 
observed at day 21 indicates the chondrogenic potential of AFSCs seeded on 
CHyA scaffolds. 
In addition to quantification of sulphated GAG content, sulphated GAG 
distribution by AFSCs on the CHyA scaffold was also assessed using safranin-O 
staining. At day 7, sulphated GAG deposition was visible predominantly around 
the periphery of the scaffolds, although sulphated GAG distribution became more 
homogenous throughout the scaffolds at later time-points. Visually, the level of 
sulphated GAG deposition was indistinguishable between normoxia and hypoxia 
groups at all time-points. These results are consistent with the sulphated GAG 
content observed previously and indicate that the AFSCs have successfully 
undergone chondrogenic differentiation by day 21 of culture, verifying their 
chondrogenic potential.  
AFSCs were also found to be capable of deposition of collagen type 2 and 
aggrecan throughout the CHyA scaffold over the 21 day culture period in both 
normoxia and hypoxia groups, further demonstrating their ability to synthesise 
cartilage-like matrix. Collagen type 2 (approximately 80% of the total tissue 
collagen) and proteoglycans (aggrecan) are the main structural representatives 
of the molecular composition of articular cartilage matrix besides water (Aigner 
and Stove, 2003). Deposition of collagen type 2 and aggrecan has been used to 
demonstrate the chondrogenic differentiation of AFSCs with previous studies 
observing similar deposition of this cartilage-like matrix (Kolambkar et al., 2007, 
Rodrigues et al., 2012). The presence of these cartilage-like matrix components 
confirm that chondrogenic differentiation of AFSCs has taken place. Collagen 
type 2 and aggrecan was observed to be distributed throughout CHyA scaffolds, 
although aggrecan staining was more prominent on the periphery of the scaffolds. 
This is similar to the study by Rodrigues et al., who observed more deposition of 
collagen type 2 compared to aggrecan by AFSCs seeded in an agarose hydrogel 
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(Rodrigues et al., 2012). Collagen type 2 is naturally synthesised before aggrecan 
during cartilage development (Goldring et al., 2006), so this balance of matrix 
deposition by AFSCs is normal. Levels of collagen type 2 and aggrecan 
deposition were visually indistinguishable between normoxia and hypoxia groups 
at all time-points. This corresponds with the gene expression of COL2 and ACAN 
observed at day 14 and 21 of culture in which there were no significant 
differences between normoxia and hypoxia groups. 
The similarity in sulphated GAG content and collagen type 2 and aggrecan 
distribution between normoxia and hypoxia groups may be explained by the pro-
chondrogenic qualities of both CHyA scaffold and the chondrogenic media in 
which the AFSCs are cultured. The CHyA scaffold has been previously shown to 
enhance sulphated GAG deposition in comparison to the CCS scaffold (Matsiko 
et al., 2012) and TGF-β3 has been demonstrated to induce elevated production 
of sulphated GAG in AFSCs (Kolambkar et al., 2007). The composition of the 
CHyA scaffold has also previously been shown to play a major role in the 
differentiation of MSCs even in the absence of chondrogenic factors (Murphy et 
al., 2012) and therefore may be driving cartilage-like matrix deposition in both the 
normoxia and hypoxia groups. However, as previously stated, the hypoxia group 
also displayed enhanced early stage chondrogenic commitment as evidenced by 
increased SOX9 and decreased COLX gene expression, suggesting that hypoxic 
pre-culture may facilitate enhanced early-stage chondrogenesis and may inhibit 
hypertrophy relative to normoxia. 
5.5 Conclusion 
In this study, it has been shown that AFSCs were capable of undergoing 
chondrogenic differentiation while seeded on a CHyA scaffold as evidenced by 
SOX9 gene expression and cartilage-like matrix deposition, demonstrating the 
potential of this novel construct for use in cartilage repair. More importantly, this 
is the first time AFSCs have been differentiated down a chondrogenic lineage on 
a porous biomaterial. Hypoxic pre-culture accelerated early stage chondrogenic 
differentiation as evidenced by a significant increase in SOX9 expression and 
was also found to inhibit late stage differentiation towards hypertrophy as 
evidenced by a significant decrease in COLX expression. The CHyA scaffolds 
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supported production of cartilage-like matrix by AFSCs throughout, whether they 
were exposed to normoxic or hypoxic pre-culture. Overall, these results 
demonstrate that this novel combination of cells and scaffold offers a potential 
new construct for cartilage repair and that hypoxic pre-culture accelerates early 
stage chondrogenic gene expression and commitment of AFSCs. 
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6.1 Discussion 
6.1.1 Overview 
Tissue engineering (TE) has been defined as ‘‘an interdisciplinary field of 
research that applies the principles of engineering and the life sciences towards 
the development of biological substitutes that restore, maintain, or improve tissue 
function’’ (Langer and Vacanti, 1993). TE is based on an understanding of 
embryology, tissue formation and regeneration and aims to grow new functional 
tissues rather than just implant spare parts (Kneser et al., 2006). While the field 
has achieved some success in the repair and replacement of tissues and organs 
using regenerative cell sources and bioactive materials, the successful post-
implantation engraftment of TE constructs designed to regenerate thick tissues 
relies on the rapid formation of stable and functional vasculature. This is due to 
the fact that cell-seeded constructs for tissue repair typically lack an inherent 
vascular network (Laschke et al., 2006, Unger et al., 2010) and the time taken for 
host vessel invasion to occur within an implanted scaffold is often too long, which 
results in avascular necrosis and implant failure. In most tissues, cells are 
capable of surviving only within the range of oxygen (O2) and nutrient diffusion 
(approximately 150-200µm) of the nearest network of blood vessels (Folkman 
and Hochberg, 1973). Therefore, the successful vascularisation of thick 
constructs for the regeneration of highly vascularised tissues remains a major 
challenge and as such, success in the field of TE has been primarily limited to 
the replacement of thin, avascular tissues such as skin.  
One approach which has emerged as a potential solution to overcome the issue 
of implant failure as a result of core degradation and avascular necrosis is to 
engineer a nascent vasculature within a construct in vitro prior to implantation.  
Consequently, this approach has become the recent focus of an increasing 
number of studies (Montano et al., 2010, Unger et al., 2010, Duffy et al., 2011). 
This method of pre-vascularisation theoretically provides functional vasculature 
within the construct prior to implantation, therefore reducing the reliance on 
vessel invasion from the host as it relies only on the anastomosis between host 
and engineered vessels to adequately supply the TE construct. One of the first 
demonstrations of this approach used vascularised tissue to envelop polylactic 
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acid (PLLA) constructs to allow for pre-vascularisation (Mikos et al., 1993). Since 
then, there have been a number of studies that have incorporated the cells of the 
vascular system for the purpose of pre-vascularising TE constructs (Unger et al., 
2007, Fuchs et al., 2009b, Holnthoner et al., 2012, McFadden, 2013). This pre-
vascularisation approach typically involves a co-culture of at least two different 
cell types; an endothelial cell type to produce nascent vessel-like structures and 
a pericytic support cell to provide both the physical and paracrine support 
required for the stabilisation of these vessel-like structures. Overall, this approach 
presents a possible solution to a problem that continues to reduce the therapeutic 
potential of thick TE constructs, but an ideal strategy has yet to be identified.  
The primary aim of the research presented in this thesis therefore, was to 
overcome the vascularisation problem by developing a novel co-culture system 
for the purpose of pre-vascularising collagen-composite scaffolds in vitro. The 
development of this co-culture could allow for the creation of a suite of 
vascularised TE constructs that have the ability to rapidly anastomose with the 
host vasculature with potential for a range of clinical applications. In addition, the 
suitability of hypoxic culture as an external stimulus to enhance vascularisation 
was investigated. In order to provide an endothelial-like cell for use in this co-
culture, the ability of amniotic fluid-derived stem cells (AFSCs) to differentiate 
down an endothelial lineage was investigated in Chapter 2. Differentiation of 
AFSCs into endothelial-like cells has been previously demonstrated (Zhang et 
al., 2009, Benavides et al., 2012), although the effect of hypoxic culture on this 
process has not. In this study, it was decided to explore the endothelial 
differentiation potential of AFSCs further, in order to establish whether they could 
produce an endothelial-like cell that could be used in a co-culture for the purpose 
of pre-vascularising a collagen-chondroitin sulphate (CCS) scaffold. It was shown 
that AFSCs displayed an early endothelial gene expression profile and acquired 
some functional endothelial cell characteristics, indicating early endothelial 
differentiation had taken place. Culture in continuous hypoxia was found to 
enhance endothelial gene expression and VEGF protein secretion but did not 
enhance endothelial-like functionality. Overall AFSCs demonstrated a less 
mature endothelial gene expression profile and phenotype when compared to 
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human umbilical vein endothelial cells (HUVECs), a commonly used endothelial 
cell control. 
As AFSCs displayed an immature endothelial phenotype, their potential in the 
role of pericyte in a co-culture with HUVECs was investigated for the purpose of 
pre-vascularising a CCS scaffold in Chapter 3. Results demonstrated that AFSCs 
in co-culture with HUVECs could form a robust network of vessel-like structures 
within the CCS scaffold. When the effect of hypoxic culture on this vessel-like 
structure formation was investigated, it was found that hypoxia reduced vessel-
like structure formation and that of the three O2 conditions studied, normoxia 
promoted the highest level of vessel-like structure formation. 
Our lab has previously developed a number of collagen-based composite 
scaffolds that have been engineered to possess distinct characteristics for use in 
specific TE applications. These scaffolds however, like all non-cell seeded 
biomaterials, do not possess an inherent vasculature and are prone to 
encapsulation and core degradation when seeded with cells, cultured for 
prolonged periods in vitro and subsequently implanted in vivo. Therefore, in 
Chapter 4, the AFSC-HUVEC co-culture developed in Chapter 3 was utilised for 
the pre-vascularisation of two collagen-composite scaffold types that are the 
closest to clinical translation in our lab: a collagen-hydroxyapatite (CHA) and 
collagen-hyaluronic acid (CHyA) scaffold. The results demonstrated that the 
AFSC-HUVEC co-culture was capable of generating a network of vessel-like 
structures within CHA and CHyA scaffolds, creating two new pre-vascularised 
constructs and proving the adaptability of the AFSC-HUVEC co-culture for use in 
the pre-vascularisation of a series of TE biomaterials. 
In Chapter 5, the knowledge gained in the earlier studies presented in this thesis 
was utilised in order to focus on another major area of TE, cartilage repair. 
Therefore, this study aimed to develop a novel construct for use in cartilage TE 
by combining AFSCs, the CHyA scaffold and hypoxic culture. Results showed 
that AFSCs undergoing chondrogenic differentiation were capable of cartilage-
like matrix deposition, demonstrating their potential for use in cartilage repair. 
Hypoxic pre-culture accelerated early stage chondrogenic differentiation as 
evidenced by a significant increase in SOX9 expression and was also found to 
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inhibit late stage differentiation towards hypertrophy as evidenced by a significant 
decrease in COLX expression. Overall, it was demonstrated that this novel 
combination of cells and scaffold was suitable for use in cartilage repair and that 
hypoxic pre-culture may enhance the potential of AFSCs for this purpose. The 
following sections will summarise the main findings of each chapter and their 
implications. 
One potential limitation of the work presented in this thesis is the use of a low 
sample size (n=3). A sample size of 3 is commonly used in studies that have 
been previously published by our group (Hastings et al., 2012, Tierney et al., 
2012, McFadden et al., 2013) and supports the analysis of statistical significance. 
However, the use of a larger sample size (e.g. n=3 with three technical repeats) 
increases the chance of finding a significant difference and is generally accepted 
as best practice for in vitro experimentation. 
6.1.2 The effect of hypoxic culture on the endothelial differentiation of 
human amniotic fluid-derived stem cells (Chapter 2) 
In order to investigate whether culture in hypoxia could enhance the ability of 
AFSCs to differentiate down an endothelial lineage for later use in scaffold pre-
vascularisation, AFSCs were stimulated using EndoGro™ media supplemented 
with 50 ng/mL of VEGF for 14 days. The AFSCs were also cultured under 
intermittent hypoxia (2% O2 for 8 h every 24 h) and continuous hypoxia (2% O2). 
Hypoxia is a well-known physiological stimulus of angiogenesis (Loges et al., 
2009) and has previously been shown to enhance the endothelial differentiation 
of a number of stem cell types (Prado-Lopez et al., 2010, Ong et al., 2010, 
Kusuma et al., 2014).  
AFSCs in normoxia, intermittent hypoxia and continuous hypoxia adopted a 
similar, albeit much less mature, endothelial gene expression profile to HUVECs. 
This endothelial expression profile manifested in the form of increased CD31, 
VEGFR2 and vWF expression in comparison to AFSCs in growth media, the 
negative control. Continuous hypoxia was found to significantly increase 
expression levels of CD31 and VEGFR2 relative to AFSCs in growth media, 
normoxia and intermittent hypoxia groups. This indicates that long-term 
continuous hypoxia may be a potent stimulus in the enhancement of endothelial 
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gene expression of AFSCs, a result that has not been demonstrated previously. 
Continuous hypoxia was also shown to enhance levels of VEGF protein 
secretion. VEGF secretion has previously been used as an indicator of 
endothelial differentiation in stem cells (Zhang et al., 2009, Thangarajah et al., 
2009, Bassaneze et al., 2010, Zhang et al., 2011b). The increase in VEGF protein 
secretion by AFSCs in continuous hypoxia corresponded with increased CD31 
and VEGFR2 gene expression seen in that group previously, indicating that 
potentially, the secreted VEGF was acting upon the AFSCs to enhance 
differentiation.  
AFSCs in all three O2 conditions were found to possess the functional endothelial-
like characteristics of uptaking acetylated low-density lipoprotein (ac-LDL) and 
tubule formation on Matrigel™. There were no visible differences in ac-LDL 
uptake between AFSCs in any of the three O2 conditions, which suggests that the 
increase in endothelial gene expression in continuous hypoxia was not high 
enough to translate into an enhanced state of functionality. This was corroborated 
by analysis of tubule formation with no differences between AFSCs in any of the 
three O2 conditions. In comparison however, total tubule length was found to be 
significantly higher at all time-points in HUVECs, demonstrating that HUVECs still 
possess a superior tubule-forming ability. 
Taken together, the results of this study demonstrated that AFSCs cultured over 
a 14 day period displayed an early endothelial gene expression profile and 
acquired functional endothelial-like characteristics, indicating early endothelial 
differentiation had taken place. Culture in continuous hypoxia was found to 
enhance endothelial gene expression and VEGF protein secretion but did not 
enhance endothelial-like functionality. Ultimately, AFSCs subjected to endothelial 
stimuli demonstrated a less mature endothelial gene expression profile and 
phenotype when compared to HUVECs, the endothelial cell control, suggesting 
that they may not be mature enough to present a viable source of endothelial-like 
cells for our desired purpose of vascularising TE scaffolds. 
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6.1.3 Pre-vascularisation of a collagen-chondroitin sulphate scaffold 
using human amniotic fluid-derived stem cells to enhance and 
stabilise endothelial cell-mediated vessel formation (Chapter 3) 
In Chapter 2, it was demonstrated that AFSCs did not present a viable source of 
endothelial-like cells. Therefore, their potential as a pericyte in co-culture with 
HUVECs was next assessed for the purpose of pre-vascularising a CCS scaffold. 
As HUVECs present a mature endothelial cell and have previously been used for 
pre-vascularisation (Rouwkema et al., 2006, Saleh et al., 2011, Strassburg et al., 
2013), they were chosen as the vessel-forming endothelial cell in this study. 
Hypoxia and the manipulation of the HIF-1 pathway have been used previously 
to enhance vascularisation of constructs (Fan et al., 2010, Hadjipanayi et al., 
2011, Stewart et al., 2011), implicating it as a potential tool for the enhancement 
of pre-vascularisation. In addition, the effect of hypoxic culture on the formation 
of vessel-like structures by the AFSC-HUVEC co-culture was also assessed.   
In order to assess the optimal co-culture seeding technique for the production of 
vessel-like structures, the effectiveness of seeding HUVECs 72 h prior to AFSCs 
at ratio of 4:1 HUVECs: AFSCs was investigated. This co-culture seeding 
technique was based on a delayed addition HUVEC-MSC co-culture previously 
developed in our lab that was shown to form vessel-like structures within a CCS 
scaffold (McFadden et al., 2013). This was compared to a co-culture seeding 
technique in which AFSCs were seeded 24 h prior to HUVECs at an inverted ratio 
of 1:4. This ratio of endothelial cell to perivascular cell has previously been 
implemented for the purpose of vascularisation in a number of studies (Melero-
Martin et al., 2008, Gawlitta et al., 2012a, Roubelakis et al., 2013). The results 
demonstrated that when HUVECs were seeded prior to AFSCs, no vessel-like 
structures were formed on either a 2D monolayer or on CCS scaffolds. One 
possibility for the inability of this seeding technique to form vessel-like structures 
is that, since the HUVECs outnumbered the AFSCs by at least 4:1, the AFSCs 
may not have been numerous enough to provide the structural and functional 
integrity to be effective as a pericyte. However, when AFSCs were seeded prior 
to HUVECs at a ratio of 1:4 HUVECs: AFSCs, the co-culture produced a robust 
network of vessel-like structures on both a 2D monolayer and a CCS scaffold. 
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This is first time that a porous scaffold has been successfully pre-vascularised 
using a co-culture containing AFSCs and demonstrates the potential of AFSCs 
as a pericyte. Vessel-like structures were also still present on both substrates at 
day 14 of culture. As previously mentioned, McFadden et al. generated a network 
of vessel-like structures within a CCS scaffold using a delayed addition co-culture 
consisting of HUVECs and bone marrow-derived MSCs. However, the vessel-like 
structures generated by a delayed addition HUVEC- mesenchymal stem cell 
(MSC) co-culture in that study were found to regress and deteriorate by day 14 
of culture (McFadden, 2013). This indicates that the AFSC-HUVEC co-culture 
may be a more suitable method for the pre-vascularisation of this scaffold type 
than the delayed addition HUVEC-MSC co-culture used previously. 
When the effect of hypoxic culture on these structures was assessed, it appeared 
that vessel-like structure formation was reduced in both intermittent and 
continuous hypoxia relative to normoxia at both day 7 and 14. However, vessel-
like structures in all three O2 conditions were shown possess a patent lumen, 
confirming their vessel-like phenotype. It was found that co-cultures in normoxia 
had a two-fold higher number of lumina than both intermittent and continuous 
hypoxia at both day 7 and 14, confirming the negative effect of hypoxia on vessel-
like structure formation. Hypoxic culture was also demonstrated to have a 
negative effect on dsDNA concentration and has been shown to negatively affect 
the proliferation of endothelial cells (Decaris et al., 2009, Ulyatt et al., 2011), so it 
is possible that reduced proliferation of HUVECs was disrupting the cellular 
balance of the co-culture and contributing to the reduced vessel-like structure 
formation observed in intermittent and continuous hypoxia.  
Despite the reduction in vessel-like structure formation, it was found that 
continuous hypoxia led to an increase in the VEGF, one of the most important 
growth factors in vessel formation (Kaigler et al., 2005, Kasper et al., 2007, 
Laschke and Menger, 2012). Therefore, one would expect that increased VEGF 
secretion in continuous hypoxia would correspond with an increase in vessel-like 
structure formation. However, Griffith et al. observed a degradation in vessel 
network formation despite an increase in endogenous VEGF secretion induced 
by hypoxia (Griffith and George, 2009), which indicates that increased VEGF may 
not correlate with increased vessel-structure formation in hypoxic conditions. 
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Continuous hypoxia displayed a similar enhancing effect on PDGF-BB secretion. 
PDGF-BB is expressed primarily by endothelial cells in order to facilitate pericyte 
migration to nascent vessels for the purpose of stabilisation and maturation 
(Hellstrom et al., 2001, Armulik et al., 2005a, von Tell et al., 2006). It was also 
observed that PDGF-BB concentration in the HUVEC monoculture was ten-fold 
higher than the concentration observed in the co-culture, which is proportional 
with the lack of vessel-like structure formation taking place in the HUVEC 
monoculture. These data suggest that AFSCs were acting as a pericyte by 
interacting with HUVECs to form vessel-like structures, which may explain the 
low PDGF-BB levels observed in the co-culture group, as endothelial cells do not 
need to produce PDGF-BB if vessels have already been stabilised. Overall, these 
data suggest that the AFSC-HUVEC co-culture exhibited a secretion pattern of 
VEGF and PDGF-BB that is consistent with successful vessel-like structure 
formation.  
In order to elucidate why increased VEGF production in continuous hypoxia did 
not correlate with enhanced vessel-like structure formation, the gene expression 
of the VEGF and its two main receptors (VEGFR1 and VEGFR2) was 
investigated. It was observed that continuous hypoxia upregulated VEGF and 
VEGFR1 while downregulating VEGFR2, an effect that has been previously 
observed (Gerber et al., 1997, Ulyatt et al., 2011, Nevo et al., 2013). It has been 
suggested that VEGFR1 may function as an angiogenic control by sequestering 
VEGF in order to “dampen” VEGFR2 angiogenic signalling (Dvorak, 2002, Pan 
et al., 2010), possibly to prevent aberrant VEGF-stimulated endothelial 
responses in response to stress (Ulyatt et al., 2011). It was theorised that this 
increase in VEGFR1 expression and decrease in VEGFR2 may be a contributing 
factor in the inhibition of vessel-like structure formation seen in intermittent and 
continuous hypoxia. 
Taken together, this study demonstrated that AFSCs can successfully function in 
the role of a pericyte and that the AFSC-HUVEC co-culture can be used to 
successfully generate a network of vessel-like structures within a CCS scaffold in 
vitro.  In addition, no beneficial effect of culturing the cells in hypoxic conditions 
was found. 
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6.1.4 Investigation of the ability of an AFSC-HUVEC co-culture to pre-
vascularise collagen-hydroxyapatite and collagen-hyaluronic acid 
scaffolds (Chapter 4) 
Having successfully demonstrated that AFSCs could act as a pericyte in an 
AFSC-HUVEC co-culture that was capable of forming vessel-like structures 
within a CCS scaffold, this study sought to investigate the ability of this co-culture 
to pre-vascularise CHA and CHyA scaffolds. The CHA scaffold is a novel scaffold 
type developed by our group that combines the highly porous, bioactive and 
biocompatible nature of a collagen scaffold with the enhanced ostogenic potential 
and the increased mechanical properties of HA. This scaffold has also displayed 
great potential for repair and has been shown to be capable of healing both 
critical-sized cranial and long bone defects in vivo (Gleeson et al., 2010, Lyons 
et al., 2014). The CHyA scaffold was previously developed by our group with the 
aim of creating a construct with the aforementioned bioactive and biocompatible 
qualities of a collagen scaffold and an inherent pro-chondrogenic nature that 
could be utilised for cartilage repair (Matsiko et al., 2012). 
The AFSC-HUVEC culture was found to be capable of successfully pre-
vascularising both scaffolds as evidenced by the presence of networks of vessel-
like structures by day 7. Encouragingly, these structures were found to be still 
present at day 14. Similar to the CCS scaffold, McFadden et al. observed that the 
delayed addition HUVEC-MSC co-culture generated vessel-like structures that 
were prone to regression (McFadden, 2012). Again, this indicates that the AFSC-
HUVEC co-culture may be a more suitable method for the pre-vascularisation of 
this scaffold type than the delayed addition HUVEC-MSC co-culture used 
previously. 
The AFSC-HUVEC co-cultures on both scaffold types displayed a similar PDGF-
BB secretion pattern to those seen in CCS scaffolds in Chapter 3. This expression 
pattern was characterised by low levels of PDGF-BB in the co-culture compared 
to the high levels observed in the HUVEC monoculture in both scaffold types. As 
previously mentioned in Chapter 3, the low levels of PDGF-BB concentration in 
the co-culture group indicate successful vessel-like structure formation, as the 
endothelial cells no longer need to produce PDGF-BB to attract pericytic cells 
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once vessel formation and stabilisation has taken place, again indicating that the 
AFSCs are successfully fulfilling their role as a pericyte. This study is the first time 
that the CHyA scaffold had been vascularised, as it has been solely used in the 
repair of cartilage, which is an avascular tissue. When pre-vascularisation of both 
the CHA and CHyA scaffolds was compared, both scaffold types were equally 
effective at supporting vessel-like structure formation, making them suitable for 
use in a variety of TE applications. 
In summary, this study (along with the results observed in Chapter 3) has 
demonstrated that a variety of collagen-composite scaffolds can be successfully 
pre-vascularised using an AFSC-HUVEC co-culture, indicating the potential of 
this pre-vascularisation approach for a wide range of enhanced regenerative 
medicine applications.  
6.1.5 Investigation of the ability of human amniotic fluid-derived stem 
cells to undergo chondrogenic differentiation within a collagen-
hyaluronic acid scaffold (Chapter 5) 
Articular cartilage is unable to heal even the most minor injuries, partly due to the 
avascular, aneural and alymphatic nature of the tissue (Bora and Miller, 1987). 
These procedures often fail to generate fully functional hyaline-like articular 
cartilage growth in the affected area. TE may offer an alternative solution in the 
form of a cell-based approach to cartilage repair but an ideal cell and biomaterial 
source has yet to be determined. This study sought to utilise the knowledge 
gained in earlier studies for the purpose of developing a novel construct for use 
in cartilage TE by combining AFSCs, the CHyA scaffold and hypoxic culture. 
AFSCs have been previously been shown to be capable of differentiating down 
a chondrogenic lineage in vitro and therefore may present a promising new cell 
type for cartilage repair (Kolambkar et al., 2007, Rodrigues et al., 2012). The 
CHyA scaffold has been shown to enhance both chondrogenic gene expression 
and cartilaginous matrix deposition by bone marrow-derived MSCs (Matsiko et 
al., 2012) while hypoxia and the HIF-1α pathway have been previously implicated 
in the development of cartilage (Schipani, 2005, Amarilio et al., 2007) and hypoxia 
also represents a more physiologically accurate microenvironment for both 
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AFSCs and articular chondrocytes (Silver, 1975, Al-Asmakh et al., 2007, Pfander 
and Gelse, 2007).  
The results demonstrated that AFSCs were capable of SOX9 expression in both 
normoxia and hypoxia groups. SOX9 is an essential regulator of the initial steps 
of cartilage formation (Bi et al., 1999) and is required for the expression of a 
number of cartilage-specific matrix proteins (Goldring et al., 2006). Hypoxic pre-
culture induced a significant three-fold increase in SOX9 gene expression relative 
to the normoxia group at day 0 indicating accelerated early-stage chondrogenic 
differentiation. It was also demonstrated that at day 21, there was a significant 
three-fold increase in gene expression of the late-stage chondrogenic marker 
COLX in the normoxia group relative to AFSCs in growth media and the hypoxia 
group. Pre-hypertrophic chondrocytes begin to express the late-stage 
chondrogenic marker COLX as they exit the terminal differentiation phase and 
enter the hypertrophic phase (Gannon et al., 1991, Chen et al., 1995, Goldring et 
al., 2006). It has been previously shown that hypoxic culture inhibits COLX gene 
expression in embryonic (Hirao et al., 2006) and adipose stem cells (Betre et al., 
2006) undergoing chondrogenic differentiation. Therefore, it is possible that 
hypoxic pre-culture has an inhibitory effect on late stage chondrogenic 
differentiation and hypertrophy. As hypertrophy is a known limiting step 
associated with many cell-based cartilage TE strategies, this inhibition of COLX 
is a promising development. 
AFSCs seeded on CHyA scaffolds were capable of producing sulphated GAG 
regardless of the O2 condition they were pre-cultured in. Sulphated GAG content 
gradually increased over the course of the culture period with the highest values 
observed at day 21 in both normoxia and hypoxia groups. In addition, AFSCs 
were also found to be capable of the deposition of collagen type 2 and aggrecan 
throughout the CHyA scaffold over the 21 day culture period in both normoxia 
and hypoxia groups, further demonstrating their ability to synthesise cartilage-like 
matrix. Visually, the level of cartilage-like matrix deposition was indistinguishable 
between normoxia and hypoxia groups at all time-points. The similarity in 
sulphated GAG content and collagen type 2 and aggrecan distribution between 
normoxia and hypoxia groups may be explained by the pro-chondrogenic 
qualities of both the CHyA scaffold and the chondrogenic media in which the 
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AFSCs are cultured. The CHyA scaffold has been previously shown to enhance 
sulphated GAG deposition in comparison to the CCS scaffold (Matsiko et al., 
2012) and TGF-β3 has been demonstrated to induce elevated production of 
sulphated GAG in AFSCs (Kolambkar et al., 2007). The composition of the CHyA 
scaffold has also previously been shown to play a major role in the differentiation 
of MSCs even in the absence of chondrogenic factors (Murphy et al., 2012) and 
therefore may be driving cartilage-like matrix deposition in both the normoxia and 
hypoxia groups. 
Most importantly, this is the first time that the chondrogenic potential of AFSCs 
on a porous scaffold has been demonstrated, emphasising their potential for 
cartilage repair. Overall, these results demonstrate that this novel combination of 
cells and scaffold offers a potential new construct for cartilage repair and that 
hypoxic pre-culture accelerated early stage chondrogenic commitment as 
evidenced by increased SOX9 and decreased COLX gene expression, 
suggesting that hypoxic pre-culture may facilitate enhanced early-stage 
chondrogenesis and inhibit hypertrophy.  
6.2 Future work 
 This thesis has demonstrated that a co-culture of HUVECs and AFSCs is 
capable of producing a robust network of vessel-like structures within three 
collagen-based scaffolds. Therefore, the obvious next stage of validating 
this vessel-like structure formation would be an in vivo assessment of the 
functionality of these pre-vascularised scaffolds. A subcutaneous 
implantation study using an immunocompromised murine model could be 
used for this purpose. Subcutaneous implantation is a commonly used 
technique that allows for the assessment of the potential of in vitro 
vasculature generated in TE constructs  implanted in vivo (Fuchs et al., 
2009a, Unger et al., 2010, Ghanaati et al., 2011b). This procedure has 
also previously been used by our group for this purpose (McFadden et al., 
2013). Although hypoxic culture was found to reduce vessel-like structure 
formation in a CCS scaffold, it did increase the secretion of the angiogenic 
growth factors VEGF and PDGF-BB. It would be interesting to assess 
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whether this enhancement of growth factor secretion could led to 
enhanced vessel invasion by the host vasculature and whether 
anastomosis with the in vitro vessel-like structures would also be 
improved. 
 
 One of the more common methods of enhancing vessel formation is to 
replicate the natural environment that these vessels encounter in vivo. 
Therefore, the use of a bioreactor system to provide haemodynamic forces 
could potentially enhance vessel-like structure formation by an AFSC-
HUVEC co-culture within a scaffold. Fluid flow has been previously shown 
to have beneficial effects for a number of TE applications including 
osteogenesis (Kreke et al., 2005, Yourek et al., 2010) and endothelial 
differentiation (Yamamoto et al., 2005, Wu et al., 2008). It has also been 
shown to positively promote vessel formation in vitro (Ng et al., 2004, Lee 
and Niklason, 2010b). The use of a flow perfusion bioreactor by our group 
has also been shown improve stem cell migration, distribution and 
osteogenesis (Keogh et al., 2011, Partap et al., 2010, McCoy et al., 2012). 
Therefore, the application of fluid flow to our co-culture system may 
enhance its vessel-like structure forming capability. 
 
 The CHA scaffold was developed by our group with the aim of creating a 
construct with enhanced osteogenic potential for use in bone repair. It 
would be interesting to try to induce osteogenic differentiation of AFSCs 
seeded on this scaffold while simultaneously pre-vascularising it using an 
AFSC-HUVEC co-culture. If this was successful, it would generate a pre-
vascularised, mineralised construct for use in bone defect repair. The 
effect of mineralisation on vessel-like structure formation could be 
analysed and vice versa. 
 The innate pro-chondrogenic characteristics of the CHyA scaffold could 
potentially be utilised in order to provide a new approach to bone repair by 
broadly imitating the process of endochondral ossification. This 
endochondral ossification centric approach does not replicate the 
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biological process of endochondral ossification but does involve the same 
steps in a different order. This would involve generating vessel-like 
structures using an AFSC-HUVEC co-culture within the CHyA scaffold 
while inducing the production of cartilage-like matrix by AFSCs. The pre-
vascularisation of the CHyA scaffold provides the vessel-like structures 
required for mineralisation without the need for host vessel invasion, 
potentially simplifying this approach to bone repair. 
 The multi-layered “Chondrocoll” scaffold previously developed by our lab 
is composed of CHA and CHyA layers and represents a potential 
therapeutic approach to the regeneration of both the osteochondral bone 
and the overlying articular cartilage (Levingstone et al., 2014). The ability 
of the AFSC-HUVEC co-culture to pre-vascularise the CHA scaffold has 
been demonstrated in this thesis, so potentially this co-culture could be 
used to pre-vascularise the CHA-based bone portion of this construct. It 
would be interesting to monitor the pre-vascularisation of the CHA portion 
of the construct while simultaneously assessing whether this would affect 
the overlying cartilage layer. The potential of this newly pre-vascularised 
construct could also be assessed in vivo.  
 This thesis has also demonstrated that AFSCs were capable of 
undergoing chondrogenic differentiation while seeded on a CHyA scaffold, 
demonstrating the potential of this novel construct for use in cartilage 
repair. However, chondrocytes and bone marrow-derived MSCs are two 
of the most commonly used cell types for cartilage TE (Yoo et al., 1998, 
Pereira et al., 2009, Buckley et al., 2010, Solchaga et al., 2011). A study 
which analysed the chondrogenic potential of both AFSCs, MSCs and 
chondrocytes would allow for the elucidation of how AFSCs compare to 
the standard cell types used for cartilage TE. It would also allow for an 
insight into how the timing of cartilage-like matrix deposition and 
chondrogenic gene expression differs between the cell types. 
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6.3 Thesis conclusions 
 The research presented in this PhD thesis has demonstrated that AFSCs 
subjected to endothelial stimuli over a 14 day culture period display an 
early endothelial gene expression profile and some functional endothelial 
cell characteristics, indicating early endothelial differentiation had taken 
place. Culture in continuous hypoxia was found to enhance endothelial 
gene expression and VEGF protein secretion but did not enhance 
endothelial-like functional characteristics. Overall, AFSCs demonstrated a 
less mature endothelial gene expression profile and phenotype when 
compared to HUVECs, the endothelial cell control.  
 
 The AFSC-HUVEC co-culture was capable of successfully pre-
vascularising a CCS scaffold, thereby demonstrating the potential of 
AFSCs to act as a pericyte. Hypoxic culture reduced vessel-like structure 
formation on both a 2D monolayer and a CCS scaffold. Despite the 
reduction in vessel-like structure formation, hypoxia was found to increase 
secretion of VEGF and PDGF-BB and upregulate VEGFR1 gene 
expression while decreasing VEGFR2, providing a possible explanation 
for the reduced vessel-like structure formation i.e. VEGFR1 may sequester 
soluble VEGF while the capacity of VEGFR2 to interact with VEGF would 
be reduced along with its expression.  
 
 The AFSC-HUVEC co-culture was also capable of generating of a network 
of vessel-like structures within CHA and CHyA scaffolds. Co-cultures in 
both scaffold types displayed a PDGF-BB secretion pattern indicative of 
vessel-like structure formation. There were no significant differences in 
dsDNA concentration or total surface area of vessel-like networks, 
indicating that both CHA and CHyA scaffolds were capable of facilitating 
similar levels of vessel-like structure formation.  
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 In the final study, it was shown that AFSCs were capable of undergoing 
chondrogenic differentiation while seeded on a CHyA scaffold. The CHyA 
scaffolds supported production of cartilage-like matrix by AFSCs 
throughout, whether they were exposed to normoxic or hypoxic pre-culture 
but hypoxic pre-culture accelerated early stage chondrogenic 
differentiation and was also found to inhibit late stage differentiation 
towards hypertrophy. Overall, these results demonstrate that this novel 
combination of cells and scaffold offers a potential new construct for 
cartilage repair and that hypoxic pre-culture may enhance the potential of 
AFSCs for this purpose. 
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